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T h e Perfect Graft: the Ongoing Quest
K.A. Harris, MD, FRCSC
Department o f Surgery, St. Joseph's Health Centre, The University o f Western Ontario, London.
Ont.

ince the introduction of bypass
grafting, investigators have
sought the optimal vascular con
duit. It must have the properties of
host acceptance, long-term patency
and durability. The recognized gold
standard for grafts in the infrainguinal position is the long saphenous
vein (reversed or in situ), but this
vein is not always available. Other
suitable autogenous tissues are
more difficult to harvest and have
variable failure rates.1 Various syn
thetic and biologic grafts have been
used in the infrainguinal region;
however, many early reports of
good graft behaviour are not easily
reproduced. Batt and colleagues in
this issue of the Journal (pages 61

S
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excellent to the very poor results
reported by Batt’s group.34 Al
though the experimental design of
their article is that of a case series,
much useful information can be
gained from this study.
All grafts were inserted into out
flow sites distal to the popliteal
artery and more than 50% were
inserted into “poor” runoff beds,
resulting in a 1-month primary pat
ency rate of less than 50% and a
1-year rate of only 18%. Although
grafts to these outflow beds charac
teristically have poor results, the
incidence of above-knee amputation
for graft thrombosis seems high.
The graft material itself was respon
sible for six serious complications

to 65) give an honest and informa
tive overview of their experience
with the chemically processed
human umbilical vein graft.
The concept of transplanting bio
logic vascular tissue is not new, and
much initial experience of bypass
grafting was gained with bovine
heterografts as well as human ho
mografts. The resultant aneurysm
formation and graft failures have
provided gainful employment for
many vascular surgeons. The con
cept of tanning human umbilical
veins was introduced by Dardick in
the 1970s.2 To prevent aneurysm
formation, this graft has been
wrapped with Dacron mesh. Results
have been variable, ranging from

ing in this periodical is not
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the Canadian Income Tax
Act
Advertisers who file Cana
dian tax returns can claim
the advertising costs of
this publication as a busi
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Examinations
(mural thrombosis, graft rupture
and infection) and possibly three
aneurysms, raising important con
cerns about graft stability. Guidoin
and colleagues have led the field in
their investigations of graft failure
and in outlining potential complica
tions possibly related to structural
defects in grafts.
The human umbilical vein graft
described in Batt’s study provides
neither stability nor satisfactory
patency. In his ongoing work on
graft stability, Guidoin and his
group have shown5 that 26% of
human umbilical vein grafts explanted after a mean duration of 9.7
months were colonized by bacteria.
He also demonstrated frequent in
flammatory responses. He has im
plicated folds on the graft surface
as facilitating bacterial colonization
and thrombosis. In the past, he has
called for more rigorous quality
control based on identification of
structural deficiencies and variable
mechanical properties identified in
virgin human umbilical vein.6
Although, ideally, the long sa
phenous vein would be used for all
lower limb revascularizations, when
it is not available alternative con
duits include other autologous
veins or prostheses. There are in
creasing numbers of reports sug
gesting that autologous vein is su
perior. These veins may be har
vested from a number of sites —
the arm, the contralateral leg, the
short saphenous system. They have
the theoretical advantage of being
autologous living tissue lined by
endothelium. However, to date no
randomized study has compared
“alternative vein’’ long-term paten
cy to that of prosthetic materials. It
is refreshing to see an honest report
of poor results of distal bypass
grafting with nonautogenous tis
sue.
Although from this study, we
cannot conclude whether the poor
results are related to the graft mate
4
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rial or the poor outflow tracts of
the selected patients, Batt and col
leagues do determine that chemical
ly processed human umbilical vein
is not a satisfactory conduit for the
very distal bypass. In addition, it is
apparent that new graft materials
must be thoroughly tested in a
variety of situations before their
general use is recommended. This
process may take many years. To
help facilitate the understanding of
many of these reports, standards
suggested by the Society for Vascu
lar Surgery have been used.7 Guidoin’s group are to be commended
for their ongoing studies into the
durability and safety of a variety of
graft materials.
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Desmopressin: Do We Now Know Its
Role?
G.F.O. Tyers, MD, FRCSC, FACS, FACC
Member. Editorial Board. Canadian Journal o f Surgery. Professor and Head. Division o f
Cardiovascular and Thoracic Surgery. Vancouver General Hospital. University o f British
Columbia. Vancouver. BC

he posterior pituitary peptide,
antidiuretic hormone (ADH)
has been useful in the treatment of
diabetes insipidus through its multi
ple effects on renal salt and water
transport. However, its effective
ness is limited by a short half-life
and potent and potentially perilous
vasoconstrictive properties, hence
its alternative name vasopressin. In
the early 1960s, workers in Czecho
slovakia set out to develop vaso
pressin analogue peptides with spe
cifically tailored biological spectra.
One result was desamino-D-arginine
vasopressin (DDAVP) or desmo
pressin. It has an antidiuretic poten
cy 2000 to 3000 times, and a
half-life more than 10 times, that of
naturally secreted ADH, and has
little or no vasoconstrictive (hyper
tensive), arrhythmogenic or enterouterotonic effects. It is now the
treatment of choice for central dia
betes insipidus.1
It is widely appreciated that the
secretion of ADH in response to
dehydration increases water absorp
tion by the kidney. However, ADH
is also secreted in response to hem
orrhagic shock and other emergen
cy conditions causing hypotension.
One of the initial targets of ADH
molecular engineering was selective
restriction of gastrointestinal and
uterine blood flow to allow ’’blood
less field” surgery, for example in
establishing a portacaval shunt.

T

Early studies also demonstrated sys
temic hemostatic effects.1-2 Intrave
nously administered DDAVP greatly
increases the levels of Factor VIII,
von Willebrand factor, and plas
minogen activator for over 6 hours.
These changes are associated with
decreases in partial thromboplastin
and bleeding times, and enhanced
fibrinolysis. They occur not only in
patients with bleeding tendencies,
including the effects of Aspirin in
gestion, but also in normal sub
jects.2-3 In addition, increased plate
let aggregation, especially at sites
of vascular injury, leads to a vari
able drop in platelet count. Al
though controlled studies have
never been done, DDAVP is now
the treatment of choice to prevent
bleeding complications after dental
extraction and similar surgery in
patients with mild to moderate he
mophilia or von Willebrand’s dis
ease.
The preceding developments led
to successful trials of the prophy
lactic use of DDAVP to minimize
postoperative bleeding in patients
with normal hemostatic function
who undergo orthopedic proce
dures,4 and in patients who have
the complex and variable coagula
tion defects that may follow openheart surgery. In 1986, in a ran
domized double-blind trial of 70
patients who underwent complex
cardiac operations, there was a sig

nificant reduction in blood loss and
homologous blood requirements
when DDAVP was given.5 Subse
quently, a nonrandomized prospec
tive study6 of patients who had a
blood loss of over 100 m l/h and
prolonged bleeding times after
open-heart surgery showed a sig
nificant reduction in transfusion re
quirements, platelet use and reoper
ation for bleeding after treatment
with DDAVP.
It was therefore hypothesized
that use of DDAVP after all openheart surgery might save immense
quantities of blood on a national
basis and markedly reduce the risks
and costs associated with bloodborne diseases, including hepatitis
and AIDS (risks of 1 /4 0 0 trans
fused units and 1 /4 0 000 trans
fused units respectively of carefully
screened blood). Unfortunately, a
subsequent trial7 involving 100 pa
tients who underwent cardiopulmo
nary bypass surgery showed no
substantial difference in total blood
loss after DDAVP administration,
even though bleeding time de
creased, Factor VIII and von Wille
brand factor levels increased and
intraoperative blood loss was less in
the treated group.
The study by Hedderich and col
leagues in this issue (pages 33 to
36) appears to confirm that DDAVP
does not reduce blood requirements
after relatively low-risk open-heart
CJS, VOL. 33, NO. 1, FEBRUARY 1990
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surgery, for example in elective cor
onary revascularization with cardi
opulmonary bypass times of ap
proximately 90 minutes as in the
previous negative study.7 However,
it does raise some questions. The
DDAVP group had one more pa
tient who required late reoperation,
two more who had internal mamma
ry artery harvesting, three versus
one patient with postoperative
bleeding more than 200 m l/h re
quiring early reoperation, and a
higher average intraoperative blood
loss. However, total blood loss and
blood loss during the first 6 hours
after surgery (the period of the
drug’s effect) were each 100 ml less
in the treatment than in the control
group. Furthermore, the preopera
tive von Willebrand factor level was
somewhat lower in the DDAVP
group and increased significantly (p
< 0.001) after administration of the
drug to a little lower, but essentially
the same, level as in the control
group. The significant (p < 0.05)
decrease in platelet count in the
treatment group may also confirm a
hemostatic action secondary to in
creased platelet aggregation at sites
of vascular injury.
Another controlled study of 150
patients prospectively randomized
to DDAVP or placebo groups has
also been published recently.8 In
relatively uncomplicated open-heart
surgical cases, it showed similarly
that DDAVP had no significant ef
fect on blood loss even though
average cardiopulmonary bypass
times were more than 150 minutes.
Again there were minor differences
between the control and experimen
tal groups; more patients in the
control group had increased preop
erative levels of von Willebrand fac
tor multimers and valvular or atrial
septal defect procedures, and more

6
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patients in the DDAVP group had
double internal mammary artery
procedures and preoperative Aspirin
ingestion. Patients in the treatment
group also had significantly higher
levels of antianginal medication.
Could the patients in the DDAVP
groups of the two most recent
studies have been at somewhat
higher risk than those in the con
trol groups?
Whatever the answer to this
question it now seems probable that
the small potential risks, such as
hypercoagulability with stroke or
myocardial infarction, of routine
DDAVP administration after every
open-heart procedure will outweigh
any potential benefits. With careful
technique, perioperative autotrans
fusion and autologous predonation,
the majority of patients can under
go elective open-heart surgery with
out transfusion. As with single-ves
sel coronary artery disease, it is
very difficult to demonstrate a sig
nificant benefit of treatment when
the risk in the control population is
very low.
On the other hand, the use and
study of DDAVP in selected pa
tients with primary or acquired pre
operative bleeding disorders, includ
ing Aspirin ingestion, and in pa
tients at increased risk of periopera
tive hemorrhage are still indicated.
High-risk patients would include
those subjected to long cardiopul
monary bypass times, reoperation
and double internal mammary ar
tery harvesting, and patients who
have prolonged postoperative bleed
ing times. The goal should be to
identify pre- and postoperatively
those patients at increased risk. In
these patients, the potential benefits
of prophylactic or therapeutic
DDAVP therapy should be more
easily confirmed or ruled out. The

majority of patients scheduled for
open-heart surgery who are not at
significant risk should probably be
spared nonselective hemostatic
therapy.
As the bloom fades from another
magic potion that it was hoped
might limit postoperative bleeding
without inducing intravascular co
agulation, it is predictable that faith
will be transferred to the next gen
eration. Can the nonselective use of
aprotinin (Trasylol) succeed where
aminocaproic acid (Amicar) and
DDAVP have failed?
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D u k es’ Classification: American Chaos
Versus British Order
Warren Schubert, MD
Department o f Surgery. The Montreal General Hospital. M cG ill University. Montreal. PQ

ssimilation of a large volume of
information and devoting long
hours to clinical work is onerous
for student, resident and practising
physician alike. The seemingly loga
rithmic increase of information to
learn is often of a complexity that is
totally unwarranted. The Dukes’
classification for staging of cancer
of the rectum is a good example of
this unwarranted complexity.
Cuthbert E. Dukes, a pathologist
from St. Mark’s Hospital in Lon
don, described, in 1932, a simple
and clear classification for stag
ing cancer of the rectum.1 Some
“purists”2 have criticized it as being
improper for staging other intesti
nal tumours, but, although his orig
inal paper did not include tumours
of the colon, Dukes did state that
his classification could “be applied
to all intestinal carcinomas”.1 Under
this classification, A was defined as
growth limited to the wall of the
rectum; B as extension of growth to
extrarectal tissues but no metastases in regional lymph nodes; and C
as metastases in regional lymph
nodes. Although many authors
have since misinterpreted or rede
fined “wall of the rectum”, Dukes
included a clear diagram (Fig. 1) in
which “the wall” referred to the
circular and longitudinal muscles of
the bowel.
Few structures of such impor
tance have been given such a pleth
ora of names as Dukes’ “wall”. The
circular and longitudinal muscles
have been referred to as the muscu
lar coat, tunica muscularis, muscularis propria and muscularis ex
terna. These are often confused
with the thin inner muscular layer,
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commonly known as the muscularis
mucosae or lamina muscularis mu
cosae. Whether muscularis interna
refers to the circular muscle of the
muscularis propria or to the mus
cularis mucosae remains unclear,
and when authors or pathologists
abbreviate the previous terms, de
scribing the depth of invasion of a
carcinoma relative to the "muscularis", the problem is compounded.
The first to suggest a relation
ship between depth of invasion and
prognosis was Lockhart-Mummery,
working in the same institution as
Dukes. In 1927, he coined his own
classification3 in which stage A can
cer had not invaded the “muscular
coat” , B involved the “muscular
coat” and C represented large, fixed
growths or extensive involvement
of nodes.
Dukes is partially to blame for
the confusion surrounding his clas
sification. Before the publication of
his classic 1932 paper, he and Gordon-Watson outlined the system
suggested by Lockhart-Mummery.3
In their paper they suggested that
stage B cancers “may be further
subdivided into B1 in which the
circular muscle is the limit of
growth, and B2 in which the longi
tudinal muscle has been reached. C
cases may also be subdivided into
Cl without glandular involvement,
and C2 with metastasis in the lym
phatic glands.”4
At St. Mark’s Hospital there
evolved an interest in the lymphatic
spread of cancer of the rectum and
its association with survival. Gabriel
and colleagues5 detailed the find
ings of 100 dissections of the anal
canal, rectum and surrounding peri

rectal tissues in which lymphatic
m etastasis was meticulously
mapped. They found that the 5-year
survival for perineal resection was
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Extent of spread of cancer of rectum.

FIG. 1. Photograph of Dukes’ classifi
cation from his original 1932 article.
Diagram was drawn by Dr. H.J.R.
Bussey, consulting research fellow at
St. Mark’s Hospital, London. At that
time, Dr. Bussey was research assis
tant under Cuthbert Dukes and was
responsible for several drawings in
Dukes’ subsequent publications. (Re
produced by permission of the Patho
logical Society of Great Britain and
Northern Ireland from Dukes CE: The
classification of cancer of the rectum. J
Pathol Bacteriol 1932; 35: 323-332.)
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91% for stage A cancers, 64% for
stage B and 16% for stage C. They
also noted that the first “ glands” to
receive metastases were those at the
same level or immediately above the
primary growth, and they usually
found lymphatic spread by “upward
uninterrupted extension”. A sub
categorization of C was devised
from Dukes’ 1932 classification.
Cancers in which the lymph-node
metastasis did not reach the mesen
teric vascular ligature around the
inferior mesenteric pedicle were
classified as Cl and had a better
prognosis than those in which lym
phatic spread reached the point of
ligature, which were classified as
C2. This C1/C2 subcategorization
was occasionally used by Dukes in
his later papers,67 and has been
used by others.8-9 However, this
subcategorization is quite different
from the C1/C2 classifications of
most other authors.
Dukes noted that the survival
rate decreased as the number of
involved nodes increased.10 He also
noted that in only 2% of cases was
there lymphatic spread before “di
rect continuity spread has extended
through the outer muscular
coats”.11 None of Dukes’ papers
made reference to a D category,
although Dukes stated that “if a
malignant growth has spread to
distant organs such as the liver,
this is described as the fourth
stage”.6 In 1958, Dukes and Bus
sey7 published an update report,
based on 2447 patients studied over
25 years. The crude 5-year survival
for patients with stage A cancer was
81.2% for stage B 64.0% and for
stage C 27.4% and, after allowing
for intercurrent deaths, the “cor
rected” 5-year survival rates were
97.7%, 77.6% and 32.2%, respec
tively.
The importance of Dukes’ work
is well recognized. A system was
finally devised to assess a patient’s
prognosis, with implications for fol

low-up and possible adjuvant treat
ment. Furthermore, a way was
found to categorize patients with
colorectal tumours to compare dif
ferent modalities of treatment.
Studies in later years (using a dif
ferent staging system) confirmed
that survival by staged groups was
similar for both rectal and colonic
cancer.12 Despite the various ramifi
cations studied by Dukes, the basic
A, B, C staging system is acknowl
edged as Dukes’ classification in
most of the British literature.
Since 1932, American authors
have tried to modify Dukes’ classifi
cation. In many cases the modifica
tions were based on fewer cases
than in Dukes’ original study.
These authors failed to prove any
advantage of their new system over
the original except to increase its
complexity and cause confusion.
The first to initiate this labyrinth of
nomenclature were Kirklin and col
leagues.13 They used a “slight mod
ification of the Dukes method”. In
131 cases, they described “type A,
lesion limited to the mucosa; type
Bl, lesion extended into the muscularis propria but did not penetrate
it; type B2, lesion penetrated
through the muscularis propria;
and type C, lesion of either type Bl,
or B2, with involvement of lymph
nodes”. This was not a refinement
of Dukes’ system; instead these
authors used terminology similar to
Dukes’ to denote completely differ
ent levels.
In 1954, Astler and Coller14
worsened the situation by suggest
ing a more complex modified
Dukes’ classification, which more
accurately should have been called
a “modified Kirklin classification”.
Using Kirklin’s system they further
subdivided Kirklin’s type C into
“Cl (limited to the wall with posi
tive nodes) and C2 (through all
layers with positive nodes)” .
In 1967, Turnbull and associ
ates15 published their findings on

the no-touch technique for colorec
tal cancer. They introduced a new
A, B, C, D staging system, but did
not refer to it as a “modified Dukes’
classification” . Another completely
different “modified Dukes’ classifi
cation” was proposed by Smith and
associates,16 based on only 100 pa
tients; one group had no patients
and another had only 1. Newland
and colleagues17 proposed a classifi
cation with as many as four stages
and nine substages. Although there
were significant differences in sur
vival between the four major stages
over 5 years, these authors failed to
show statistical differences between
many of the more complicated sub
stages. In yet another system used
by the Gastrointestinal Tumor
Study Group,18 stage C was subdi
vided into C l, those patients who
had one to four involved nodes, and
C2, those having five or more in
volved nodes.
Finally, a truly radical departure
from the A, B, C staging of cancer
was the invention of the TNM clas
sification of malignant tumours
used by the International Union
Against Cancer.19 Relatively few cli
nicians can remember this system
without looking it up.
Several large studies have been
based on incorrect definitions of
Dukes’ classification,20-23 but in re
viewing the major texts written by
British authors, they have clearly
not been led astray by the American
“ modified D ukes’ classifica
tions”.9-24 On the other hand, Amer
ican authors have supported trends
toward pandemonium; some25 have
even decided to change the spelling
from Dukes’ classification to
Duke’s classification.
Leading American texts are in
disagreement as to which classifica
tion should be used. For example,
the surgical textbook Principles o f
Surgery has gone through an inter
esting evolution. The first through
third editions advocated the use of
CJS, VOL. S3, NO. 1, FEBRUARY 1990
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Astler and Coder's system with the
addition of type D, for distant le
sions, and the fourth and fifth edi
tions rediscovered Dukes’ 1932
classification. However, the fourth
edition went on to describe the
“ latest and most detailed modified
(Australian) Dukes’ classification” ,
that of Newland and colleagues,17
which included the substages A l,
A2, A3, B l, B2, C l, C2, D1 and
D2. Although the substages failed
to prove a difference in longevity,
this classification is more worthy of
the eponym “ modified Dukes’”
than others, in that stages A1 to A3
combined agree with Dukes’ origi
nal classification of stage A, Bl and
B2 combined agree with Dukes’
stage B and C l and C2 agree with
Dukes’ 1935 classification; only D1
and D2 are new.
The 11th edition of Sabiston’s
Textbook o f Surgery advocated the
use of a “modified Dukes classifica
tion” incorrectly described by DePeyster and Gilchrist.26 In Sabis
ton’s 12th and 13th editions
Dukes’, Kirklin’s and Astler’s clas
sifications are mentioned, but it is
stated that the American Joint Com
mittee Classification based on the
TNM staging of cancer of the colon
and rectum “ should be utilized in
any reference to colon or rectal
cancer” .
In Way’s textbook, Dukes’ prop
er classification is presented27 and
an explanation given that stage D
has become common usage to as
sign patients with “distant metasta
sis or locally unresectable tum or” .
Spiro28 stated that the Dukes’ clas
sification is the most widely accept
ed, but made no attempt to describe
it, giving instead a redefinition of
the classification as described by
the Gastrointestinal Tumor Study
Group.
In the third edition of Sleisenger
and Fordtran’s Gastrointestinal Dis
ease, Dukes’ stage A is incorrectly
described as being “ limited to the
10
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mucosa and submucosa” .29 This in
accuracy is resolved in the fourth
edition.
Clearly, there must be some con
formity in the staging of colorectal
cancer. This is particularly impor
tant in comparisons of therapeutic
regimens. The use of the eponym
“modified Dukes’” must be discon
tinued, since it has been inappropri
ately used to describe classifications
that Dukes would not recognize.
The obsession to subdivide and sub
categorize a simple system must be
resisted, especially since most of the
complicated classifications offer
nothing for patient management. I
(an American) wish to join Goligher30 and Roseman and Straus31 in
their plea to Americans for a return
to the simplicity of the Dukes’ 1932
classification in which A represents
tumours limited to the wall, B ex
tension through the wall and C
lymph-node metastasis. An attempt
to edify rather than mystify medical
students is occasionally healthy. If
in future new subdivisions are need
ed to institute different therapeutic
m odalities, th ese subdivisions
should not be referred to as a
“modified Dukes’ classification”.
With the current political trends,
Canadian-American free trade, in
creased exchange of ideas and pos
sible further conformity, it is to be
hoped that the “high tech” quag
mires of the American classifica
tions will not also flow north.
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nant) request authoritative information
on diet and weight reduction. This
appendix provides the perfect answer.
The chapter on statistical methods in
cancer research should alert any reader
who is contemplating even a simple
study to seek the assistance of a bio
statistician.
The chapter on heat imaging in
cludes an overenthusiastic promotion of
mammography. This is well balanced,
however, by the chapter on breast
screening and follow-up. Unfortunately,
the overenthusiastic recommendations
for adjuvant radiotherapy in the chapter
on radiation are not balanced. Most
modern radiotherapy centres have con
cluded that adjuvant radiotherapy after
total mastectomy and axillary dissection
does more harm than good. This chap
ter suggests that it is nearly innocuous
and may be curative. The author appar
ently clings to the outmoded concept
that breast cancer is a localized (rather
than systemic) disease at the time of
detection and is potentially curable
postoperatively by extended radiotherapeutic efforts to sterilize regional
nodes. The suggestion that preoperative
adjuvant radiotherapy especially to the
internal mammary nodes may be associ
ated with improved survival impairs the
credibility of this chapter even more.
One can only hope that the radiothera
pists to whom the readers of this sec
tion may be referring their patients will
be better informed.
This book will be of value to all

surgeons whose practice embraces a
considerable number of patients with
breast disease. It is an excellent refer
ence for other health professionals and
should be in the library of every teach
ing hospital.

BOOK REVIEW S

CANCER OF THE BREAST. 3rd edi
tion. Edited by William L. Donegan
and John S. Spratt. 796 pp. IUust.
W.B. Saunders Company, Philadel
phia; W.B. Saunders Company Canada
Limited, Toronto, 1988. $142.75.
ISBN 0-7216-1819-7.

Not so long ago, a surgeon familiar
with the relevant anatomy and patholo
gy and the surgical techniques required
to diagnose and extirpate breast cancer
could deal competently with the disease.
Today, a competent surgeon requires
knowledge in fields far removed. This
textbook has addressed this problem
and fulfils the need well. The fact that
the two authors are recognized experts
in rather diverse fields — one in general
surgery, the other in community medi
cine — provides a unique flavour to the
comprehensive coverage of the subject.
The sections on anatomy, physiolo
gy, diagnosis, pathology, staging and
surgical management are excellent;
however, the same information is avail
able in a number of other first-class
textbooks. Not available in other texts
are the excellent chapters on epidemiol
ogy and etiology, cell kinetics, growth
rates, nursing care, psychosocial fac
tors, physical fitness and weight con
trol. The section on nutrition is out
standing and even includes an appendix
detailing sources of additional informa
tion for patients who seek diet counsel
ling. Many women presenting with
breast disease (either benign or malig

Leo Mahoney. BA. MD. MS. FRCSC,
FACS
Associate Professor o f Surgery.
Director.
St. Michael’s Hospital Breast Centre.
55 Queen St. E.
Ste. 405.
Toronto. Ont.
M5C 1R6

DISORDERS OF THE SPLEEN. Pa
thophysiology and Management. Edit
ed by Carl Pochedly, Richard H. Sills
and Allen D. Schwartz. 464 pp. Illust.
Marcel Dekker, Inc., New York, 1989.
$125.00 (US). ISBN 0-8247-7933-9.

In ancient medicine the spleen was a
mystical organ, and in modern times the
mystery persists. There are few text
books devoted to the spleen. Diseases
o f the Spleen, therefore, is a welcome
addition to that section of the medical
library. Because of the decreasing indi
cations for splenectomy in recent years,
surgeons and pathologists now have

continued on page 74
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HOW I DO IT

Modified Subtotal Cholecystectomy for
High-Risk Patients
Amitai Bickel, MD; Ida Lunsky, MD; Solly Mizrahi, MD; Benjamin Stamler, MD
hen high-risk patients in
poor condition must undergo
cholecystectomy, the procedure
should be performed rapidly, main
taining a stable hemodynamic state.
Occasionally, the gallbladder is
found to be necrotic, severely in
flamed with a thickened wall or
embedded into the liver tissue. The
anatomy may be thoroughly obliter
ated by a diffuse inflammatory proc
ess. In such cases, division and
removal of the gallbladder from its
bed might prolong the operation
and be accompanied by serious
bleeding (particularly in conditions
such as cirrhosis and portal hyper
tension). A subtotal cholecystecto
my, leaving part of the posterior
wall of the gallbladder attached to
the liver, should avoid these prob
lems.

W

Operative Technique

Discussion

After abdominal exploration, the
fundus of the gallbladder is grasped
between two forceps. A small trocar
is inserted through the fundus and
the content evacuated. A thin suc
tion tube is inserted into the gall
bladder to evacuate secretions dur
ing the operation and to delineate
the cystic duct. The gallbladder wall
is cut using electrocautery, adjacent
to the liver, on both sides of the
gallbladder, which is opened up
(Fig. 1). With a diathermy from
within, the posterior wall is cut
transversely at the proper level to
complete the removal of the gall
bladder from the liver, leaving a
portion of its posterior wall behind.
Electrocoagulation of the posterior
wall mucosa is then carried out and
the cholecystectomy completed.

Although incomplete cholecystec
tomy does not resemble cholecystostomy1 with respect to its rapidity
and relative ease and cannot be
done under local anesthesia, it does
have certain advantages.
Unlike cholecystostomy, subtotal
cholecystectomy is a definitive oper
ation, rendering further gallstone
formation impossible. Such a tech
nique could be used in high-risk
patients when the operator suspects
that gallbladder dissection will be
accompanied by severe bleeding and
prolonged operating time.
This technique should not be
used as a last resort when an at
tempt at total resection has failed.
Cutting out the posterior wall by
coagulation diathermy does not
cause pronounced bleeding even
when performed before ligation of
the cystic artery. However, after
opening the gallbladder and discon
necting it from its posterior wall,
exposure of the cystic vessels is
greatly improved.
Electrocoagulation of the posteri
or-wall mucosa may prevent the
development of postoperative infec
tion and the possible occurrence of
gallbladder carcinoma.2-3
In the modified technique, we
used coagulation diathermy instead
of a scalpel and did not suture the
remaining edges of the posterior
wall, as in the original procedure.4
The technique we used differs
from electrosurgical obliteration of
the gallbladder described by Thorek.5 In that description, the tech
nique of removing the redundant
portion of the gallbladder is some-

Patients
Results
Between 1984 and 1987, eight
high-risk patients, ranging in age
from 49 to 79 years, underwent
modified subtotal cholecystectomy.
All suffered from severe cholecysti
tis. Four patients had obstructive
jaundice; two of them had ascend
ing cholangitis and sepsis. Preoper
ative work-up included tests of liver
function, ultrasonography (all pa
tients) and endoscopic retrograde
cholangiopancreatography (three
patients).

In all eight patients, severe chole
cystitis accompanied by marked an
atomical and inflammatory changes
was found. Choledocholithiasis, ne
cessitating exploration of the com
mon bile duct, was discovered in
four patients. One patient had
macronodular cirrhosis. Another
had carcinoma of the pancreas.
All patients made a smooth re
covery. There were no cases of
wound infection.

From the Department o f General Surgery, Nahariya Government Hospital, Nahariya, Israel
Accepted fo r publication Nov. 16, 1988
Reprint requests to: Dr. Am itai Bickel, Department o f General Surgery, Nahariya Government
Hospital, PO Box 21, Nahariya, 22100, Israel
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what different and seems to take
more time. The electrocoagulated
edges of the gallbladder are approx
imated by interrupted sutures, and
the falciform ligament is applied.
We regard the latter step as unnec
essary.
Although we use this technique
infrequently, our impression is that
it provides a safe and simple alter
native to cholecystectomy in highrisk patients.
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FIG. 1. Modified subtotal cholecystectomy. Gallbladder wall is cut adjacent to liver
(top left). Posterior wall is cut transversely, using electrocoagulation (middle
right). Procedure is completed, leaving posterior wall attached to gallbladder bed
(bottom).

5. T horek M: Electrosurgical obliteration of
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SESAP VI Question
Item 206
Which of the following agents produces direct cellular damage to the liver?
(A) Ether
(B) Halothane
(C) Enflurane
(D) Isoflurane
(E) None of the above
For the question above, select the one answer that is best of the five given.
For the critique of Item 206 see page 75.
(Reproduced by permission from SESAP VI Syllabus; Surgical Education and Self-Assessment Program No. 6.
For enrolment in the Surgical Education and Self-Assessment No. 6, please apply to the American College of
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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CANADIAN ASSOCIATION OF CLINICAL SURGEONS

R esults of Fine-Wire Localization Breast
Biopsies at the Cancer Control Agency of
British Columbia
M.G. Clay, MD, FRCSC
Over the past 7 years at the Cancer Control Agency of British Columbia, fine-wire
localization breast biopsies were performed with increasing frequency for
mammographic findings suggestive of malignant disease. Because the rate of biopsy
specimens negative for malignant disease was high, a policy was instituted to review
all mammograms before carrying out a biopsy. As a result, the rate of positive
biopsy findings increased from a mean of 29% to 33% and a further 16% of biopsy
specimens were positive for premalignant disease. Of patients in whom a diagnosis
of malignant disease was made, 60% had in-situ disease compared with 8.5% in the
province overall. As a result of the earlier diagnosis, less radical surgery was
possible. These findings support the value of mammography with fine-wire
localization biopsy as a valid method for making an earlier diagnosis of breast
cancer.

Au cours des 7 dernieres annees, l’Agence de surveillance du cancer de ColombieBritannique a eu de plus en plus recours a la biopsie de localisation a l’aiguille fine
lorsque les resultats de l’examen mammographique suggeraient la possibility d’une
lesion mammaire maligne. A cause du taux eleve de biopsies negatives pour la
presence de tumeurs malignes, on a instaure une politique de revision de tous les
mammogrammes avant de proceder aux biopsies. II en a resulte une baisse du taux
moyen des biopsies positives de 29% a 33% et, de plus, un autre 16% des biopsies a
revele la presence de lesions premalignes. Parmi les patientes chez qui on a
diagnostique une lesion premaligne, 60% souffraient d’un cancer in situ comparativement a un taux de 8.5% pour l’ensemble de la province. Consequence d’un
diagnostic plus precoce, des interventions moins radicales ont ete possibles. Ces
resultats montrent l’importance de la mammographie combinee a la biopsie de
localisation a l’aiguille fine comme methode pour obtenir un diagnostic plus precoce
du cancer du sein.

he lack of significant improve
ment in the long-term survival
of women who have breast carcino

T

ma continues to stimulate efforts to
diagnose the disease earlier. Mam
mography is an important feature
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of these efforts. As the availability
of mammography has increased, so
has the frequency of fine-wire local
ization biopsies.
During the 7 years that fine-wire
localization biopsy has been per
formed at the Cancer Control Agen
cy of British Columbia, findings of
malignant disease from the biopsy
specimens have ranged from 44% in
the initial year when only 27 biop
sies were performed to 21% 2 years
later when 138 biopsies were done
(mean of 29% from 1983 to 1986
inclusive). We considered these re
sults unsatisfactory. In an attempt
to overcome the high frequency of
benign biopsy specimens, we insti
tuted a policy whereby all mammo
grams thought to demonstrate pos
sible areas of malignancy are re
viewed by Agency radiologists be
fore the biopsy is carried out. Insti
tution of this policy resulted in a
rate of biopsy specimens positive
for malignant disease of 33% in
1988 (Table I).
In each of the last 6 years, we
have diagnosed between 30 and 40
malignant tumours from fine-wire
localization biopsies, with a consid
erable variation in the number of
biopsies performed annually. In
1986, before we initiated the current
review process, the rate of biopsy
specimens found positive for malig
nant disease was 33% which was
equalled only by the 1988 figures
after we had begun the review proc
ess. Discounting our initial year of
CJS, VOL. 33. NO. 1, FEBR U A R Y 1990
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performing this procedure, the
highest recovery ever achieved was
26%.

Biopsy Findings
Review of the patients who had
breast biopsy in 1988 demonstrat
ed that 77 had “benign” lesions
and 38 had carcinoma (Table II). Of
the benign lesions, 58 (50% of the
total number of patients in the
series) were completely benign, the
diagnoses being fibrocystic disease,
fibroadenoma and intramammary
lymph nodes. However, in 19
women (16% overall) marked epi
thelial atypia was noted, and in 6 of
them histologic changes approach
ing, but not reaching, in-situ carci
noma were demonstrated.
Analysis of the 38 women who,
in 1988, had a diagnosis of malig
nant disease demonstrated that 23
(61%) had in-situ disease and 15
(39%) invasive disease. This distri
bution is in direct contrast to the
distribution overall through the
province where, in 1987, the latest
year with complete reports, only 144
(8.5%) of the 1698 new patients who
had a diagnosis of breast carcino
ma, had in-situ disease and the
other 1554 (91.5%) had invasive dis
ease. Such contrasting figures
strongly support the value of the
mammography program with finewire localization biopsy as a valid
approach to the early diagnosis of
breast carcinoma.
In addition to the possibility of
increased long-term survival as a
T a b le

result of early diagnosis, the poten
tial for conservative surgery in our
patients was increased. Of the 23
women with in-situ disease, 4 had
lobular carcinoma (Table III); of the
19 with intraductal disease, 5 had
comedocarcinoma with the antici
pated risk of widespread intraductal
disease in the involved breast.
Women with invasive disease dem
onstrated the expected distribution;
only 1 had a lobular tumour and the
other 14 had invasive ductal carcino
ma.

Treatment
The treatment of most patients
was dictated by the histologic find
ings. Of the four women who had
in-situ lobular carcinoma (Table IV),
two initially underwent wide exci
sion; one who had apparently com
plete resection of the residual dis
ease was thought to require no
further treatment; another had such
widespread in-situ disease that a
total mastectomy was considered
necessary. Analysis of the mastecto
my specimen failed to reveal any
residual disease. A third woman had
wide excision and the specimen
demonstrated generalized noninvasive disease. She underwent a modi
fied radical mastectomy in the prov
ince where she lived. We would not
have been as radical and would
have advised a total mastectomy
without axillary dissection; in fact,
this woman had no involved nodes.
The final woman had a total mas
tectomy as her initial treatment, but

T a b le II. B r e a k d o w n o f " B e n ig n " L e s io n s
F o u n d o n F in e - W ir e L o c a liz a tio n B io p s y in
1988
T y p e ot le s io n

No. (% )

" C o m p le t e ly ” b e n ig n

5 8 (5 0 )
1 9 (1 6 )

P r e m a lig n a n t
A ty p ia
A p p ro a c h in g in s itu

13
6

T o ta l

7 7 (6 6 )

T a b le III. B io p s y R e s u lts o f P a tie n ts W ith
C a r c in o m a
T y p e ot c a n c e r

M a lig n a n t
In - s itu lo b u la r
In tra d u c ta l ( c o m e d o 5 )
In v a s iv e
L o b u la r
D u c ta l
T o ta l

N o . ( % of to ta l)
o f p a tie n ts
2 3 (2 0 )
4
19
1 5 (1 3 )
1
14
3 8 (3 3 % )

D a ta o n F in e - W ir e L o c a liz a tio n B io p s ie s P e r fo rm e d B e tw e e n 1 9 8 2 a n d 1 9 8 8

Year

T o ta l
b io p s ie s

No.
p o s itiv e

%
p o s itiv e

1982
1983
1984

27
116
138

44
26
21

1985
1986
1987
1988

133
120
146
115

12
30
29
30
40
35
38
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she had previously had lobular car
cinoma involving her other breast;
we consider her treatment appropri
ate.
Of the five patients with intraduc
tal disease who had comedocar
cinoma, only one had wide excision
(Table V); fortunately there was no
residual disease in the surgical
specimen. We believe that patients
with comedocarcinoma require a
total mastectomy because of the
high risk of multifocal disease. This
opinion is justified by our findings
in the four other patients treated by
total mastectomy who were found
to have widespread residual disease,
one with extensive involvement
throughout the breast.
The remaining patients with insitu disease had ductal carcinoma
without a comedo component (Ta
ble VI). One had no further treat
ment because the tumour was
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23
33
24
33

T a b le IV . T r e a tm e n t o f F o u r P a tie n ts W ith
L o b u la r C a r c in o m a in S itu
P ro c e d u re
W id e e x c is io n
W id e e x c is io n + to ta l
m a s te c to m y
W id e e x c is io n + m o d ifie d
ra d ic a l m a s te c to m y
T o ta l m a s te c to m y

No.
1
1
1
1

FINE-WIRE LOCALIZATION BREAST BIOPSIES

found to be contained within a
fibroadenoma. A second patient had
another disseminated nonmammary
malignant tumour and received che
motherapy for the other tumour
without further treatment of the
breast lesion. Seven patients had
wide excision; of these, only two
had no residual disease demonstrat
ed in their second specimen. Of the
five with residual disease, three had
no invasion and, since their disease
was considered to have been re
moved completely, they had no fur
ther treatment. The other two had
infiltrating disease in the second
specimen; one underwent a modi
fied radical mastectomy and the
specimen showed no nodal involve
ment, but the other, who also had a
modified radical mastectomy, was
found to have disease in one node.
She had adjuvant chemotherapy
and radiotherapy added to her treat
ment. Fourpatients had a total
mastectomy without axillary dissec
tion, two because of patient choice,
one because the breast was too
small to be treated by wide local
excision and the other because she
had previously had carcinoma of
the contralateral breast; she and
T a b le V .

one of the patients who had select
ed the mastectomy as her preferred
treatment had no residual disease.
The patient whose breast was too
small had minimal residual disease
and received no further treatment;
the fourth patient, who also had
selected mastectomy as her treat
ment, was found to have disease at
the deep resection margin so she
received chest wall irradiation as
adjuvant therapy. The final patient
in this group had a modified radical
mastectomy since she had diffuse
intraductal involvement and had
previously had a primary malignant
tumour of the breast.
In the group of women who had
invasive disease discovered by finewire biopsy (Table VII), the one
with lobular carcinoma underwent a
wide local excision with axillary
node dissection. Her nodes were not
involved and therefore she had no
further treatment.
The patients with infiltrating duc
tal carcinoma were treated either by
wide excision and axillary dissection
or by modified radical mastectomy,
except for three patients who, be
cause of age or other disease, un
derwent a course of radiotherapy

T re a tm en t o f Five Patients W ith C om edocarcinom a

P ro c e d u re

R e s id u a l d is e a s e

Wide excision
Total m astectom y
M odified radical m aste cto m y

T a b le V I.

N o r e s id u a l d is e a s e

0
3

1

0
0

1

T reatm ent o f 14 Patients W ith In-situ Ductal Carcinom a

P ro c e d u re

No fu rth e r treatm ent
C hem otherapy
Wide excision
Total m astectom y
M odified radical m astectom y

T a b le V II.

N o . of

R e s id u a l

N o r e s id u a l

p a t ie n t s

d is e a s e

d is e a s e

_

_

-

-

5 (2 invasive)
2
1

2
2
0

1
1
7
4
1

T re a tm en t o f 14 Patients W ith Invasive Carcinom a
W i d e e x c is io n

T y p e of

No

cancer

tre a tm e n t

R a d ia t io n

_

_

1

2

Lobular
Ductal

M o d ifie d

and

r a d ic a l

a x i l l a r y d is s e c t io n

m a s te c to m y

1
5

_
6

instead of further surgery. Of the
five patients who had wide excision
and axillary dissection, none had
nodal involvement, but one had the
mastectomy completed because of
disease at the margins of the ex
cised specimen; another had radio
therapy after her operation because
of intramammary lymphatic involve
ment within the diseased area. Only
one of the women treated by modi
fied radical mastectomy had nodal
disease (1 node of 19 recovered). It is
notable that only 1 of the 15 women
who had invasive disease had tu
mour in her axillary nodes.

Conclusions
Our yield of positive breast biop
sies has improved over the last 6
years, but the number of malignant
lesions diagnosed has remained rel
atively stable. As a result, the num
ber of patients offered fine-wire bi
opsies has decreased. We believe
that mammograms should be re
viewed by radiologists in continuing
efforts to improve the accuracy of
preoperative radiologic assessment.
The early diagnosis afforded by
mammography has allowed a larger
number of women to be treated by
conservative surgery than would be
the case if diagnosis depended on
the discovery of a breast mass by
physical examination. This is main
ly because of the large proportion
of in-situ carcinomas in our series,
and also because of the small size
of the invasive lesions at the time of
diagnosis.
We believe that our patients’ sur
vival has not been compromised
because of our approach. We ex
pect a significantly improved surviv
al rate from breast carcinoma diag
nosed by mammography because of
the greatly increased number of
cancers diagnosed earlier than
would have been allowed by tradi
tional methods.*
CJS. VOL. 33. NO. I. FEBRUARY 1990
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monas infections of the urinary tract, a good clinical response accompanied by bacterial
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Labour and Delivery: The safety and efficacy of CefizoxTM use during labour and delivery
has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations (less than
4% of serum concentrations at 1 hour after dosing). The clinical significance of this is
unknown; therefore caution should be exercised if CefizoxTM jS to be administered to /^
nursing woman.
Infants and Children: The safety of CefizoxTM in infants less than 6 months of age has ncjij
been established. In children six months of age and older, treatment with CefizoxTM has
been associated with transient elevated levels of eosinophils, SGOT, SGPT and CPK
(creatine phosphokinase). The CPK elevation may be related to intramuscular
administration.
Elderly Patients: The elimination of ceftizoxime may be reduced due to an age-depend^
reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse
Reaction

SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding methicillinresistant strains); Staphylococcus epidermidis; Escherichia coli; Klebsiella sp., (including K.
pneumoniae); Streptococcus sp. (excluding enterococci but including Group A B-hemolytic
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(including B. fragilis); Peptococcus sp., and Peptostreptococcus sp.
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the causative organisms and to determine their susceptibilities to ceftizoxime. Therapy with
CefizoxTM may be initiated before results of the susceptibility studies are known. However,
modification of the treatment may be required once these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have shown
hypersensitivity to ceftizoxime or other members of the cephalosporin group of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful inquiry
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reactions to cephalosporins, penicillins, or other drugs. CefizoxTM should be given
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causes of colitis should also be considered.

Incidence
> 1 % but <5%

Hypersensitivity:

Rash
Pruritus
Fever

Liver:

Transient elevation of SGOT,
SGPT and alkaline phosphatase

Blood:
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Leukopenia
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Renal:

Transient elevation
of BUN and creatinine

INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus epidermidis;
Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides sp. (including B.
fragilis)] Peptococcus sp.; and Peptostreptococcus sp.
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Incidence
< 1%

Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test

Local:

Injection site: burning, cellulitis,
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pain, induration, tenderness,
parasthesia

Genitourinary:
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Gastrointestinal:
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j
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information available on symptoms or treatment. In cases of suspected overdosag
supportive therapy should be instituted according to symptoms. Serum ceftizoxime leve
can be reduced by hemodialysis.
|
DOSAGE AND ADMINISTRATION
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CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly or intre
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Dosage and route of administration should be determined by the condition of the patien
severity of the infection and susceptibility of the causative organism(s). The intraveno^
route may be preferable for patients with bacterial septicemia, or other severe or lir
threatening infections.
|
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hours after evidence of bacterial eradication has been obtained. For B-hemolytic strept<
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TABLE 1
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Frequency and Route
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1
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General: Transient elevations of BUN and serum creatinine have been observed in clinical
studies. However, there is no other evidence that CefizoxTM (sterile ceftizoxime sodium) has
produced alterations in renal function. Renal status should be periodically evaluated,
especially in seriously ill patients.

Other Sites

2-3

1 gq8h orq12h, IVorIM

Severe or
Refractory

3-6

1 g q8h, IV or IM, to
2g q8h or q12h, IVor IM*

Life-Threatening

9-12

3 o r4 g q8h IV

Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible organisms
including species originally sensitive to the drug. Careful observation of the patient is
essential. If superinfection occurs during therapy, appropriate measures should be taken.
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‘ When administering 2 g intramuscularly, the dose should be divided and injected i.ftd
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Because of the serious nature of urinary tract infections due to Pseudomonas aeruginc&a
and because many strains are only moderately susceptible to CefizoxTM, higher dosage
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Adults with Impaired Renal Function: In patients in whom the creatinine clearance is
1.32 mUs (79 mUmin) or less, the dosage of CefizoxTM must be reduced. Following an initial
loading dose of 500 mg to 1.0 g IM or IV, the maintenance dosing schedule presented in
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Diaphragmatic Resection in Association
With Right Hepatectomy
C.H. Scudamore. MD. MSc. FRCSC, FRCS(Edin), FRCS, FACS;* C.R. Shackleton, MD, FRCPC,
FRCSC;* J.S. Fache, MD. FRCPC;t A.D. Forward, MD, FACS, FRCSC;*
S.R. Erb, MD. FRCPCJ

Ten cases of combined diaphragmatic and hepatic resection for tumours involving
both structures are described. A complete work-up, including ultrasonography and
computed tomography, usually can predict potential direct spread to the diaphragm.
Up to 50% of the diaphragm can be excised and reconstructed without the need for
prosthetic mesh or tissue transfer. Diaphragmatic resection does not appear to cause
long-term postoperative morbidity. Diaphragmatic invasion by primary or secondary
tumours does not preclude resection for cure. Pulmonary function studies are not
necessary if there is no serious pre-existing lung disease.

On decrit 10 cas de resections diaphragmatique et hepatique concomitantes pour
atteinte tumorale de ces deux structures. Un examen complet, comprenant une
echographie et une tomodensitometrie, peut habituellement predire la possibilite
d’un envahissement direct du diaphragme. Jusqu’a 50% du diaphragme peut etre
excise et reconstruit sans qu’il y ait necessity d’utiliser une toile prosthetique ou de
transferer des tissus. La resection diaphragmatique ne semble pas etre la cause de
morbidity postoperatoire a long terme. L’envahissement diaphragmatique de tumeurs primitives ou secondaires n’empeche pas une resection a visee curative. Des
examens de la fonction pulmonaire ne sont pas necessaires s’il existe pas de maladie
pulmonaire preexistante serieuse.

resection for benign and
H epatic
malignant conditions has be
come more common over the past
20 years. Death rates for hepatic
resection have fallen to approxi
mately 5% in noncirrhotic pa
tients.1-3 A number of large series
describing hepatic resection for pri
mary and secondary tumours have
provided data for asssessing mortal
ity and long-term morbidity.4-7
Not infrequently, a tumour aris
ing in the right hepatic lobe ex
tends beyond the capsule and be
comes adherent to or invades the
overlying diaphragm. For such con-

ditions, combined surgical resection
of the diaphragm and liver is neces
sary. Because little has been written
about this combined procedure, we
report our experience in 10 pa
tients. Controversy exists regarding
the surgical strategy when a malig
nant tumor extends into the adja
cent diaphragm.

Patients and Methods
All 10 patients (6 men, 4 women)
were treated by the by the hepatobi
liary team at the Vancouver General
Hospital, University of British Co

From the departm ent o f Surgery, fDepartment o f Radiology and f Department o f Medicine,
Vancouver General Hospital, University o f British Columbia. Vancouver. BC
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Correspondence to: Dr. C.H. Scudamore, Department o f Surgery, Vancouver Genera! Hospital
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lumbia between 1983 and 1987.
This series is a retrospective review,
since no patient was excluded from
exploratory laparotomy because of
suspected diaphragmatic involve
ment. The patients ranged in age
from 30 to 76 years (mean 46
years).
Preoperatively, all patients under
went an extensive general medical
and metastatic work-up, which in
cluded chest roentgenography, real
time ultrasonography and computed
tomography. Specific investigations
were added when indicated by the
clinical situation. These included
preoperative and postoperative lung
function studies in three patients,
laparoscopy in two and lung tomog
raphy in two others. In nine pa
tients fine needle aspiration was
attempted for cytologic study; it
confirmed the operative diagnosis in
seven patients. Patients with large
tumours underwent selective mes
enteric angiography, including ve
nous phase portography. Nine pa
tients presented with malignant tu
mours, four metastatic (three colon
ic, one breast) and four primary
(three hepatomas, one mesotheli
oma). One had an echinococcal cyst
invading the diaphragm.
Right hepatic lobectomy was per
formed in five patients: extended
right hepatic lobectomy in three
and segmentectomy in two. Median
sternotomy was required to control
hepatic veins in one patient who
had a hepatoma greater than 30 cm
in diameter. With respect to dia
phragmatic resection, four patients
had central resection, three had
peripheral resection, two had pe
ripheral and central resection and
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only one had an extended resection
to include the abdominal wall. Mesh
repair was not necessary in any of
the 10 patients, even though more
than 50% of the diaphragm was
resected in one case. Eight patients
required tube thoracostomy. No pa
tient required a right lateral thora
cotomy.
When diaphragmatic extension of
the tumour is evident, the operative
technique should be modified so
that en bloc resection can be per
formed. The entire liver should be
mobilized to determine the extent of
disease and ensure that no other
tumours are present in the remain
ing liver. We routinely perform op
erative ultrasonography as well as
bimanual palpation. The lymphnode-bearing areas are carefully in
spected and a biopsy is done if
metastatic disease is suspected.
We open the diaphragm 2 to 3
cm away from any adherent tissue
and explore the thoracic aspect of
the diaphragm. Adherence to lung,
pleural spread, malignant effusion
or mediastinal nodal spread pre
cludes resection. If no contraindica
tions exist, the tumour-bearing liver
and diaphragm are dissected free,
leaving a 2-cm margin of normal
tissue. If the liver is mobile and the
defect is small, we carry out repair
immediately after a tube thoracosto
my has been performed under direct
vision. If the defect is large and
access to the diaphragmatic edges
is difficult, the hepatic resection is
completed to allow adequate access
for repair.
The follow-up in these 10 pa
tients was from 3 months to 5
years.

removal of a large hematoma as a
result of a generalized oozing from
the posterior-inferior diaphragmatic
surface. One patient died on postop
erative day 2 because of an ob
structing mucous plug which pre
vented reintubation. All patients
suffered from atelectasis, but in
only two was major atelectasis (col
lapse of a lobe) or pneumonia diag
nosed postoperatively. Two patients
had a right pleural effusion after
the chest tube was removed. There
were no recorded wound infections
or prolonged periods of endotrache
al inhibition. There were no epi
sodes of eventration or herniation
through the diaphragm (Fig. 1).
The mean hospital stay was 11
days.
Ultrasonography was the most
accurate preoperative investigation

for predicting diaphragmatic in
volvement (in 8 of the 10 patients,
Fig. 2). In one of the remaining two
cases, proximity to the diaphragm
could have been diagnosed, but was
not reported. Computed tomogra
phy is useful in predicting diaphrag
matic involvement especially if a
right pleural effusion is identified,
but this study lacks the dynamic
qualities that ultrasonography can
provide (Fig. 3).
Aspiration cytology was almost
routine before laparotomy, except
when the tumour was small and
inaccessible. No complications de
veloped as a result of tumour aspi
ration. In the patient who presented
with a mesothelioma, the aspiration
biopsy was interpreted as adenocar
cinoma. The echinococcal cyst was
not aspirated. Hepatic angiography
was performed when a major hepat
ic resection was anticipated. It pro
vided valuable results in identifying
anatomic variants preoperatively,
thus adding to the safety and speed
of the hepatic resection. Further
more, angiography may identify
vascular encasement by metastatic
disease and so prevent a fruitless
laparotomy. However, the need for
preoperative angiography is contro
versial.8
Spirometry was performed in
three patients before and after oper-

Results
Two patients required reopera
tion in the early postoperative peri
od because of bleeding; one had an
arterial bleeder on the cut edge of
the diaphragm, the second required
22
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FIG. 1. (Top) Preoperative chest film
showing tumour elevating right dia
phragm. (Bottom) On postoperative
day 7 chest tube has been removed, but
subphrenic drain remains.

FIG. 2. Real-time ultrasonography
showing right hepatic lesion (white
arrow) invading diaphragm (black ar
row).

DIAPHRAGMATIC RESECTION AND HEPATECTOMY

ation. However, the results 7 days
postoperatively were essentially the
same as those preoperatively except
for a minor decrease in the forced
expiratory volume at one second
(Fig. 4). This was thought to be
secondary to pain and weakness in
the abdominal wound. Spirometry
performed 6 weeks after surgery
gave normal results.
Recurrent disease resulted in two
late deaths; one patient had system

ic metastases and the other had
recurrent tumour in the remaining
liver. One patient with a large hepa
toma is alive with brain metastasis.

Discussion
Despite notable advances in sur
gical technique, major hepatic re
section remains a therapeutic chal
lenge. Patients left with residual
disease do not do as well as those in

FIG. 3. Scan shows tumour (arrow) invading posterior lateral diaphragm.

FIG. 4. Results of spirometry done on postoperative day 7 on 66-year-old woman in
whom 80 cm2 of central diaphragm had been removed. (Left) Slightly decreased
lung volumes as compared to control. FEV 1 = forced expiratory volume in one
second, FVC = forced vital capacity. (Right) Mildly restrictive flows but no change
in flow as compared with preoperative values. MMFR = maximal midexpiratory flow
rate (L/s).

whom all recognized disease is re
moved.2-’
Although many have reported en
couraging results after hepatic re
section for secondary malignant dis
ease in selected patients,6 few have
been specific about spread to the
diaphragm. Since no large series of
hepatic resections has addressed the
problem of diaphragmatic exten
sion, the prognosis of combined
resection remains essentially un
known. Many authors report extrahepatic spread as a contraindica
tion for resection.15' 10
Adson6 reported that 18% of pa
tients who underwent hepatic resec
tion for colonic metastases had extrahepatic extension. These patients
probably did poorly because Adson
did not include those who had extrahepatic disease in the overall
survival results. Fortner and col
leagues2 reported only two patients
with diaphragmatic extension in
their series of 247 consecutive pa
tients who had colonic hepatic me
tastases treated by hepatic resec
tion. Both patients died within 7
months of operation.
One of the problems in attempt
ing to analyse the experiences of
others is the difficulty in staging
hepatic metastases. Fortner and col
leagues2 included anatomic and
pathologic criteria in their staging
system so that a small tumour
isolated to a resectable portion of
the liver, theoretically stage I,
would be considered a stage II
lesion if it involved a major vessel
or the bile duct, or extended direct
ly to the diaphragm. There did not
seem to be a substantial difference
in survival between patients who
had stage I or stage II tumours in
Fortner’s series, suggesting that di
rect extension outside the liver cap
sule does not have a negative im
pact on survival if the tumour is
resectable. The criteria for resection
of Logan and colleagues1 would
exclude tumours not confined to
the liver, which would include tuCJS, VOL. 33. NO. 1, FEBRUARY 1990
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mours with diaphragmatic exten
sion. Earlier attempts at staging of
metastatic liver tumours was simply
an estimated percentage of liver
occupied by tumour; however, Pack
and Ariel11 added a (+) after each
stage, signifying the presence of
extrahepatic tumour. Since no relia
ble data exist for direct diaphrag
matic extension, these staging sys
tems may be misleading.12'13
We believe that direct extension
to the diaphragm has the potential
of lymphatic spread into other
channels. One patient had a solitary
hepatic metastasis which was moni
tored for 11 months. At the time of
resection, there was extension into
the diaphragm and diaphragmatic
lymphatics, which was noted only
after a portion of diaphragm was
removed. This extension and lym
phatic invasion likely resulted from
this solitary metastasis. The lym
phatic extension might have been
prevented had the patient under
gone excision earlier.
Hepatoma is one of the world’s
commonest lethal malignant lesions
and is infrequently seen in white
persons.13 Although it has been
mentioned anecdotally, diaphrag
matic resection in combination with
hepatectomy is not an absolute con
traindication for resection of hepa
toma,14 but few authors have de
scribed the long-term results after
diaphragmatic resection. Since most
Asian patients with hepatoma have
cirrhosis, diaphragmatic resection
in combination with hepatectomy is
seldom an option. In noncirrhotics,
or those who have small hepatomas
on the hepatic surface, diaphrag
matic resection should be consid
ered.
The fibrolamellar variant of hepa
toma is most frequently seen in
young, noncirrhotic white patients
and is characterized by its slow
growth. This variant should be ma
naged aggressively. If the tumour
involves the diaphragm, it should
24

be removed with the specimen with
clear resection margins if possi
ble.1516
Diaphragmatic resection has been
described for mesothelioma, but for
the thoracic rather than the perito
neal type. Our patient who had
mesothelioma was initially assessed
2 years before operation; at that
time the biopsy specimen was inter
preted as showing adenocarcinoma.
When a repeat biopsy was done, a
mesothelioma was diagnosed and a
combined hepatic and diaphragmat
ic resection was performed. The
patient is disease free 2 years lat
er.17
Resection of the diaphragm for
hydatid disease of the liver has been
well described.18 We included this
case only to illustrate that the full
thickness of the diaphragm need
not be excised. It is not established
whether a full-thickness portion of
diaphragm must be taken to pre
vent regional spread if a tumour is
partially invading the diaphragm. A
frozen section of the resection mar
gins should be obtained before dia
phragmatic reconstruction is at
tempted.19-21
Until prospective data are avail
able, we believe that direct exten
sion of a hepatic tumour into the
adjacent diaphragm is not a contra
indication for resection, provided
the whole lesion can be removed en
bloc.
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Follow-up of Patients Who Have
Undergone Ileogastrostomy
C.K. Dingee, MD; I.G.M. Cleator, MB, ChB, FRCSC, FRCS(Edin), FRCS, FACS;
J.K. MacFarlane, MD, CM, MSc, FACS, FRCSC; R.M. Christensen, MD, FACS, FRCSC;
C.L. Birmingham, MD, FRCPC; J. Appleby, MD; R.H. Gourlay, MD, FRCSC
Patients who have had ileogastrostomy for the treatment of morbid obesity require
close, long-term follow-up. From a prospective study of a large number of variables
in 12 consecutive patients, and from experience with more than 200 patients who
have undergone this procedure since 1982, a protocol has evolved. The authors
outline the associated morbid conditions, operative complications and biochemical
alterations that are important in the management of these patients.

Les patients ayant subi une ileogastrostomie dans le cadre d’un traitement contre
l’obesite morbide doivent etre suivis de pres sur une longe periode. II a ete possible
d’etablir un protocole d’apres une etude prospective d’un grand nombre de variables
realisee sur 12 patients de suite et grace aux enseignements pratiques tires de plus
de 200 patients qui ont subi cette operation depuis 1982. Les auteurs decrivent les
conditions associes morbides, les complications operatoires et les modifications
biochimiques qui sont si importantes dans les soins et le traitement de ces patients.

for the treatment
I leogastrostomy
of morbid obesity has been de
scribed by Cleator and Gourlay.12
At St. Paul’s Hospital in Vancouver,
the procedure has been performed
in over 200 patients since its intro
duction in 1982. Other surgeons as
far away as Australia are now carry
ing out this procedure. Close fol
low-up of patients who undergo
ileogastrostomy is essential, and
their availability for long-term as
sessment is a prerequisite for sur
gery. The purpose of this paper is
to introduce our protocol for the
pre- and postoperative assessments
of morbidly obese patients.

The Surgical Procedure
As previously described,1 an end-

to-end jejunoileal bypass is con
structed, with the proximal jejunum
measuring 25 cm and the distal
ileum 50 cm (Fig. 1). The proximal
end of the resultant blind loop is
closed and a wide antecolic anasto
mosis is carried out between the
distal blind loop and the parietal
cell mass area of the anterior stom
ach.

who have undergone ileogastrosto
my since 1982 has identified the
late complications that may be ex
pected.
Statistical analysis of the physio
logic variables was carried out by
constructing confidence intervals to
bracket the true change in variables
in the 12 patients.

Results
Significant changes (p < 0.05)
were noted in a number of variables
(Table I). There was a significant
decrease in serum carotene, iron
and blood urea nitrogen levels.
There was a significantly (p < 0.05)
large fall in cholesterol, LDLcholesterol and triglyceride levels
and a smaller but still significant
decrease in the HDL-cholesterol
level. The alkaline phosphatase, as
partate aminotransferase and lactic
dehydrogenase levels increased sig
nificantly. However, there was a
high incidence of hepatic steatosis

Patients and Methods
Our protocol evolved from an
analysis of the data from a series of
12 consecutive morbidly obese pa
tients who underwent ileogastrosto
my. A large number of variables
were measured pre- and postoperatively (Table I). Long-term follow
up of these and 200 other patients
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FIG. 1. Ileogastrostomy.
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preoperatively. Long-term follow-up
showed that at 18 months 86.3% of
the patients had normal liver func
tion; the remainder had minimal
disturbance of liver function, with
less than 10% increase in liver en
zyme levels. There was a mean
weight loss of 22.9 kg (range from
10.9 to 36.5 kg). The 3-day calorie
counts demonstrated a postopera
tive decrease in calorie consumption
of 320 to 3870 kcal (mean 1975
kcal) (1339 to 16 192 kJ [mean
8263 kJ]).

The Protocol
A comprehensive computer form
is used to enter data prospectively.
Each patient is given a study num
ber. Standard demographic data are
recorded. Patients are defined as
being morbidly obese according to
the Metropolitan Life Insurance
Company 1983 tables.3 The age of
onset of obesity, the coexistence of
obesity in parents and siblings and
the qualitative calorie intake are
included to stress the important
contribution of heredity, environ
ment and psychosocial factors.
Excess weight affects all organ
systems and there is a direct rela
tionship between the degree of mor
bid obesity and the incidence of
cardiovascular, pulmonary, locomo
tor, endocrine, gastroenterologic
and renal problems that shorten
life.43 It is mandatory to recognize
and assess serious coexisting condi
tions in obese patients. In our pro
tocol, the presence of coincidental
disease is noted under each organ
system. Not only are medical condi
tions for which ileogastrostomy is
contraindicated readily identified,
but an accurate preoperative record
is made of preexisting disease,
which otherwise might later be in
terpreted as a result of the opera
tion (Table II).
The ideal candidate for bypass
surgery is young (aged 18 to 50
26
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years), intelligent, well motivated
and psychologically stable6 Most of
these patients have had repeated
failures of attempts to reduce

weight medically with diet, behavi
our modification and medication.
Some have had surgical procedures
previously. The salient features of

Table I. Blood Biochemistry: Deviations From Normal Values in St. Paul’s Hospital, Vancouver,
Laboratory
Variable
measured

Test
Malabsorption
Fat soluble vitamins
A
D
K
Fat
Carbohydrate
Liver function

Carotene, Mmol/L
Calcium, m m ol/L
Prothrombin time, s
72-h stool, g/d
Glucose, m m ol/L
Albumin, g/L
Protein, g/L
Alkaline phosphatase, U/L
Aspartate aminotransferase,
U/L
Lactate dehydrogenase, U/L
Bilirubin, Mmol/L
Electrolytes
Na, mmol/L
K, mmol/L
Cl, mmol/L
Mg, mmol/L
Renal function
Blood urea nitrogen, m m ol/L
urea
Creatinine, Mmol/L
Hematologic measurements Hemoglobin, g/L
Leukocytes, x 109 /L
Platelets, x 109 /L
Partial thromboplastin time, s
Thyroid function
Thyroxine, pmol/L
Thyroid stimulating hormone,
mU/L
Lipid studies
Cholesterol, mm ol/L
HDL-cholesterol, m m ol/L
LDL-cholesterol, mm ol/L
Triglycerides, mm ol/L
Miscellaneous
Iron, Mmol/L
Uric acid, Mmol/L
Phosphorus, m m ol/L

Preop

Postop

Significance

1.92
2.30
12.32
34.2
5.31
40.2
67.3
83.25

0.33
2.30
12.72
143.4
5.23
40.2
67.0
113.58

<0.05

32.33
192.17
9.58
140.25
4.13
106.33
0.81

55.18
227.83
10.6
143.33
3.60
108.17
0.68

<0.05
<0.05

4.00
75.14
139.10
7.57
292.33
29.09
15.19

2.95
73.37
135.30
6.66
262.92
31.61
14.67

<0.05

2.71
5.65
1.01
3.56
2.06
16.97
375.32
1.05

2.14
3.08
0.65
1.71
1.57
11.95
347.96
1.04

<0.05

<0.05

<0.05

<0.05
<0.05

<0.05
<0.05
<0.05
<0.05
<0.05
<0.05

Table II. Information Obtained on the Preoperative Assessment Form
Date information taken
Sex
Date of birth
Height in cm
Weight in kg
Bone structure (light
medium, heavy)
Ideal weight
Age onset of obesity
Average daily caloric
intake
Mother/father obese
No. brothers
No. brothers obese
No. sisters
No. sisters obese
Coincidental conditions
(yes = 1, no = 2)
Cardiac
Hypertension

Thrombophlebitis
Other
Asthma (specify)
Chronic obstruction
Sleep apnea
Other (specify)
Osteoarthritic knees
Spinal pain
Gout
Other (specify)
Diabetes mellitus
(diet controlled)
Oral hypoglycemia
Insulin dependence
Cushing’s syndrome
Stein—Leventhal syndrome
Other (specify)
Cholelithiasis
Fatty liver
Peptic ulcer

Other (specify)
Renal-parenchymal
Obstructive stones
Other
No. pregnancies
Hysterectomy
Previous admission to
psychiatry
Lithium or major tranquillisers
at any time
Other (specify)
No. previous hospital
admissions for obesity
No. previous hospital
admissions for other
Previous surgery for obesity
Previous surgery for other
reasons

ILEOGASTROSTOMY
the medical and psychiatric history
are recorded on an assessment form
(Table II). Although it has been
used mainly for follow-up of ileogastrostomy patients, this form can
also be used in the follow-up of
patients who undergo gastroplasty
or other obesity procedures.
All complications encountered in
the postoperative period are tabulat
ed (Table III). From our experience
with 200 patients, the most fre
quent complications are wound in
fections (6.6%), respiratory compli
cations (2.2%) and electrolyte dis
turbances requiring correction
(6.8%). Although 70% of patients
had loose bowel movements at 3

months after operation, this prob
lem subsequently resolved.
Milk and milk products are dis
couraged in the early postoperative
period. The only dietary supplement
is one multivitamin tablet daily.
Patients are followed up by the
attending surgeons at monthly in
tervals until the bowel and blood
biochemistry have stabilized, then
at 3-monthly intervals for 1 year
and every 6 months for 1 year. In
addition, when the patient lives in a
geographically remote area, the re
ferring physician receives a copy of
the protocol and checks on the
patient between visits to the sur
geon. At each visit, the patient is

T a b le III. Inform ation Obtained on the Postoperative Assessment Form

Date of operation
Postoperative complications
Pulmonary
Failure
Atelectasis
Pneumonia
Embolism
Other
Cardiac
Failure
Arrhythmia
Pericarditis
Other
Wound
Sepsis
Dehiscence
Subphrenic abscess
Intra-abdominal abscess

Gastrointestinal
Stomal ulcer
Liver failure
Anastomotic leak
Other
Renal
Stones
Sepsis
Other
Lower limb
Phlebothrombosis
Other complications (list)
Separation
Alive
normal convalescence
stay increased by com plications
Died in hospital
date
cause

T a b le IV. Laboratory Inform ation Obtained on Admission, at 3-M onth Intervals fo r 1 Year and at

6-M onth Intervals Thereafter
Date
Weight in kg
Girth measurement
waist
hips
Average daily caloric intake
last week
Cholesterol
HDL-cholesterol
LDL-cholesterol
Triglycerides
Glucose
Hemoglobin
Leukocyte count
Alkaline phosphatase
Aspartate aminotransferase
Potassium

Blood urea nitrogen
Creatinine
Uric acid
Carotene
Iron
Magnesium
Calcium
Vitamin B12
Folic acid
Urinalysis
normal
abnormal
specify abnormality
Bowel status
flatus and bloat
no. formed bowel m ovem ents/d
no. loose bowel m ovem ents/d

weighed, and waist and hip mea
surements are taken. A number of
blood tests (those shown to change
substantially postoperatively) are
also done. They are: lipid profile,
complete blood count, tests of liver
and renal function, and selected
tests to screen for malabsorption
(Table IV). Persistent oxaluria has
been noted in several patients. This
is not corrected by the oral adminis
tration of calcium. Vegetables,
which are high in oxalates, for
example, are discouraged.
At each follow-up visit, the pa
tient is also questioned regarding
any change in bowel habit, the
frequency and consistency of stool
and the presence of excessive flatus
or bloating. Dietary indiscretion was
the cause of bloating in some pa
tients, and at 18 months after oper
ation 35% experience bloating occa
sionally. The bloating can be cor
rected in many patients by the use
of 250 mg of Flagyl daily.
Ileogastrostomy has been sug
gested as an effective treatment for
morbid obesity, and we have found
this protocol to be effective in the
management of these patients, both
preoperatively and postoperatively.
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Hydatid Cyst Presenting As a Breast
Lump
J.M. Radhi, MB, ChB, MRCPath; M.J. Thavanathan, MB, BS, FRCS(Edin)*
Cystic hydatid disease is caused by the parasite Echinococcus granulosus.
Indigenous infections are seen among the Indians and Inuit. Man is an occasional
intermediate host in whom the disease is manifested by the presence of one or more
hydatid cysts, usually located in the liver or lung and rarely at other sites such as
the breast, as in this case report. The cyst is usually asymptomatic; in this it case
was discovered on routine mammography. On aspiration biopsy, 1 ml of clear fluid
was removed, but there was a residual lump which was successfully excised.

L’hydatidose est causee par le parasite Echinococcus granulosus. On peut rencontrer des infections indigenes parmi les Amerindiens et les Innus. L’homme est un
hote intemediaire occasionnel chez qui la maladie se manifeste par la presence d’un
ou plusieurs kystes hydatiques habituellement localises au foie ou aux poumons et,
rarement, a d’autres endroits tels que le sein, comme on le signale dans cet article.
Le kyste est habituellement asymptomatique. Dans le present cas, il fut decouvert
lors d’une mammographie de pratique courante. A la ponction-biopsie, 1 ml de
liquide clair fut retire, laissant une masse residuelle qui fut excisee avec succes.

C

ompared with the European
form, hydatid cysts in northern
North America and Alaska are smal
ler, more delicate in structure,
cause fewer symptoms and compli
cations and have an excellent prog
nosis.1 We describe the case of a
31-year-old woman who had a
breast lump which, on pathological
examination, was found to be a
hydatid cyst. To our knowledge,
this represents the first case of

hydatid disease of the breast report
ed in Newfoundland and Labrador.

Case Report
A 31-year-old Inuit woman pre
sented with a lump in the right
breast which had been detected by
her family doctor on routine exami
nation. She did not have any pain
or discharge from the nipple. There

From the Charles S. Curtis Memorial Hospital, Grenfell Regional Health Services, St. Anthony,
Nfld.

was no family history of breast
cancer. She was taking Triphasil
contraceptive pills.
On examination, the left breast
was normal. The right breast was
slightly smaller and there was dif
fuse, brownish speckling of the
skin. A mobile lump, 2 X 1.5 cm in
dimension, was palpable in the 12
o’clock position. Both nipples were
normal. There was no axillary or
supraclavicular lymphadenopathy.
Abdominal examination did not re
veal any organomegaly. The chest
x-ray film appeared normal. On nee
dle aspiration of the lump in the
right breast, 1 ml of clear fluid was
obtained. Post-aspiration examina
tion revealed a residual lump, so an
excisional biopsy was done.
The mass appeared to be a cyst
with thickened membranes. On
gross examination, the specimen
measured 4 X 3 X 3 cm and
consisted of fibrofatty tissue, in
which was included an open fibrous
walled cyst measuring 2.5 cm in
diameter with a semitranslucent,
shiny inner surface (Fig. 1). Micro
scopically, the fibrocollagenous wall
was infiltrated by lymphocytes and
eosinophils. Within the lumen were
germinal layers, laminated mem
branes, scolices and hooklets, char
acteristic of a hydatid cyst.

*Surgeon, Melville Hospital, Grenfell Regional Health Services. Goose Bay. Labrador
Accepted for publication Jan. 16, 1989
Reprint requests to: Dr. J.M. Radhi, Pathologist, Charles S. Curtis Memorial Hospital, Grenfell
Regional Health Services, St. Anthony, Nfld. AOK 4S0
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larval tapeworms of the genus Echi
nococcus. Echinococcus granulosus
is the most common species, but
Echinococcus multilocularis and
Echinococcus olgarthrus also infect
man.
This disease used to be a serious
problem in sheep-raising regions,
especially Australia, New Zealand
and Iceland. Today, it is most prev
alent in East Africa, Mediterranean
countries, some parts of the USSR
and Middle East, South America,
Uruguay, Chile and Argentina. In
fections are seen among Indians in
the southwestern United States and
in Indians and Inuit in the northern
regions of North America.1
The definitive host includes many
species of carnivores, the most im
portant being the dog. Gravid proglottids pass in the feces and rup
ture, releasing eggs that are swal
lowed by the intermediate host
mammal. The eggs hatch in the
intestine, releasing oncospheres
that penetrate the intestinal muco
sa, enter the blood stream and
develop into hydatid cysts in vari
ous organs and tissue. The life

FIG. 1. Thick-walled cyst having semitranslucent inner surface.
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cycle is completed when a cyst is
ingested by a definitive host.
Hydatid disease of the breast is
extremely rare.2 In our patient, the
breast lump was noted incidentally
on a routine medical examination.
Typically, the patient presents with
a long history of a breast lump, and
mammography reveals an opacity
with calcification which must be
differentiated from that of a calci
fied fibroadenoma. Immunologic
tests such as intradermal and indi
rect hemagglutination tests are
rarely performed and vary in degree
of reliability.3
From the clinical standpoint, the
differences between E. granulosus
of northern North America and the
standard European type are out
standing. The laminated membrane
is delicate, bluish and semitranslucent, reminiscent of waxed paper, in
the North American hydatid cyst
but, in the European type, it resem
bles the white of a boiled egg.1
Some of the peculiarities recognized
by Cameron4 led Wilson and associ
ates5 to propose that the North
American form be designated a vari
ety of E. granulosus and called E.
granulosus var. canadiensis. The
larval stage of this form has adapt
ed to development in large deer,
especially moose, reindeer and cari
bou. The wolf is the natural defini
tive host and dogs can become
infected; domestic animals such as
sheep, cattle and pigs are resistant
to the parasite. In the European
type, the cysts most commonly
occur in the liver, whereas the lung
is the most commonly affected

organ in the North American type.
The size of the cyst in the latter
type rarely exceeds 6 cm in diame
ter, but in the former, cysts may be
much larger. Cyst rupture and
other complications are less fre
quent in the North American type.
If the cysts do rupture, the risk of
secondary growth of germinal ele
ments or anaphylaxis is not great,
and the prospect of spontaneous
cure without complications seems
excellent.
It has been suggested that the
clinical differences between the Eu
ropean and North American forms
of E. granulosus may be explained
by the fact that man is apparently
not as suitable a host for the North
American type of the parasite as he
is for the European type.5
We thank Dr. M. Gillett for his com
ments, Mrs. Cora Snow for typing the
manuscript and Mr. Anthony Cronhelm
for the photography.
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Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table
with recommended mode of reconstitution according to route of administration).
P R E S C R IB IN G IN F O R M A T IO N
Action
In vitro studies indicate that the bacterial action ol Claforan (cefotaxime sodium) a semi synthetic cephalosporin
antibiotic, results from inhibition of cell wall synthesis.

Adults
The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the infection
and condition of the patient.
Guidelines for Dosage of Claforan (cefotaxime sodium)

Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible
strains of the designated micro organisms in the diseases listed below.
Lower respiratory tract in fe c tio n s : pneumonia and lung abscess caused by Streptococcus pneumoniae
(formerly Diplococcus pneumoniae), other streptococci (excluding enterocci, e.g. S. faecalis), Straphylococcus
aureus (penicillinase and non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract infe c tio n s: caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae),
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
B acterem ia/S e pticem ia: caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing, S. epidermidis,
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus
Intra-abdom inal in fe c tio n s: caused by Escherichia coli, and unspecified Klebsiella species.
Gynecological infe c tio n s: including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by
E. coli, Group A streptococci and Staphylococcus epidermidis, anaerobic bacteria including unspecified Peptococcus
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures
were achieved, bacteriological follow up was not available.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci.
Claforan has been shown to be active against some strains of Pseudomonas
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re evaluated once these results become available.
Prophylactic U s e : The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively)
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudom em branous colitis has been reported w ith the use of cephalosporins (and other broad spectrum
antibiotics); therefore, it is im po rtant to consider its diagnosis in patients who develop diarrhea during
the adm inistration of Claforan. This colitis can range from m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic.
Moderate to severe cases should be managed with fluid, electrolyte and protein supplemntation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions).
Precautions
Claforan (cefotaxime sodium) should be prescribed with cauton in individuals with a history of lower gastro
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child-bearing potential requires that the anticipated benefits be weighed against the
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the
patient's condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended,
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and
prolonged serum antibiotic concentrations.
Positive direct Coomb's test is known to develop in individuals during treatment with the cephalosporin group of
antibiotics, including cefotaxime sodium.
In laboratory tests a (also positive reaction to glucose may occur with reducing substances but not with the use
of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
Hypersensitivity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%): Colitis,
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan
treatment. Hemic and Lym phatic System ( < 1%): Mild, reversible leukopenia, granulocytopenia and thrombo
cytopenia have been reported. Some patients developed positive direct Coomb's test during treatment with
Claforan. G enitourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient elevations in SGOT, SGFT,
serum LDH and serum alkaline phsphatase levels have been reported Kidney ( < 1%): Increased serum creatinine
and BUN have occasionally been observed. Central Nervous System (0.2%); Headache.

Daily Dose
Type of Infection

(g)

Frequency and Route

Uncomplicated Gonorrhea

1

1 g IM (single dose)

Uncomplicated infections

2

1 g every 12 hours IM or IV

Moderately severe to severe infections

3-6

1-2 g every 8 hours IM or IV

Very severe infections (e.g. septicemia)

6-8

2g every 6-8 hours IV

Life-threatening infections

up to 12

2 g every 4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are
as follows.
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery
The total cumulative prophylactic dose should not exceed 6g in a 12 hour period
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended
Neonates:
0-1 week of age
50 mg / kg IV q 12 h
1-4 weeks of age
50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe
infections.
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary
tract infections and may be required for several months after therapy has been completed; persistent infections may
require prolonged treatment. Doses less than those recommended should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 the dose of Claforan should be
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient)
may be used to convert these values into creatinine clearance.
M ales:

Weight (kg) x (140 - age)

Females:

0.85 x above value

72 x serum creatinine

Administration
Intra m u scu la r: Claforan should be injected well within the body of a relatively large muscle such as the upper
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a
blood vessel.
Intravenous: The intravenous route is preferable for patients with bacteremia, bacterial spticemia, or other severe
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes.
Using an infusion system, it may also be given over a longer period of time through the tubing system by which
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue
temporarily the administration of other solutions at the same site.
ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP.
Stability
Solutions of Claforan reconstituted in 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP in the
ADD-V&ntage* flexible containers maintain satisfactory potency for 12 hours at room temperature.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vcintage* vials containing 1.0 and 2.0 g of cefotaxime sodium
(expressed as acid on a dry basis).
S tora ge: Claforan in the dry state should be stored at room temperature protected from light and heat.
Product monograph available on request.
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Desmopressin Acetate in Uncomplicated
Coronary Artery Bypass Surgery: a
Prospective Randomized Clinical Trial
Giles S. Hedderich, MD; Dimitri J. Petsikas, MD; Bernard A. Cooper, MD, FACP, FRCPC;
Mavis Leznoff, RT; Albert J. Guerraty, MD, FRCSC; Normand L. Poirier, MD, FRCSC;
James F. Symes, MD, MSc, FRCSC; Jean E. Morin, MD, FACS, FRCSC
Bleeding in coronary artery bypass procedures increases morbidity and exposes
patients to the risks associated with blood transfusion. Desmopressin acetate
(DDAVP), a synthetic vasopressin analogue, may limit bleeding during cardiac
surgery. In a prospective randomized trial, the authors evaluated the ability of
DDAVP to reduce perioperative bleeding during uncomplicated coronary bypass
operations.
Sixty-two patients who underwent coronary artery bypass grafting were
randomized to receive intraoperatively either a placebo or DDAVP. Both groups
were similar with respect to operative characteristics and preoperative hematologic
profiles, von Willebrand factor levels increased postoperatively in both placebo (2.77
± 1.06 versus 2.17 ± 1.51 U) and DDAVP groups (2.75 ± 0.94 versus 1.80 ± 0.88
U). Only the increase in the DDAVP groups was significant (p < 0.001). There was
no difference in total blood loss between the placebo (1826 ± 849 ml) and DDAVP
groups (1716 ± 688 ml). Total red cell transfusions were similar in placebo (3.4 =t
1.3 units of blood) and DDAVP groups (3.6 ± 0.8 units).
These results do not support the intraoperative use of DDAVP to reduce
perioperative bleeding in routine coronary artery bypass surgery.

Les pertes sanguines peroperatoires lors de pontages coronariens augmentent la
morbidity et exposent les patients aux complications des transfusions. L’acetate de
desmopressin synthetique (DDAVP) peut possiblement diminuer les pertes sangui
nes. Dans cette etude, les auteurs evaluent de fafon prospective la valeur de son
usage pour diminuer les pertes sanguines peroperatoires lors de pontages
aortocoronariens conventionnels.
Soixante-deux patients ont re?u soit un placebo ou du DDAVP. Les deux groupes
avaient des profiles hematologiques semblables. Le niveau du facteur von Wille
brand augmenta dans les deux groupes; placebo (2.77 ± 1.06 versus 2.17 ± 1.51 U)
et DDAVP (2.75 ± 0.94 versus 1.80 ± 0.88 U). Seulement l’augmentation dans le
groupe DDAVP etait significative (p < 0.001). II n’y a pas de difference dans les
pertes sanguines entre le groupe placebo (1826 ± 849 ml) et DDAVP (1716 ± 688
ml). La quantite de sang transfusee n’est pas differente entre les deux groupes —
placebo (3.4 ± 1 .3 unites de sang) et DDAVP (3.6 ± 0.8 unites).
Cette etude ne supporte pas l’usage de DDAVP lors d’operations pour pontages
coronariens de routine en vue de diminuer les pertes sanguines.
From the Cardiovascular & Thoracic Surgery Service and Division o f Hematology-Medical
Oncology, Royal Victoria Hospital, McGill University, Montreal, PQ
Accepted fo r publication Feb. 15, 1989
Reprint requests to: Dr. Jean E. Morin, Ste. S8.30, Royal Victoria Hospital, 687 Pine Ave W.
Montreal. PQ H3A 1A1

lthough the morbidity and
mortality after coronary artery
bypass have been reduced, perioper
ative bleeding continues to pose
problems. Most patients who re
quire re-exploration because of he
morrhage have bleeding due to the
surgical procedure, 12 but others
have diffuse hemorrhage due to
abnormal hemostasis. Coagulopa
thies associated with cardiopulmo
nary bypass include thrombocyto
penia, qualitative platelet defects,
decreased clotting-factor concentra
tions and fibrinolysis.3-5 Excessive
protamine sulfate, unneutralized
heparin,6 heparin rebound7 and anti
platelet agents may also contribute.
It has also been suggested that
cryoprecipitate-thrombin glue ,8 fi
brin glue ,9 the serine protease in
hibitor aprotinin , 10 and the synthet
ic vasopressin analogue desmo
pressin acetate (DDAVP) 11 all mini
mize blood loss after cardiopulmo
nary bypass procedures. Desmo
pressin acetate may act by releasing
endogenous Factor VIILvon Wille
brand factor 1213 and increasing
platelet aggregation . 1415 A previous
study 11 demonstrated a substantial
reduction in blood loss when
DDAVP was administered during a
variety of cardiac procedures. To
assess the effect of intraoperative
DDAVP administration on perioper
ative bleeding and transfusion re
quirements after uncomplicated cor
onary artery bypass operations, we
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undertook a randomized prospec
tive clinical trial.

Patients and Methods
Sixty-two consecutive patients
(47 men, 15 women) who under
went uncomplicated coronary artery
bypass grafting were entered into
the study. Patients were assigned to
either treatment (31) or placebo
(31) groups using a computer
generated random number table.
Preoperative intake of antiplatelet
agents (within 7 days) was noted.
Immediately after administration of
protamine sulfate, patients received
a 100-ml saline infusion over 15
minutes containing a placebo or
desmopressin acetate (Ferring Phar
maceuticals, Malmo, Sweden) (0.3
Mg/kg). Blood was collected before
the induction of anesthesia, and at
1 and 24 hours postoperatively, to
measure hemoglobin concentration,
platelet count, prothrombin time
(PT), partial thromboplastin time
(PTT), fibrinogen concentration and
plasma Factor Vllhvon Willebrand
factor activity. All samples were
obtained from a flushed arterial
catheter.
Platelet-poor plasma was pre
pared by centrifugation from blood
collected in vacutainer tubes (Becton-Dickinson Canada Ltd., Missis
sauga, Ont.) containing buffered so
dium citrate. Aliquots were stored
in polypropylene tubes at -2 0 °C .
von Willebrand factor antigen was
assayed by ELISA assay (Diagnostica, Stago Co., Asniere-sur-Seine,
France) using micro-ELISA plates
(Linbro Scientific Co., Hamden,
Conn.) and a Behring ELISA II
reader (Behring Diagnostics, Hoechst Canada Inc., Montreal, PQ).
Values obtained with this method
correlated well when compared with
those determined using Laurel
rockets and commercial antiserum.
Fibrinogen levels were determined
34
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using a commercial version of the
Clauss technique (Fibriquick; Orga
non Teknika Corp., Oklahoma City,
Okla.). Prothrombin time and PTT
were determined automatically
using a Coag-a-Mate X-2 (Organon
Teknika Corp.). Intraoperative
blood loss was determined by tabu
lating suction drainage and by
weighing sponges. Postoperatively,
mediastinal sump and chest-tube
drainage were measured hourly for
18 hours. The volume of red cell
transfusion was tabulated intraoperatively and for 48 hours postopera
tively. Perioperative myocardial in
farctions were diagnosed if new
characteristic changes were present
on the electrocardiogram.
The data are expressed as the
mean ± standard deviation. Statisti
cal analysis was by Student’s f-test
(two-tailed) for the comparison of
sample means and by the x 2 test for
comparison of nominal data.

Results
The mean age of the patients was
59 ± 9 years in the placebo group
and 61 ± 10 years in the DDAVP
group. Calculated body surface area
was 1.88 ± 0.19 m2 in the placebo
group and 1.90 ± 0.19 m2 in the
DDAVP group. Thirteen patients in
the placebo group and 12 in the

DDAVP group took antiplatelet
agents in the 7 days preceding
surgery. Both groups had similar
preoperative hemoglobin concentra
tions, platelet counts, fibrinogen
and Factor VIILvon Willebrand fac
tor plasma levels and prothrombin
and partial thromboplastin times
(Table I). There were no significant
differences between the groups with
respect to the number of coronary
bypasses performed, previous coro
nary bypass surgery, unilateral or
bilateral internal mammary grafts,
and the duration of extracorporeal
circulation (Table II). Three patients
(10%) in the placebo group and two
(6.5%) in the DDAVP group suf
fered perioperative myocardial in
farction. There were no periopera
tive deaths.
Four patients were re-explored
for postoperative bleeding of more
than 200 m l/h; three were in the
DDAVP group. One of the three
had diffuse oozing while the other
two had identifiable bleeding points,
as did the fourth patient in the
placebo group. The three patients
with surgical bleeding were exclud
ed from further study.
There were no significant differ
ences in total blood loss or in the
number of units of red cell transfu
sion. Blood loss intraoperatively
and at each postoperative interval
were similar (Table III).

Table 1. Preoperative Hematologic Profile (Mean ± SD)
Measurement

DDAVP

Placebo

Platelets, x 109/L
Hemoglobin, g/L
Prothrombin time, % of control
Partial thromboplastin time, % of control
Fibrinogen, g/L
von Willebrand factor, U (arbitrary units)

247 ± 75
136 ± 18
100.22 ±9.47
99.61 ± 19.51
3.22 ± 1.13
2.17 ± 1.51

242
141
97.03
100.75
2.88
1.80

± 61
± 20
±7.15
±26.62
± 0.83
±0.88

Table II. Operative Characteristics (Mean ± SD)
Characteristic
Duration of extracorporeal circulation, min
No. of coronary artery bypasses per patient
No. of redo operations
No. of single mammary artery procedures
No. of double mammary artery procedures

Placebo

DDAVP

89 ± 24
3.4 ± 1.3
3
13
16

92 ± 21
3.6 ± 0.8
4
15
16

DESMOPRESSIN IN CORONARY BYPASS

Postoperatively there was only a
small, but significant, reduction in
the platelet count in the DDAVP
group (Table IV). Factor Vllhvon
Willebrand factor levels were similar
between the groups; however, the
levels before operation (1.80 ± 0.88
U [arbitrary units]) and 1 hour
postoperatively (2.75 ± 0.94 U) in
the DDAVP group were significant
ly different (p < 0.001). Although
factor Vllhvon Willebrand factor
plasma levels increased similarly in
the placebo group (2.77 ± 1.06
versus 2.17 ± 1.51 U), the differ
ence was not significant.

Comment

Desmopressin acetate has benefi
cial effects in various congenital
and acquired hemostatic disorders,
including hemophilia,816 von Willebrand’s disease,8-17 uremia,15 as well
as intrinsic and Aspirin-induced
platelet defects.18 Its use has also
limited blood loss associated with
cardiopulmonary bypass.11-19 The
primary mechanism of action seems
to be the release of endogenous
stores of Factor Vllhvon Willebrand
factor (specifically, the high mole
cular weight forms of Factor VIIIrelated antigen).13-15-16-20 Additional,
indirect effects on platelets and the
blood vessel wall have been sug

gested.18-21 Increases in Factor VIII:von Willebrand factor levels corre
late with shortening of the bleeding
time in various hemorrhagic disor
ders.18
A previous prospective study as
sessed the prophylactic use of
DDAVP in various open-heart surgi
cal procedures.11 The drug was also
administered immediately after prot
amine sulfate was given. Total
blood loss was significantly de
creased in the DDAVP group com
pared with controls. Red cell trans
fusions in the first 3 postoperative
days, however, were not statistically
different. Czer and colleagues19
noted attenuation of bleeding and a
reduction in the use of blood pro
ducts after the administration of
DDAVP to patients who had exces
sive bleeding after cardiac surgery.
In our study, both groups of
patients were similar with respect to
patient characteristics, preoperative
hematologic profile and operative
procedures. Most patients had one
or both internal mammary arteries
utilized. Platelet counts decreased
in both groups postoperatively, but
this difference may not be clinically
important. The postoperative plate
let count, however, was lower in the
DDAVP group than in the controls.
After DDAVP administration, Kobrinsky and colleagues18 noted simi
lar decreases in platelet counts and

T a b le III. B lo o d L o s s (M e a n ± SO )
D D A VP

P laceb o

Blood loss

1826
775
642
243
148
3 .4

T o ta l, m l
In tra o p e ra tive
0 - 6 h
6 -1 2 h
12 - 1 8 h
T o ta l red c e ll tra n s fu s io n s , u n its

±
±
±
±
±
±

849
474
421
176
89
1.3

1716
845
544
263
156
3 .6

±
±
±
±
±
±

688
440
390
320
95
0 .8

T a b le IV . P o s to p e ra tiv e H e m a to lo g ic P ro file (M e a n ± S D )
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±
±
±
±
±
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1 .2 8
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1 4 .5
4 3 .2
2 .7 5
3.81

±
±
±
±
±

43
1 .3
14.1
0 .9 4
0 .9 4

p v a lu e
< 0 .0 5
NS
NS
NS
NS

volume. The underlying mechanism
may be the drug-induced release of
an abnormal platelet aggregating
factor.14
The intraoperative administration
of DDAVP did not alter total blood
loss or red cell transfusion require
ments in our patients who under
went uncomplicated coronary by
pass procedures. Similar results
have been reported by Rocha and
associates22 in patients who under
went valvular and congenital heart
surgery. Moreover, no significant
differences were observed in in
traoperative blood loss or during
any postoperative interval. The
1-hour postoperative Factor VIII:
von Willebrand factor levels were
significantly increased compared
with preoperative levels in the treat
ment group. A similar rise was
noted in the control group. This
difference, although not statistically
significant, parallels changes seen
with major surgery,23 including
open-heart procedures,1 and other
stressful stimuli.24 It is thought to
be mediated by catecholamines and
other vasoactive drugs.25 In con
trast, Salzman and associates11
noted no change in Factor Vllhvon
Willebrand factor levels after
DDAVP administration, but de
creased levels in the control group.
In this study, we assessed the
effects of DDAVP, given intraoperatively, on blood loss and red cell
transfusion requirements in patients
who had uncomplicated coronary
artery bypass grafting. Operative
procedures consisted exclusively of
coronary revascularization, in con
trast to previous studies of DDAVP
in cardiac surgery.1119-22 In addition,
the duration of extracorporeal cir
culation was up to 44% shorter
than that reported in previous
studies.1119 This is highly signifi
cant since platelet factors are pro
gressively depleted with the dura
tion of extracorporeal circulation,26
resulting in decreased platelet agCJS, VOL. 33. NO. 1, FEBRUARY 1990
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gregation,26-27 hemostatic defects
and increased bleeding. BeurlingHarbury and Galvan28 found signifi
cant depletion of releasable platelet
adenosine diphosphate when their
patient group was categorized by
bypass times more than and less
than 90 minutes. Platelets that
have undergone release reaction
when given to a thrombocytopenic
animal are less effective in reducing
bleeding times than are normal
platelets.29 Desmopressin acetate in
fusion in normal subjects will in
crease Factor Vllhvon Willebrand
factor levels, but will change bleed
ing times only slightly18 or not at
all.12 Shorter pump times in our
study may have preserved intrinsic
clotting mechanisms, making
DDAVP unnecessary, and resulting
in no differences between the
groups.
Prophylactic intraoperative use of
DDAVP may contribute to prema
ture vein graft thrombosis after
coronary bypass.1119 Perioperative
myocardial infarction rates (10%
and 6.5% in the placebo and
DDAVP groups, respectively) in the
present study were less than in the
control group of a recent study.19
Nevertheless, this possibility and
the failure to demonstrate therapeu
tic benefit in the present study
serve to discourage the intraopera
tive use of DDAVP in uncomplicat
ed coronary bypass surgery.
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ORIGINAL ARTICLES

Acute Abdomen in the Patient With a
Ventriculoperitoneal Shunt
D. Patrick, MD;* P. Marcotte, MD;t G.E. Garber, MD, FRCPC
When patients who have a ventriculoperitoneal shunt present with an acute
abdomen, shunt infection may be the cause. The authors relate the cases of three
such patients. Two underwent a laparotomy which failed to show any abnormality
and which in retrospect might have been avoided. They review the literature and
present a systematic approach to the diagnosis and management of this problem.
Specific clues from the patient’s history, physical examination and further
investigation may clarify the diagnosis. When shunt infection cannot be excluded
and the clinical setting does not warrant immediate laparotomy, shunt
externalization, cerebrospinal fluid culture, empiric antibiotic therapy and close
observation of the patient are recommended.

Quand un patient porteur d'une derivation ventriculoperitoneale est vu en abdomen
aigu, on doit soupgonner une infection de derivation. Les auteurs decrivent trois cas
de ce type. Deux patients subirent une laparotomie qui ne revela aucune anomalie et
qui, en retrospective, aurait pu etre evitee. Les auteurs passent la presse medicale
en revue et proposent une approche systematique du diagnostic et du traitement de
cette affection. Des indices specifiques issus de l’anamnese du patient, de l’examen
physique et d’autres examens peuvent permettre de clarifier le diagnostic. Quand la
possibilite d’une infection de derivation ne peut etre eliminee et que le tableau
clinique ne commande pas une laparotomie immediate, la mise a nu de la derivation,
la culture du liquide cephalorachidien, la mise en route d’une antibiotherapie
empirique et une etroite observation du patient sont recommandees.

he ventriculoperitoneal (VP)
shunt is a therapeutic modality
that effectively relieves the symp
toms and signs of hydrocephalus of
diverse causes. However, this device
is a foreign body and its use is often
complicated by such problems as
infection (5% to 27% of cases12) or
mechanical malfunction.

T

When the VP shunt becomes
infected, the patient will often show
signs of fever and have a headache
and neurologic dysfunction. Howev
er, in some instances, the infection
may be insidious and affect the
peritoneal membrane and may
mimic the presentation of a variety
of intra-abdominal disorders.3 The
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clinician is then faced with a diag
nostic dilemma.
In this paper, we describe the
cases of three patients with a VP
shunt who presented with the signs
and symptoms of peritonitis. In re
trospect, two of these patients un
derwent potentially avoidable ab
dominal surgery because the acute
abdomen was precipitated by the
VP shunt infection. We review the
literature on this interesting clinical
problem and suggest a systematic
approach to its diagnosis and man
agement.

Case Reports
Case 1
A 57-year-old man presented in
May 1986 with a ruptured right
middle cerebral artery aneurysm.
After evacuation of the hematoma
and clipping of the aneurysm, his
full recovery was impaired by hy
drocephalus, requiring lumbar-per
itoneal and ventriculoperitoneal
shunt insertion, associated meningi
tis and ventriculitis. At the end of
September, he was discharged to a
rehabilitation facility.
On Oct. 15, he returned to the
emergency room complaining of
right lower quadrant pain, anorexia,
nausea and vomiting. On examina
tion he was alert, oriented and had
a supple neck. Head and neck,
chest and cardiovascular examina
tions were unremarkable. His
scaphoid abdomen was rigid and
CJS, VOL. 33, NO. 1, FEBR U A R Y 1990
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there was right lower quadrant
guarding and rebound tenderness.
Bowel sounds were present but di
minished. The leukocyte count was
10.3 X 109/L with 8.9 X 109/ L
granulocytes. The remaining labo
ratory results were unremarkable.
Because the patient had recently
been on tetracycline, it was felt that
he possibly had a masked acute
appendicitis. A slightly inflamed ap
pendix was removed at surgery.
Pathological examination of the ap
pendix showed a well-preserved mu
cosa with no evidence of appendici
tis. Culture of a peritoneal swab
grew Staphylococcus epidermidis.
Postoperatively, the patient had a
persistent low-grade fever which ap
peared to be resolving at the time
he was discharged from hospital on
Oct. 22. Five days later he returned
to hospital with fever and an im
paired level of consciousness. He
was unresponsive and had a temper
ature of 39.5°C. His bone flap was
bulging but not tense. Chest, car
diovascular system and abdominal
findings were unremarkable. Lum
bar puncture gave negative results
and computed tomography showed
mild ventricular dilatation. The leu
kocyte count was 17.3 X 109/L
with 15.9 X 109/L granulocytes.
The diagnosis was presumed to be
shunt infection, so vancomycin hy
drochloride and rifampin were start
ed. The lumbar-peritoneal shunt
was removed and the ven
triculoperitoneal shunt external
ized, then revised. The patient's
sensorium gradually cleared over
the week after externalization. Cul
ture of the removed lumbar perito
neal shunt showed heavy growth of
S. epidermidis with the same sensi
tivity pattern as that grown from
the swab of the patient’s appendix
during the previous hospitalization.
Case 2
A 74-year-old Roman Catholic
38
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priest with a history of severe ath
erosclerosis presented in September
1986 with a subarachnoid hemorrh
age. His course was complicated by
normal-pressure hydrocephalus,
which was managed by inserting a
ventriculoperitoneal shunt.
He returned to hospital Feb. 1,
1987 complaining of right lower
quadrant pain and anorexia. He was
afebrile. Head, neck, chest and neu
rologic examinations showed no ab
normalities. The right lower quad
rant was tender, but there were no
firm peritoneal signs. The leukocyte
count was 12 X 109/L with 8.3 X
109/L granulocytes. Abdominal
x-ray films were noncontributory.
Because the patient’s condition
worsened, he was taken to the
operating room with a presumptive
diagnosis of appendicitis. A normal
appearing appendix was removed
surgically. Pathological examina
tion confirmed that the appendix
was only mildly infected, and there
was no evidence of luminal inflam
mation to suggest appendicitis. The
patient recovered and was dis
charged.
He was readmitted on Feb. 23
because of abdominal pain, head
ache and confusion. On examina
tion, he was febrile (body tempera
ture 38.6°C) and exhibited mild
photophobia. There was now right
upper quadrant tenderness. The
leukocyte count was 16.9 X 109/ L
with 14.0 X 109/L neutrophils.
The serum levels of alkaline phos
phatase, alanine aminotransferase
and aspartate aminotransferase
were 332 U/L, 103 U /L and 47
U/L, respectively. Ultrasonography
of the abdomen revealed fluid
around the gallbladder. A HIDA
scan showed patent cystic and com
mon bile ducts. Barium enema ex
amination gave normal results. Pe
rihepatic fluid was drained and grew
no bacteria.
Because of the patient’s decreas
ing mental status, we consulted a

neurosurgeon. Cerebrospinal fluid
was sampled from the shunt reser
voir. The fluid contained 640 X
109/ L leukocytes with 83% neutro
phils and was cultured for S. epider
midis.
Vancomycin was initially adminis
tered pending final culture results.
Removal of the shunt resulted in
rapid improvement. Once sensitivi
ties were known, treatment was
continued with penicillin G and
when the shunt was reinserted 2
weeks later, vancomycin was used
again to cover methicillin-resistant
strains.
Case 3
In 1979, a 39-year-old man pre
sented to another hospital with su
barachnoid hemorrhage from intra
cranial aneurysm. After surgical
clipping, he was left with substan
tial neurologic deficits and required
insertion of a ventriculoperitoneal
shunt to relieve communicating hy
drocephalus. Over the next 4 years
he required numerous revisions of
his shunt because of recurrent mal
function and infection.
In November 1986, he presented
to the emergency department with a
4-day history of right lower quad
rant pain and nausea. His neck was
supple, findings on chest and car
diovascular examinations were un
remarkable and normal bowel
sounds were present. He had right
lower quadrant guarding. The
erythrocyte sedimentation rate was
47 m m/h and the leukocyte count
was 11.4 X 109/L .
Because the cause of the pain
was uncertain, he was admitted for
investigation. Computed tomogra
phy findings of the brain were nor
mal. Ultrasonography of the abdo
men and small-bowel barium study
suggested thickening of smallbowel wall. Barium enema examina
tion gave normal findings. The dif
ferential diagnosis included appen-
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dicitis, ischemic colitis and focal
inflammation due to the shunt.
Symptoms appeared to clear sponta
neously over the next 2 weeks; then
the patient experienced neurologic
decompensation and right lower
quadrant pain. There was also pain
over the shunt reservoir. The eryth
rocyte sedimentation rate was 42
mm/h, leukocyte count 10.4 X
109/L and repeated computed to
mography of the head demonstrated
hydrocephalus.
The shunt was externalized and
cerebrospinal fluid cultures grew S.
epidermidis. He was treated with
cloxacillin, and a new shunt was
inserted 8 days later, leading to
resolution of symptoms and hydro
cephalus.

Discussion
These three cases illustrate the
difficulties in diagnosis and choice
of therapy when patients who have
a VP shunt present with peritonitis.
Although this problem is addressed
to a limited extent in the pediatric
literature, this presentation in
adults has seldom been reported
and there is no clear consensus on
its management. We have reviewed
the relevant literature and examined
our own experience to arrive at a
proposed approach.
Certain clues from the patient’s
history, physical examination, labo
ratory testing and imaging investi
T a b le

1. C lin ic a l

gations (Table I) may implicate the
shunt as the cause of the present
ing symptoms. These patients com
monly present with nausea, vomit
ing and abdominal pain.134 Such
symptoms are entirely nonspecific.
A history of headache, stiff neck,
declining level of consciousness or
photophobia would suggest con
comitant meningeal irritation or hy
drocephalus and thus implicate the
shunt. As revealed in our three
cases and in another series by Rekate and colleagues,3 a history of
recent shunt revision substantially
increases suspicion that the shunt
is the likely cause. Most shunt
infections are a result of intraopera
tive seeding by gram-positive micro
organisms at the time the shunt is
inserted.5
Unless there are clear signs of
neurologic decompensation, meningismus or hydrocephalus, the local
ized or generalized peritoneal signs1
on physical examination will not be
helpful in localizing the problem. A
palpable abdominal mass may indi
cate a shunt-associated pseudocyst.4
This entity is thought4 to represent
a chronic inflammatory response to
the presence of the shunt tip and
to be associated with colonizing
organisms of low virulence in the
peritoneal cavity. Most patients in
whom a shunt pseudocyst develops
after VP shunt insertion have a
clear history of infection; the cyst
fluid will often be positive for S.
epidermidis or other organisms.46'7

F e a tu re s U s e fu l in D is tin g u is h in g S h u n t In fe c tio n F ro m P rim a ry In tra -a b d o m in a l
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N o n s p e c ific

H is to ry

N ausea, v o m itin g , fe v e r,
a b d o m in a l pain
L o ca l o r generalized p e rito n e a l
s ig n s

P h y sicia l e x a m in a tio n

G eneral la b o ra to ry te s ts
B lood cu ltu re s
C e re b ro sp in a l flu id c u ltu re s
Im ag in g (u ltra s o n o g ra p h y o r
co m p u te d to m o g ra p h y )

L e u k o c y te co u n t, e ry th ro c y te
se d im e n ta tio n rate
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p a lp a b le a b d o m in a l
pseudocyst

G ra m -p o s itiv e b a cte re m ia
P o s itiv e
P seudocyst

General laboratory investigations
are often not helpful in making the
diagnosis. An elevated leukocyte
count or erythrocyte sedimentation
rate are frequently consistent with
ongoing inflammation but have no
discriminating value. The presence
of bacteremia is rare but if gram
positive bacteria such as staphylo
cocci are isolated, primary shunt
infection is highly likely.8-9 Gram
negative bacteremia may be seen in
both primary abdominal emergen
cies and shunt-related peritonitis,
especially in infants. The series of
Reynolds and associates,1 describ
ing 19 children with shunt-associat
ed peritonitis, reported that 90% of
shunt cultures gave positive results;
65% grew gram-positive and 23%
gram-negative organisms.
Cerebrospinal-fluid sampling has
yielded variable results. Cultures
are more frequently positive when
drawn from the shunt reservoir or a
pseudocyst than from ventricular or
lumbar p uncture.8 A lthough
Hubschmann and Countee8 reported
100% of reservoir cultures positive
for S. epiderm idis, Rekate and col
leagues3 revealed that it is not un
usual to have negative reservoir
cultures and that infection may
seem to be limited to the peritoneal
end of the shunt.
Both ultrasonography and com
puted tomography appear to have
some diagnostic merit.10 When a
pseudocyst is demonstrable, symp
toms of peritonitis are likely related
to its presence. Worsening hydro
cephalus suggests shunt blockage,
which often may be precipitated by
infection.
Shunt externalization, collection
of cerebrospinal fluid for culture
and sensitivity, and empiric antibiot
ic therapy are indicated when the
clinical picture clearly implicates
shunt infection. In cases of shuntassociated peritonitis,13'8 external
ization of the peritoneal tip of the
catheter combined with parenteral
CJS, VOL. 33, NO. 1, FEBRUARY 1990
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antibiotic therapy usually leads to
resolution of clinical symptoms in
less than 24 hours. The antibacteri
al agent should have a spectrum
sufficient to cover methicillin-resistant staphylococci (i.e., vancomycin),
pending results of culture and sen
sitivity studies.
When the clinical picture does
not distinguish between a primary
peritoneal and a shunt-associated
source of symptoms, the clinician
may face a dilemma. Should he
proceed with a potentially “negative
laparotomy” or should he external
ize the peritoneal end of a normal
shunt, necessitating future revision?
We advocate externalization as
an early diagnostic and therapeutic
maneuver. Fluid from the distal end
of the shunt can then be sent for
Gram’s staining and culture. If the
results of these investigations are
positive, shunt infection is strongly
implicated. If negative, they are less
helpful and one must rely on the
clinical course of events. Since clini
cal symptoms usually resolve within
24 hours after externalization of an
infected shunt, residual symptoms
after this time are more likely at
tributable to primary intra-abdomi
nal disease, and laparotomy should
be considered.
Physicians are understandably re
luctant to tamper with what may be
a functioning and uninfected shunt.
We believe there are two compelling
reasons to favour shunt externaliza
tion, even when primary intra
abdominal disease may be present.
First, the shunt is at grave risk of
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becoming secondarily infected, thus
requiring removal anyway. Second,
sound surgical principles dictate
that removal of a foreign body such
as the shunt may be a necessary
prerequisite to the resolution of a
closed-space infection, whatever the
primary cause. Hence, shunt exter
nalization is rational for both shunt
infection and primary intra-abdomi
nal sepsis.

Recommendations
In summary, when a patient who
has a VP shunt presents with fever
and evidence of peritoneal inflam
mation, a careful clinical work-up
should take place. When a shunt
infection is strongly implicated as
the source of the problem, shunt
externalization, cerebrospinal fluid
culture, empiric antibiotic therapy
against methicillin-resistant staphy
lococci and close clinical observa
tion are indicated. When the diag
nosis is still in doubt, however, and
laparotomy is not immediately indi
cated by a precipitous clinical de
cline, we strongly recommend these
same steps. In the latter case, exter
nalization is both a diagnostic and
therapeutic procedure and may
avert unnecessary laparotomy. Sub
sequent clinical decline or lack of
improvement within 24 hours
should lead to consideration of a
primary intra-abdominal source of
infection, in which case laparotomy
and broader spectrum antimicrobial
therapy are indicated.
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Management of Duodenal Injuries
G. Cuddington, MD, FRCSC; C.H. Rusnak, MD, FRCSC; R.D.A. Cameron, MD, FRCSC;
J. Carter, MD, FRCSC
Between 1975 and 1986, 42 patients with duodenal trauma were seen at six major
hospitals serving the province of Saskatchewan. Twenty-six patients had blunt
trauma and 16 penetrating trauma. The mean age of the patients was 25 years and
38 were male. An assessment of patient management revealed an unacceptable rate
of duodenal fistulas (17%) and death (14%). Detailed analysis suggests that duodenal
injuries must be diagnosed early with prompt and appropriate surgical correction.

Type IV injuries are full thickness
with a severe pancreatic injury, in
cluding ductal disruption or exten
sive devitalization of tissue.

Findings
De 1975 a 1986, 42 patients souffrant de traumatisme duodenal ont ete admis dans
six hopitaux importants desservant la province de Saskatchewan. Vingt-six patients
souffraient de traumatismes fermes, alors que les 16 autres presentaient des plaies.
L’age moyen des patients etait de 25 ans et 38 etaient des hommes. L’evaluation du
traitement des patients a revele un taux inacceptable de fistules duodenales (17%) et
de deces (14%). Une analyse approfondie indique la necessity de diagnostiquer tot
les lesions duodenales et de proceder rapidement a la correction chirurgicale
appropriee.

The 42 patients in this study
ranged in age from 1 to 78 years
(mean 25 years). There were 38
males and 4 females. The mecha
nism of injury (Table I) was blunt
trauma in 26 patients and penetrat
ing trauma in 16.
Presentation

uodenal injuries, although rela
tively infrequent, remain an im
portant cause of morbidity and mor
tality in the trauma patient. The
retroperitoneal location of the duo
denum offers protection, and duo
denal injuries are found in only 3%
to 5% of laparotomies performed for
trauma.1' 3 Duodenal injuries are fre
quently associated with injuries to
the pancreas, colon, liver, aorta and
inferior vena cava. In addition, the
injured site is exposed to the gastr
ic, duodenal and pancreatic secre
tions which may interfere with heal
ing. These factors contribute to a
reported mortality of 6.5% to
20%,2-6 even in recent series, and to
a similarly high morbidity.
We have studied retrospectively
42 patients with duodenal trauma,

D

seen, between 1975 and 1986, at
six major hospitals serving Regina
and Saskatoon. The objective was
to review patient management and
to identify the factors associated
with morbidity and mortality. Pa
tients whose initial treatment was
performed elsewhere were excluded.
Medical records were reviewed to
identify the type and mechanism of
injury, associated injuries and treat
ment given, complications and out
come.
Duodenal injuries were classified
according to the system proposed
by Roman and colleagues.1 Types I
and II are partial and full-thickness
injuries, respectively, with no asso
ciated pancreatic trauma. Type III
injuries are full thickness with a
minor associated pancreatic injury.

F rom the D epartm ent o f Surgery, U niversity o f Saskatchew an, U niversity H ospital, Saskatoon,
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Seven patients (17%) had isolated
duodenal injuries and 35 (83%) had
associated injuries (Table II).
Table I. Mechanism of Duodenal Injury
Mechanism
Blunt trauma
Motor vehicle accident
Fall
Crush injury
Child abuse
Penetrating trauma
Gunshot wound
Knife wound
Shotgun wound

No. of patients
26
18
2
5
1
16
11
4
1

Table II. Associated Injuries (35 Patients)
Associated injury
Intra-abdominal
Liver
Pancreas
Colon
Small bowel
Stomach
Biliary tract
Major blood vessel
Other
Musculoskeletal
Chest
Spinal cord
Head

No. (% of total)
11 (26)
9(21)
7 (1 7 )
6 (1 4 )
7 (1 7 )
5(12)
5(12)
8(19)
7(17)
2 (5)
2 (5)
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Twelve patients (29%) presented in
shock (systolic blood pressure less
than 90 mm Hg).
Peritoneal lavage was performed
in eight patients who had blunt
trauma and was positive in seven of
them. Of these seven patients, three
had isolated duodenal injury and
four associated intra-abdominal in
juries. There was only one false
negative peritoneal lavage; it oc
curred in a patient who had a
partial-thickness duodenal injury.
The serum amylase level was ele
vated in 20 (67%) of 30 patients in
whom it was measured; 5 had as
sociated pancreatic injury. Twentyfour (56%) of the 42 patients had
an elevated leukocyte count.
Radiologic Findings

Plain abdominal x-ray films were
obtained in 34 patients. Fifteen
showed nothing abnormal, 11
showed nonspecific signs of intraperitoneal injury (free air, fluid
or displacement of bowel) and 8
showed retroperitoneal gas in the
right upper quadrant, highly sug
gestive of a specific duodenal inju
ry. In two of these eight patients,
the finding of retroperitoneal gas
was not identified by the surgical
team, but was subsequently report
ed by the radiologist.
Contrast studies of the upper
gastrointestinal tract, performed in
five patients, were diagnostic of
duodenal hematoma in two and
showed a leak in only one of the
three patients with full-thickness
injuries.
Computed tomography was used
in only one patient, several days
after a motor vehicle accident. This
patient had persistent pain but neg
ative results of upper gastrointesti
nal series. The investigation was
performed with the aid of oral con
trast medium, but failed to demon
strate the injury in the second part
of the duodenum.
42
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Injury Classification

This series included 7 type I
injuries (hematoma or serosal tear),
26 type II injuries (transmural inju
ry), 8 type III injuries (full thick
ness with pancreatic contusion or
hematoma) and 1 type IV injury
(with major pancreatic ductal dis
ruption).
Timing o f Surgery

Figure 1 shows the interval be
tween injury and operative repair in
the 35 patients who had a full
thickness duodenal injury, divided
into those with and without compli
cations (abscess or duodenal fistula)
or death related to the duodenal
injury. The time to repair was not
known in one patient and another
died at the time of anesthetic induc
tion, 9 hours after injury.
Treatment o f the Injury

Of the seven patients with a type
1 injury, five sustained duodenal
hematoma and, although three of
these underwent laparotomy for
other reasons, none required specif
ic treatment for this injury. Two
other patients had seromuscular
lacerations, which were simply over
sewn.
Eighteen of the 26 patients with
type II injury were treated by

debridement and suture closure.
Three of these patients also had a
feeding jejunostomy and two had
decompressive gastrostomy. Five
other patients had primary closure
accompanied by tube duodenostomy
(or a nasogastric tube threaded into
the duodenum in one patient). The
remaining three patients were treat
ed by the pyloric exclusion proce
dure.7 This consists of oversewing
the pylorus with an absorbable su
ture followed by gastrojejunostomy,
after the injury has been repaired.
Five of the type III injuries were
treated by primary repair and drain
age of the lesser sac. Of the remain
ing three patients, one underwent a
pyloric exclusion procedure, one pa
tient died upon induction of anes
thesia before the injury was re
paired and the last patient had a
completely transected duodenum
which was managed with an end-toside duodenojejunostomy and over
sewing of the distal duodenum.
One patient sustained a type IV
injury. A stab wound to the head of
the pancreas caused disruption of
the main pancreatic duct and an
associated duodenal injury. This
was managed by a Whipple’s proce
dure.
All patients with full-thickness
duodenal injuries had drainage of
the periduodenal area with either a
Penrose or a closed-suction drain.
Nine patients had a feeding jejunos
tomy inserted.

Complications (Table III)

FIG. 1. Time interval from injury to
repair in 33 patients with full-thick
ness injuries who underwent opera
tion. Shaded bars = without complica
tions, dotted bars = with complica
tions.

A duodenal fistula developed in
six patients (17% of those with
full-thickness injuries). In four the
injury resulted from blunt trauma.
The interval from injury to opera
tive repair was longer than 24
hours in four of these six patients.
In two this was because the duode
nal injury was not recognized at the
initial laparotomy; in one case the

DUODENAL INJURIES

more obvious injuries were orthope
dic, so no general surgery consulta
tion was obtained until several days
later when intra-abdominal sepsis
was evident; the final patient did
not seek medical attention until 4
days after a motor vehicle accident.
All fistulas followed type II inju
ries and were repaired by primary
closure and drainage, with a tube
duodenostomy being used as ad
junctive treatment in only one pa
tient, despite the prolonged interval
to repair in four of the patients.
Two patients died of sepsis relat
ed to their duodenal fistulas. Two
required reoperation, and in the
other two patients the fistula was
well controlled by drains placed at
the initial operation, and they re
quired only supportive care. The
average length of stay for the survi
vors with fistulas was 47 days as
opposed to 18 days for the remain
der of the group without fistulas.
Although late (post-discharge)
complications were not sought, one
patient who underwent a pyloric
exclusion procedure had a serious
gastrointestinal hemorrhage caused
by a stomal ulceration 1 year after
injury. This was managed by opera
tion with reversal of the pyloric
exclusion.

Mortality
There were six deaths (14%),
three being directly related to the
duodenal injury. The three deaths
not directly related included two
T a b le III. Complications (Full-Thickness

Injuries)
C o m p licatio n

Duodenal fistula
Intra-abdominal abscess
Wound infection
Pancreatic fistula
Leak from feeding
jejunostomy
Diagnosis missed at
laparotomy

N o. of p a tie n ts

6
2
3
2
2
2

from hemorrhage and one due to
myocardial infarction.
Of the patients who died of
causes related to the duodenal inju
ry, one, whose injury was missed at
the initial laparotomy, was operated
on 6 days later, with only suture
closure and drainage. The second
patient’s injury was not identified
for 4 days, after initial treatment of
orthopedic injuries, and again re
pair was only simple suture closure
and drainage. The final patient sus
tained a rupture of the duodenum
in a motor vehicle accident, but
intra-abdominal injury was not iden
tified during resuscitation and he
died during induction of anesthesia,
when the injury manifested itself 9
hours later. In retrospect, the radi
ologist identified retroperitoneal air
on the plain abdominal x-ray film,
but this finding was not appreciated
by the surgical team.

Discussion
Injuries to the duodenum are not
commonly seen by the busy trauma
surgeon.8 This 12-year review of
the six major hospitals servicing
Saskatchewan revealed only 42 du
odenal injuries. This series reaf
firms that predominantly rural areas
have a greater incidence of blunt
duodenal trauma (62% in this re
view).910
Duodenal injury, when discov
ered, is of paramount importance
due to the extraordinarily high
rates of serious complications and
of death. The most common compli
cation is that of duodenal fistula,
reported as occurring in 3% to 22%
of cases.27911 Duodenal fistulas
(17% in this series) were more com
mon with blunt injuries and with
delayed treatment. Four out of six
duodenal fistulas were from blunt
abdominal trauma, and four were
treated more than 24 hours from
the time of injury.

The death rates for duodenal in
juries range from 6.5% to 12.5%2“5-7
The death rate in our series was
14%. The main determinant of mor
bidity and mortality in many series,
particularly in blunt abdominal
trauma, is related to delayed diag
nosis or delayed surgical repair
from the time of the injury. Roman
and colleagues1 identified 10 pa
tients in their series in whom the
diagnosis was delayed over 24
hours; 4 of the 10 died and 3 of the
10 had duodenal fistulas. Snyder
and colleagues11 found four patients
whose surgery for blunt abdominal
trauma was delayed more than 24
hours. Two of them died and in the
other two fistulas developed. Flint
and associates12 noted that duode
nal lacerations would not have been
discovered in 6 of 19 patients were
it not for the policy of mobilizing
the duodenum at all laparotomies
for blunt trauma.
In our series, the three deaths
directly related to duodenal injury
were all due to delayed diagnosis; in
one, the diagnosis was missed at
the initial laparotomy, the second
injury was not detected at initial
assessment (retroperitoneal air was
noted on the abdominal film retro
spectively), and the final injury re
mained undetected for 4 days while
the patient was being treated for
orthopedic injuries.
Acute awareness is needed to
make an early diagnosis together
with early operative intervention to
prevent unnecessary morbidity and
mortality.
Hasson and colleagues5 demon
strated the value of tube decom
pression in duodenal injuries. The
overall mortality of duodenal repair
was clearly less with decompression
(9% versus 19.4%). The primary
repair with tube decompression ver
sus primary repair without tube
decompression showed a fistula rate
of 2.3% versus 11.8%. The rate of
tube duodenostomy fistula in this
CJS, VOL. 33, NO. 1, FEBRUARY 1990
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collected series was an alarming
19.4%.
In our series there was no single
method used for repair with which
to make a statistical analysis. The
pyloric exclusion procedure was
used in four patients, three times in
patients whose injury was over 12
hours old. There were no complica
tions in these patients; however, in
one patient stomal ulceration devel
oped later at the gastrojejunostomy
site and required reoperation. Kashuk and colleagues13 in their study
favoured pyloric exclusion over
tube decompression in types III and
IV duodenal injuries. In their trau
ma centre they decreased the occur
rence of duodenal fistulas from 13%
to 4% and the postoperative death
rate by a similar percentage.
The surgeon, having made an
early diagnosis and discovered a
duodenal injury, should determine
the mechanism of injury, the time
from injury and extent of duodenal
and associated injuries to decide on
the appropriate method of repair.
Most type I injuries (intramural
hematomas), obstructive or nonob
structive, can be successfully ma
naged conservatively with nutrition
al support.14 If hematoma does not
resolve in 12 to 14 days, then
reassessment using a gastrointesti
nal series may lead to the recom
mendation that surgical evacuation
is necessary.
The uncomplicated type II (full
thickness) injury can be managed
by primary repair. The pyloric ex
clusion procedure should be used
for type II injuries when the duode
nal repair is tenuous and when
repair is delayed beyond 12 hours.
Omental and serosal patches have
also been used but no clear benefit
has been shown.15 In our series,
drainage was instituted for type II
injuries. However, Stone and Fabi
an16 suggested that drainage is un
necessary in this circumstance.
A type III injury may be treated
44
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by primary repair and pancreatic
drainage if the injury is less than 12
hours old and the duodenum is not
extensively devitalized. For the
more extensive duodenal injury or
delayed repair, the pyloric exclusion
procedure is indicated. Type III in
juries require drainage to decrease
the potential morbidity of a pancre
atic fistula.6
Type IV injuries are full thick
ness with a severe pancreatic injury,
including extensively devitalized tis
sue or major ductal disruptions. If
the pancreatic injury is in the neck,
body or tail, then distal pancreatec
tomy, primary duodenal repair and
diversion of the gastroduodenal
stream is the procedure of choice.
If, however, there is a severe injury
to the head of the pancreas, then
pancreatoduodenectomy may be
preferable. The death rate is high in
this group because of the frequent
presence of major associated inju
ries.
In types II, III and IV injuries,
the extent of the duodenal injury
may preclude primary reconstruc
tion, so the surgeon will need to
use his ingenuity to restore gas
trointestinal continuity (e.g., Rouxen-Y anastomosis, duodenojejunos
tomy). At our centre, we believe
that threading the nasogastric tube
into the duodenum is an acceptable
method of tube decompression for
these injuries. All these patients
(particularly those with types III
and IV injuries) should be consid
ered candidates for a feeding jejunostomy.
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Effect of Hypothermia and Cardioplegia
on Intramyocardial Voltage and Myocardial
Oxygen Consumption [Republication]
R.W. Landymore, MD, FRCSC; A.E. Marble, PhD, PEng
Intramyocardial voltage and myocardial oxygen consumption were measured in the
fibrillating heart between the temperatures of 37°C and 25°C and in the arrested
heart after infusion of potassium cardioplegic solution in 10 adult mongrel dogs.
Electrical activity from the myocardium was recorded using specially designed
plunge electrodes, and intramyocardial voltage was monitored by an in-line
voltmeter. Myocardial oxygen consumption gradually decreased from 5.8 ± 0.6 ml
0 2/m in at 37°C to 2.3 ± 0.5 ml 0 2/min at 25°C. In contrast, hypothermia did not
cause a similar decrease in intramyocardial voltage which remained within a range of
1.8 ± 0.5 mV to 2.4 ± 0.5 mV between the temperatures of 37°C and 25°C. The
infusion of potassium cardioplegic solution resulted in a dramatic decrease in
voltage to 43 ± 5 gV, and myocardial oxygen consumption fell to 0.5 =t 0.3 ml
0 2/m in. Our data demonstrated that the mean voltage of the fibrillating heart
remains constant between the temperatures 37°C and 25°C and myocardial oxygen
consumption decreases with hypothermia, which suggests that voltage does not
correlate with the level of myocardial oxygen consumption. Myocardial oxygen
consumption and intramyocardial voltage, however, decrease dramatically when
cardioplegia is instituted.

Chez 10 chiens batards adultes, on a mesure le voltage intramyocardique et la
consommation d’oxygene du myocarde sur le coeur en fibrillation maintenu a des
temperatures de 37°C et de 25°C et sur le coeur a l’arret apres perfusion d’une
solution cardioplegique de potassium. L’activite electrique du myocarde a ete
enregistree a l’aide d'electrodes de conception speciale, et le voltage intramyocardi
que a ete monitorise a l’aide d’un voltmetre en ligne. La consommation myocardique
d’oxygene a baisse progressivement de 5.8 ± 0.6 ml d’0 2/m in a 37°C jusqu’a 2.3 ±
0.5 ml d’0 2/m in a 25°C. Par opposition, l’hypothermie n’a pas cause une baisse
similaire du voltage intramyocardique, lequel est demeure dans l’intervalle de 1.8 ±
0.5 mV a 2.4 ± 0.5 mV entre les temperatures de 37°C et de 25°C. La perfusion
d’une solution cardioplegique de potassium a entralne une baisse spectaculaire du
voltage de 43 ± 5 g\, et la consommation myocardique d’oxygene a chute de 0.5 ±
0.3 ml d’0 2/m in. Ces resultats demontrent que le voltage moyen du coeur en
fibrillation demeure constant entre 37°C et 25°C et que la consommation d’oxygene
du myocarde s’abaisse dans des conditions d’hypothermie; ceci indique que le
voltage n’est pas relie au niveau de consommation d’oxygene du myocarde. La
consommation myocardique d’oxygene et le voltage intramyocardique baissent
toutefois de fa?on spectaculaire quand une cardioplegie est mise en route.
From the Maritime Heart Center, Victoria General Hospital, Halifax, NS
Supported by Medical Research Council o f Canada grant no. R1524369-760

nduction of myocardial arrest
with cold potassium cardioplegic
solution decreases myocardial ener
gy requirements by lowering myo
cardial temperature and preventing
electrom echanical activity. Al
though cardioplegia initiates a rapid
electrom echanical arrest, sm allamplitude electrical potentials may
be recorded from the myocardium,
using specially designed plunge
electrodes, within 10 to 15 minutes
after the infusion of potassium car
dioplegic solution when there is no
visual mechanical activity and when
the electrocardiogram is isoelec
tric.12 These small-amplitude elec
trical potentials have a fundamental
frequency of 3.0 Hz and may persist
for more than 30 minutes before
electromechanical activity resum es.1
Although the importance of smallamplitude electrical activity during
cardioplegic arrest is uncertain, pre
liminary investigations in our labo
ratory suggest that such activity is
associated with impaired functional
recovery of the myocardium after
90 minutes of ischemia.3 To estab
lish the relationship between in
tramyocardial voltage and myocar
dial metabolism we designed a
study to measure oxygen consump
tion (a) in the fibrillating heart
between the temperatures of 37°C
and 25°C , (b) during small-ampli
tude electrical activity and (c) in the
cardioplegic-arrested heart.

I
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Materials and Methods
Ten, adult, mongrel dogs, weigh
ing between 21 and 25 kg, were
CJS, VOL. 33, NO. 1, FEBRUARY 1990
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sedated with 1 ml of Innovar. Anes
thesia was induced and maintained
with Somnutol. Ventilation was pro
vided with a Bird Mark 7 (Bird
Corp., Palm Springs, Calif.) pres
sure-regulated ventilator.
The left femoral artery was cannulated with a no. 14F USCI arteri
al cannula (C.R. Bard Inc., Billerica,
Mass.) for cardiopulmonary bypass,
and venous return was provided by
two 34 USCI cannulas. The cavae
were snared and the left ventricle
was vented. Cardiopulmonary by
pass was established with a Med
tronic impellar pump (model
1835-00U) driven by a Medtronic
circulatory assist console (model
1810) that would deliver nonpulsatile flow at a rate of 2.5
L/min-m~2 (Medtronic Inc., Circu
latory Systems Division, Roseville,
Miss.).
The right atrium was opened
while the dog was on bypass and a
no. 12F USCI catheter was inserted
into the coronary sinus and brought
out directly through the wall of the
atrium for measurement of coro
nary sinus flow. A snare was passed
externally around the coronary
sinus to prevent migration of the
catheter and to ensure that the
effluent from the catheter repre
sented the entire coronary sinus
flow. Coronary sinus blood was col
lected in a graduated cylinder for
60 seconds, the total flow being
used for the calculation of myocar
dial oxygen consumption. An aver
age of three measurements of coro
nary sinus flow was used for each
calculation of myocardial oxygen
consumption.
Plunge electrodes were posi
tioned over the anterior wall of the
left ventricle and connected to re
cording and signal conditioning
equipment. Intramyocardial voltage
was measured with an in-line RMS
voltmeter (John Fluke Manufactur
ing Co., Everett, Wash.). The tech
nical details related to the recording
46

of small-amplitude electrical poten
tials from the myocardium during
cardioplegic arrest have already
been detailed.1 Myocardial tempera
ture was measured and recorded on
chart paper with specially con
structed plunge electrodes. The
thermistor probes were calibrated
before each experiment with a mer
cury thermometer.
Oxygen saturation was monitored
continuously with two Oxy-Sat me
ters (SM-0100; Bentley Laborato
ries, Irvine, Calif.). Oxygen-sensing
equipment was positioned in the
arterial circuit and also placed in
line with the coronary sinus drain
age. Myocardial oxygen consump
tion (MV02) was measured at twodegree intervals between the tem
peratures of 37°C and 25°C and
was calculated from measurements
of oxygen saturation, coronary
sinus flow (CSF) and hemoglobin
(Hb) according to the following for
mula: MV02 (ml/min) = (% arterial
saturation - % venous saturation)
X Hb X 1.34 X CSF (ml/min).
Myocardial temperature was then
increased to 30°C and cardiac ar
rest was initiated by infusing potas
sium cardioplegic solution directly
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into the oxygenator.4 Crystalloid
cardioplegic solution containing 25
mmol/L of potassium3 was infused
directly into the oxygenator until
complete cardiac arrest was ob
tained. Cardiac arrest was defined
by the absence of visual mechanical
activity and loss of electrical activity
on the surface electrocardiogram
and from the plunge electrodes.
Intramyocardial voltage and myo
cardial oxygen consumption were
measured in the arrested heart and
were monitored continuously until
gross electromechanical activity re
sumed.
The results are reported as the
arithmetic mean ± the standard
error of the mean.

Results
Intramyocardial voltage and myo
cardial oxygen consumption are il
lustrated in Fig. 1. Intramyocardial
voltage during ventricular fibrilla
tion varied between 1.8 ± 0.5 mV
and 2.4 ± 0.5 mV between the
temperatures of 37°C and 25°C.
The mean intramyocardial voltage
did not decrease as the core temper-
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FIG. 1. Mean intramyocardial voltage and myocardial oxygen consumption (MV02)
during hypothermia and cardioplegic arrest. ± = standard error of mean.

MYOCARDIAL METABOLISM DURING CARDIAC OPERATIONS

ature was lowered. In contrast,
myocardial oxygen consumption
gradually decreased from 5.8 ± 0.6
ml 0 2/m in at 37°C to 2.3 ± 0.5 ml
0 2/m in at 25°C. The infusion of
cardioplegic solution resulted in a
dramatic decrease in both the intramyocardial voltage and myocar
dial oxygen consumption. Voltage
recorded in the arrested heart mea
sured 43 ± 5 mV and myocardial
oxygen consumption decreased to
0.5 ± 0.3 ml 0 2/m in. Intramyocardial voltage and myocardial oxygen
consumption remained low until the
onset of ventricular fibrillation.
Small-amplitude electrical poten
tials were recorded from the myo
cardium just before the onset of
ventricular fibrillation. However,
the transition from a complete ar
rest to ventricular fibrillation was so
rapid that we could not measure
coronary sinus flow, and, thus,
could not calculate myocardial oxy
gen consumption during the pres
ence of the small-amplitude fibrilla
tion waveforms.

Discussion
Infusion of potassium cardiople
gic solution into the ascending
aorta will initiate a rapid electrome
chanical arrest but may not main
tain a complete electrical arrest.
Independent investigators12 have
recorded small-amplitude electrical
potentials from the myocardium
with specially designed plunge elec
trodes after the infusion of the
cardioplegic solution when the
heart is quiescent and the elec
trocardiogram is isoelectric. Smallamplitude electrical activity origi
nates in the HIS bundle and is
conducted to the ventricles within a
few minutes.5 This activity is char
acterized by the onset of smallamplitude fibrillation waveforms
which have a mean voltage two to
three times greater than the cardio

plegic arrest potential, which usual
ly lies between 10 and 40 m V .6
These small-amplitude electrical po
tentials are usually recorded within
5 to 15 minutes after the infusion
of cardioplegic solution and may be
present for more than 30 minutes
before electromechanical activity re
sumes.6 Earlier investigations in our
laboratory suggested that the pres
ence of small-amplitude electrical
activity may be associated with im
paired recovery of myocardial func
tion after ischemic arrest.3 To ex
plore further the relation between
intramyocardial voltage and myo
cardial metabolism, we measured
myocardial voltage and oxygen con
sumption in the fibrillating heart
between the temperatures of 37°C
and 25 °C in the cardioplegic arrest
ed heart and, finally, we attempted
to measure myocardial oxygen con
sumption and intramyocardial volt
age during small-amplitude electri
cal activity.
Our observations indicate that
myocardial oxygen consumption
gradually decreases as the tempera
ture of the fibrillating heart is low
ered from 37°C to 25°C. Because
Buckberg and colleagues78 demon
strated that hypothermia decreased
myocardial energy requirements by
lowering myocardial oxygen con
sumption, we expected that moder
ate hypothermia would have similar
effects on the magnitude of the
fibrillation waveforms, since hypo
thermia is known to reduce the
contractile force of the myocardi
um. However, moderate hypo
thermia did not reduce the mean
voltage of the fibrillation waveforms
between the temperatures of 25 °C
and 37°C, indicating that the volt
age of the fibrillating heart does not
correlate directly with the level of
myocardial oxygen consumption.
Cardiac arrest was initiated by
infusing the cardioplegic solution
into the oxygenator rather than
into the ascending thoracic aorta.

This was necessary in order to
preserve coronary sinus flow, so
that myocardial oxygen consump
tion could be calculated. Cardio
plegia induced an electrical and me
chanical arrest in all animals. Ven
tricular fibrillation and plunge-elec
trode activity ceased after the car
dioplegic solution was infused and
intramyocardial voltage decreased
from 2.1 mV in the fibrillating heart
at 30°C to 40 mv. The cessation of
electromechanical activity was asso
ciated with a marked reduction in
myocardial oxygen consumption,
and both voltage and myocardial
oxygen consumption remained low
until the spontaneous onset of ven
tricular fibrillation. Small-amplitude
electrical potentials were recorded
from the plunge electrodes just be
fore ventricular fibrillation resumed,
but because the transition between
the arrested state and electrome
chanical activity was so short that
we could not measure coronary
sinus flow and thus calculate myo
cardial oxygen consumption during
small-amplitude electrical activity.
Brandt and associates4 monitored
the electrical status of the myocar
dium during cardioplegic arrest
using an identical experimental
model. They never recorded electri
cal activity from the plunge elec
trodes after the infusion of the
cardioplegic solution, which led
them to conclude that cardioplegia
always initiated and maintained a
complete electrical arrest. Our data
and Brandt’s observations4 comple
ment each other but are in contrast
to numerous earlier investiga
tions,1”3-56910 which indicated that
small-amplitude electrical potentials
may be recorded from the myocardi
um within 10 to 15 minutes after
infusion of the cardioplegic solu
tion. Cardiac arrest for these experiments1”3-5-6-9-10 was induced by
infusing potassium directly into the
aortic root. Infusion of cardioplegic
solution into the clamped ascending
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thoracic aorta almost completely
abolishes coronary flow, which pre
vents rapid fluctuations of intracel
lular potassium. The gradual de
cline of intracellular potassium as
sociated with this technique results
in a slow transition between the
arrested myocardium and the onset
of gross electromechanical activity.
Thus, small-amplitude electrical po
tentials may develop and persist for
more than 30 minutes before ven
tricular fibrillation resumes. In con
trast, infusion of cardioplegic solu
tion into the oxygenator preserves
coronary flow and presumably
causes rapid washout and decline of
intracellular potassium, leading to
the sudden onset of ventricular ex
citation.
The metabolic significance of
small-amplitude electrical activity is
not fully understood, although an
earlier investigation3 suggested that
such activity was associated with
postischemic depression of left ven
tricular function. Unfortunately, we
were unable to calculate myocardial
oxygen consumption during smallamplitude electrical activity. Howev
er, we measured the voltage of the
fibrillating heart during hypo
thermia and following the induction
of potassium cardioplegia. Interest
ingly, the mean voltage of the myo
cardium during ventricular fibrilla
tion remained relatively constant as
myocardial temperature was low
ered. Considering that myocardial
oxygen consumption progressively
decreases with hypothermia, one
must assume that voltage does not
correlate directly with the level of
myocardial oxygen consumption.
Therefore, the increase in the rest
ing potential associated with the
onset of small-amplitude activity
may indicate increased myocardial
oxygen consumption but may not
directly reflect the level of myocar
dial metabolism. The significance of
small-amplitude electrical activity
during cardioplegic arrest remains
48
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uncertain, requiring further clarifi
cation to determine its effects on
myocardial metabolism and preser
vation.
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Inflammatory Abdominal Aortic
Aneurysms and Ureteric Obstruction
S.B. Radomski, MD;* F. Michael Ameli, MB, ChB, FRCS(Edin), FRCSC, FACS;*
M.A.S. Jewett, MD, FRCSCt
Inflammatory abdominal aortic aneurysms are rare, but when they occur the ureters
may be involved in the perianeurysmal fibrosis. Treatment of this ureteric
involvement is controversial. The authors present one such case, review the
literature and describe what they believe is the appropriate method of diagnosis and
treatment. This includes the use of computed tomography, retrograde pyelography,
ureteral stenting, repair of the aneurysm and ureterolysis.

Les anevrismes inflammatoires de l’aorte abdominale sont rares mais, quand ils
surviennent, il peut y avoir atteinte des ureteres par la fibrose perianevrismale. Le
traitement de l’atteinte ureterale est conteste. Les auteurs en signalent un cas, font
la revue de la litterature et decrivent ce qu’ils croient etre la methode appropriee de
diagnostic et de traitement. Elle fait appel a la tomodensitometrie, a la pyelographie
retrograde, a la pose d’un manchon ureteral, a la reparation de l’anevrisme et a
l’ureterolyse.

abdominal aortic
I nflammatory
aneurysms represent 2.5% to
10% of all infrarenal aortic aneu
rysms.1-4 In the past, the diagnosis
was difficult to make preoperatively, but with the introduction of
computed tomography and ul
trasonography, the diagnosis is
being made earlier. The first report
ed case of ureteric obstruction sec
ondary to an inflammatory reaction
around an aortic aneurysm was
made in 1935 by James.5 Since then
there have been many case reports
of perianeurysmal fibrosis and uret
eric obstruction. However, contro
versy regarding the management of

ureteric obstruction still remains. In
this report we present a case of
ureteric obstruction associated with
an inflammatory abdominal aortic
aneurysm and describe what we
believe is the appropriate method of
diagnosis and management.

Case Report

A 73-year-old woman was admit
ted for elective repair of an abdomi
nal aortic aneurysm diagnosed by
ultrasonography. She complained of
dizziness and upper abdominal dis
comfort. She had no back or flank
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pain and no claudication. She was a
nonsmoker and had no history of
diabetes or heart disease. The re
mainder of her history was nega
tive. She was on no medications.
On physical examination, the
only notable finding was a tender
5-cm abdominal aortic aneurysm
and a right popliteal Baker’s cyst.
All of her peripheral pulses were
palpable and she had no bruits. She
had no flank tenderness.
Results of urinalysis and urine
culture, and the serum electrolyte
levels were normal. Her erythrocyte
sedimentation rate and serum creat
inine level were mildly elevated at
26 m m /h (normal 0 to 20 m m /h)
and 132 mmol/L (normal 50 to
110 mmol/L) respectively. The
electrocardiogram and chest x-ray
film appeared normal. Her VDRL
test result was negative.
Computed tomography demon
strated an infrarenal abdominal aor
tic aneurysm, measuring 5.5 cm,
with a thickened wall. There was a
right hydronephrosis and the right
ureter was involved in the wall of
the aneurysm (Figs. 1 and 2). An
intravenous pyelogram confirmed
the presence of a moderate right
hydronephrosis with medial devia
tion of the right ureter, but the
level of obstruction was not clearly
defined (Fig. 3). As a result, right
retrograde pyelography was carried
out and a right ureteric stent insert
ed (Fig. 4).
At operation, a thick-walled shiny
abdominal aortic aneurysm was
CJS, VOL. 33, NO. 1, FEBR U A R Y 1990
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found and the level of obstruction
was just above the left sacroiliac
joint. The left ureter was easily

identified and not involved in the
inflammatory aneurysm. However,
ureterolysis of the right ureter was

necessary as it was involved in the
wall of the aneurysm. In addition,
the duodenum was adherent to the
aorta and there was a severe inflam
matory reaction around the iliac
vessels. A 16-mm Dacron graft was
inserted and the aneurysm repaired
without difficulty.
Postoperatively, the ureteral
stent was kept in place for 7 days.

FIG. 1. Computed tomogram reveals infrarenal abdominal aortic aneurysm,
measuring 5.5 cm, with thickened wall. Note right ureter involved in wall of
aneurysm.
FIG. 3. Intravenous pyelogram shows
right hydronephrosis.

FIG. 2. Computed tomogram shows right hydronephrosis.
50
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FIG. 4. Right retrograde pyelogram.
Note level of obstruction at right sa
croiliac joint.

INFLAMMATORY ANEURYSMS AND URETERIC OBSTRUCTION

During this time the patient re
ceived antibiotics. Her postoperative
course was smooth and she was
discharged from hospital 11 days
after surgery. At that time, her
urine culture was negative and her
serum creatinine level normal at 98
mmol/L.
Three months after surgery she
was well and an intravenous pyelogram appeared normal (Fig. 5).

Discussion
This woman clearly had an in
flammatory abdominal aortic aneu
rysm with ureteric obstruction.
Only 23% of patients with inflam
matory aneurysms will have ureteric
encasement due to perianeurysmal
fibrosis.4 In the past, diagnosis has
been missed, resulting in increased
morbidity and mortality.6 Medial
displacement of the ureter can be
an early radiologic sign of perianeu
rysmal fibrosis7 but is not patho
gnomonic.78 In a large review by
Pennell and associates,9 10% of
those with inflammatory aneurysms
had lateral deviation of the ureters.

FIG. 5. Intravenous pyelogram 3
months after aneurysm repair and
ureterolysis. Note resolution of right
hydronephrosis.

Computed tomography has signifi
cantly improved the detection of
inflammatory aneurysm and ureter
al obstruction. In Pennell’s review,9
computed tomography and ul
trasonography were 70% and 60%
accurate, respectively, in diagnosing
inflammatory aneurysms. Ureteral
obstruction secondary to an abdom
inal aortic aneurysm often goes
undetected because symptoms are
nonspecific. Findings such as ure
mia or anuria are seen in only 14%
to 21% of cases.1011 In 1961, Culp
and Bernatz12 at the Mayo Clinic
reported that only 10% of 400
patients surgically treated for ab
dominal aortic aneurysms presented
with urologic symptoms, most com
monly pain.
The course of treatment for ure
teral obstruction and inflammatory
aneurysm remains highly controver
sial. Some4-613 suggest that in the
absence of complete ureteric ob
struction aneurysm repair alone is
sufficient. They believe that this
promotes resolution of the inflam
matory process and relieves the
ureteric obstruction.13 However,
many others101114-17 recommend
both aneurysm repair and ureterol
ysis for definitive treatment of the
ureteric obstruction. Darke and col
leagues16 reported that the only
patient in their series who did not
initially undergo ureterolysis re
quired it 18 months later. Further
more, Loughlin and associates14 in
1984 reported that their only pa
tient who did not undergo ureterol
ysis had persistent left hydrone
phrosis. Steroids have been advo
cated to treat the inflammatory
changes and ureteral obstruction.
However, Pennell and colleagues9
had five patients who had been on
long-term prednisone therapy be
fore surgery who still had severe
inflammatory changes.
Thus, we believe it is crucial to
perform computed tomography preoperatively to assess both the aorta

and genitourinary system. We per
form computed tomography on all
patients who have an abdominal
aortic aneurysm in order to define
the nature of the aneurysm (i.e.,
inflammatory, dissecting). Comput
ed tomography is noninvasive,
highly predictive of aneurysmal
size, gives no false-negative results
and can localize the proximal extent
of the aneurysm.1819 Furthermore,
it provides a modified form of an
intravenous pyelogram, so that hy
dronephrosis can be detected. Al
though in our opinion computed
tomography is the investigation of
choice for evaluating an abdominal
aortic aneurysm, we recognize that
the scanner may not be available in
all hospitals in Canada. In these
circumstances, ultrasonography can
be used, although it does not give
as much information. If there is any
evidence of ureteric involvement we
then carry out retrograde pyelogra
phy, which, in our opinion, provides
more information than intravenous
pyelography. We can define the
exact location and cause of obstruc
tion. Furthermore, it allows us to
insert a ureteral stent if the ureter
is intimately involved in the inflam
matory aneurysm with or without
ureteric obstruction. The insertion
of a ureteral stent allows easier
identification of the ureter and
hence prevents injury to the ureter
during repair of the aneurysm and
ureterolysis. Ureteral stents are also
useful in case of injury to the
ureter; they can act as a splint once
the ureter is repaired.

Conclusions
The diagnosis and management
of ureteric obstruction secondary to
inflammatory abdominal aortic an
eurysms have been variable and
controversial. The diagnosis can be
made initially by computed tomog
raphy followed by retrograde pyeC./.V, VOL. 33, NO. 1, FEBRUARY 1990
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lography. Once the diagnosis is
established, the ureteral obstruction
can be managed by insertion of a
ureteral stent and ureterolysis,
which can be performed safely and
effectively during repair of the in
flammatory abdominal aortic aneu
rysm.
Although inflammatory aortic an
eurysms are rare, possible ureteral
involvement should always be sus
pected by both the vascular surgeon
and urologist.
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Hinged Total Knee Replacement
Indications and Results
H.U. Cameron, MB, ChB, FRCSC;* Y.B. Jung, MDt
Twenty-seven hinged (Guepar II) knee replacements were performed on 26 patients
with a follow-up of 1 to 7 years (mean 3 years). Indications for the procedure were
bone loss (nine cases) nonunion of tibial or femoral fractures (four), anteroposterior
instability (five), mediolateral instability (eight) and recurvatum instability (one).
Results were good or excellent in 66.6%. Two patients required revision and there
were three other implant-related complications. All press-fit stems were radiolucent
to some extent and some radiolucency was present close to the knee in all revisions
of stem components. No radiolucency was present in revisions of non-stem cemented
components.
Although the introduction of variable stem length, semi-constrained knees has
reduced the need for implants such as the Guepar II prosthesis, the results,
especially in terms of radiolucency, are surprisingly good. The authors conclude
that a hinged knee remains of value in desperate situations.
Vingt-sept protheses a charniere du genou (Guepar II) ont ete posees chez 26
patients. La periode de surveillance des suites therapeutiques va de 1 a 7 annees
(moyenne de 3 ans). L’intervention avait ete rendue necessaire a cause d’une
degenerescence osseuse (neuf cas), de l’absence de soudure d’une fracture du tibia
ou du femur (quatre), d’une instability anteroposterieure (cinq), mediolaterale (huit)
ou de la courbure posterieure (une).
Les resultats on ete bons ou excellents dans 66.6% des cas. Deux patients ont eu
besoin d’une revision et il y eut trois autres complications reliees aux protheses.
Toutes les tiges ajustees sous pression avaient une transparence relative aux rayons
X et une certaine opacite etait presente a proximite du genou dans tous les cas de
revision de la tige. Aucune transparence radiologique n’etait presente lors des
revisions de protheses cimentees, sans tige.
Meme si la venue de protheses semi-contraintes a tiges de longueur variable a
reduit l'utilisation des protheses de type Guepar II, leurs resultats, surtout au plan
de la transparence radiologique, sont etonnamment bons. Les auteurs concluent que
les protheses a charniere du genou ont encore leur place dans les cas desesperes.

of various types have
H inges
been used for total knee re
placement since the 1950s, and the
reported results have not been par

ticularly good (Fig. I).1-8 Currently,
there are few indications for a stabi
lized knee prosthesis. Most cases
can be handled by a semi-con-
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strained condylar type prosthesis.
In an attempt to determine the
indications for a hinged implant and
the results that can be achieved, all
cases of Guepar II (Howmedica Inc.,
Rutherford, NJ) hinge replacements
carried out by the senior author
were reviewed.

Methods
All patients with Guepar II re
placements carried out by the se
nior author were followed up pro
spectively at 6-month intervals
using the Hospital for Special Sur
gery rating system9 and radiologically, using 3-foot standing films,
lateral and skyline views. The
bone-cement interface was studied
after the fashion of Bargar and
colleagues1 and DeLee and Charnley.10
Because it became apparent that
radiolucency starts at the knee and
extends proximally and distally
along the stems, we found it conve
nient to divide the stems into three
parts in both planes: a type I lucency extending over one-third of the
stem closest to the knee, a type II
lucency over two-thirds of the stem
closest to the knee and a type III
lucency over the whole stem. Grade
1 means that the width of the
radiolucent line is 1 mm or less,
grade 2, 2 mm or less and grade 3
greater than 2 mm.
Technical Aspects
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par I stems were manifestly too
small and the cementing technique
was inadequate. In all cases in this
series in which the prostheses were
cemented in place, canal brushing,
plugging, pressure lavage, cement
injection and pressurization were
carried out.
When a patella had been re
placed, the original was left in situ.
The patella was replaced if a lateral
release was not carried out. When a
wide lateral release was necessary,
fears of further devascularizing the
patella precluded replacement.11 Re
placement, when done, was with an
inset, non-cemented, plastic button
(Tricon P; Richards Manufacturing
Co., Memphis, Tenn.).

Findings
Twenty-seven Guepar II knee
prostheses were inserted in 26 pa
tients (11 men, 15 women) who

ranged in age from 48 to 86 years
(mean 68 years). The follow-up was
from 1 to 7 years (mean 3 years).
Two patients had died by the time
of this review, but since they had
been followed up for more than 3
years they were included. Knee re
placement was done in one patient
who had had poliomyelitis and had
never undergone knee surgery, in
four who had nonunion of bones
around the knee, in three who had
failure of knee fusion and in the
remainder (19) as revision. Of the
19 who had knee revision, 7 had
one revision, 9 two, 1 three and 2
five or more.
Complications at surgery includ
ed two longitudinal tibial shaft frac
tures, from attempting to insert too
large a tibial component into too
small a tibia. Only one size of tibial
component is available and the com
ponent had to be customized intraoperatively in the machine shop.
Both patients were treated with

FIG. 1. Tibial component in this original Guepar prosthesis has loosened, resulting
in substantial osteolysis of surrounding bone. Cementing in new stem prosthesis
will result in rapid development of radiolucency around new stem in area of old
stem.
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screw closure of the split and bone
grafting. The tibial component was
simply press-fitted in these cases.
Postoperative Complications
One patient had a severe stroke
but recovered completely. One pa
tellar tendon ruptured 3 months
postoperatively and had to be wired
back in place (Fig. 2). One patient,
who had a 30° quadriceps lag be
fore revision due to a patellar ten
don rupture, continued to have a
20° lag in spite of tendon repair at
the time of surgery. One patella
that had been dislocated for years
required a huge lateral release for
recentering; it subsequently became
avascular and disintegrated. The
original patellar component, which
had been left in place, had to be
removed along with the necrotic
bone.

FIG. 2. Patellar tendon ruptured, 3
months after surgery. Patient had
avascular necrosis after initial total
knee replacement. Patella was wired
back using three multiphase wires
(stainless steel wires tend to break
under these circumstances). These
components have been press-fitted. Ob
vious radiolucency surrounds femoral
component but is minimal on tibial
side.

HINGED TOTAL KNEE REPLACEMENT

Two patients had severe patella
Baja (i.e., a low-riding patella).
Their range of movement was 0° to
30° and 0° to 60° only, but be
cause they were pain free they did
not wish to undergo revision. In
one patient, removal of the previous
femoral component resulted in such
severe bone loss that in spite of
three allografting procedures the
femoral tube remained unsatisfacto
ry.12 Her postoperative course was
complicated by infection which
cleared with debridement, but the
femoral component was in too short
a segment of femur and loosened
within 6 months. She has subse
quently undergone revision and
more bone graft was added.
One patient who had a tibial
shaft fracture and a press-fitted
stem continued to have “end pain”
at the stem tip. When the fracture
had healed she underwent revision,
and a new tibial component was
cemented in place. She required a
further 2.5 cm of allograft to build
up the tibia to gain sufficient
length.
Knee ratings were difficult. The
majority of these patients were sal
vage cases and had other problems.
The majority had had at least one
other joint replaced; 60% used
walking aids and although some did
not strictly require it, all were en
couraged to use them.

Twenty-one patients had no pain,
5 had some aching on use of the
limb, including 1 who had recently
undergone another revision. Pain is,
of course, activity related, and if
activities have been reduced it is
difficult to tell how pain free these
patients would be if their other
limbs were normal. For example,
one patient used a wheelchair most
of the time not because of the knee
problem but because of feet, back,
neck and shoulder problems.
Range of motion was usually
over 100° except in the two pa
tients with patella Baja and two
who had knee-fusion takedown.
The latter two had flexion to 50°
and 75° respectively. Two patients,
including the one who had had
poliomyelitis, had a quadriceps lag.
Using the Hospital for Special
Surgery rating system, 1 knee
scored poor, 8 fair and 18 good or
excellent.
Of great interest is the radiologic
review, which considered press-fit
and cemented components; the ce
mented group was subdivided into
those who had revision of a previ
ous stem component and those who
did not.
Of patients who were press-fitted
(four), all showed some degree of
radiolucency. Only one patient,
however, had symptoms severe
enough to require revision. All the

Table 1. Type* and Gradet of Radiolucency
Non-cem ent

Femoral stem

Tibial stem

C em ent revision of stem

Non stem

AP

Lat

AP

Lat

AP

Lat

11-2
111-1
III-2
1-1
111-1
1-1
III-2
0-0

II-2
III-2
III-2
111-1
II-3
1-1
III-2
0-0

1-1
11-1
11-1
III-3
1-1
1-1
1-1
1-1
0
1-1

1-1
11-1
1-1
1-1
1-1
1-1
1-1
1-1
0
1-1

Nil

Nil

Nil

Nil

*1 = radiolucency around 1/3 of the prosthesis closest to the knee, II = radiolucency around 2/3
of the prosthesis closest to the knee, III = complete radiolucency.
t1 = radiolucency less than 1 mm, 2 = radiolucency less than 2 mm, 3 = radiolucency greater
than 2 mm.

revisions of previously cemented
stem knees (six) showed some ra
diolucency, although interestingly
in the tibial stems a type I and
grade 1 only (Table I). The femoral
side showed more radiolucency but,
with the exception of a patient who
had undergone revision, none
showed a type III radiolucency.
In the remaining 17 cases there
was no radiolucency (Fig. 3).

Discussion
The radiologic findings are the
most interesting aspect of this
study. Over the short term (i.e., less
than 7 years), added constraints did
not appear to result in early loosen
ing of a well-fixed stem. These
findings are contrary to all previous
studies1 and require an explanation.
Previous hinged prostheses had rel
atively short stems and were insert
ed with original cement techniques.
In hips, the universal use of short
stems such as the Charnley-Muller
have been abandoned and this study
suggests that short stems in con
strained knee prostheses should
also be abandoned.
A short stem means that the
interface loads are concentrated on
a small area while a longer stem
allows better stress distribution.
Furthermore, from experience with
hip prostheses, it is known that
loosening rates are higher if the
metal stem does not fill at least 50%
of the canal. The distal femoral
canal is so big that it is difficult to
do this and the Guepar II stem fails
to fulfil this criterion, even though
it is much bigger than any other
stem available.
Improved cementing techniques
with brushing, canal plugging, la
vage and pressure injection also
help in stabilizing the implant and
should be used routinely in cemented-stem knees as they are in hips.
The press-fit components func-
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tioned well, although all loosened
to some extent. Only one patient
had symptoms severe enough to
require revision. The absence of
pain in the other cases is remark
able because the Guepar II stem is
not designed for press-fitting. This
provides clinical proof of the find
ings of Andriacchi and Galante’s13
recent study which suggest that
rotatory loads on the knee are not
as high as was feared.
The fact that all cemented stems
revised from previous cemented
stems show some degree of radiolucency is cause for concern. It sug
gests, as in hips, that cemented
revision may not be particularly
durable and that there is a role for a
noncemented long-stem prosthesis
in such cases.14
The infection rate in this series

was low compared with that report
ed in other series,1 but this may
merely be a statistical anomaly re
sulting from small numbers. We
used antibiotic-loaded cement rou
tinely in addition to prophylactic
antibiotics.
There were two main indications
for use of the Guepar II — the
length of the stem and the need for
stability.

cases) and when there was nonun
ion of the proximal tibia (two cases)
and distal femur (two cases) (Fig.

Stem Length

Three types of instability exist:
post-patellectomy, mediolateral and
recurvatum instability.
• Post-patellectomy instabili
ty.1516 Patellectomy results in re
moval of an important anteropost
erior knee stabilizer. If both cruci
ate ligaments have also been re
moved, it is necessary to use a
stabilized prosthesis, either a true
hinge such as the Guepar or a
posterior stabilized knee prosthesis.

The Guepar II has the longest
and heaviest stem of all knee prostheses available in Canada. It was
used when there was extensive bone
loss requiring massive allografting
(six cases), when revision of a previ
ous long stem component such as
the Guepar I was required (three

FIG. 3. Five years after implantation, no radiolucency can be seen. Had this been
operated on today, distal femur would have been rebuilt with allograft bone.
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4) .
The knee in some cases could
have been handled with a semi-constrained prosthesis with a custom
long stem, but custom implants are
extremely expensive.
Instability

FIG. 4. This patient had nonunion of
supracondylar femoral fracture which
had been plated and grafted. Knee was
ankylosed. One year after implantation
union has occurred.
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This was the reason for using the
Guepar II in five cases in this series,
two being knee-fusion takedowns.17
• Mediolateral instability. It is
now universally accepted that liga
ment balancing is required in total
knee replacement for a semi-con
strained implant to be successful. In
ligament balancing, the tight side is
loosened until the tension in the
collateral ligaments is the same.
Ligament tightening on the loose
side has not been successful.2 In
primary knee replacement when the
deformity is intra-articular, liga
ment balancing is always possible,
but this is not necessarily the case
when the deformity is extra-articu
lar because ligaments may have to
be over-lengthened, and for this
they have a limited capacity.18
In a revision situation, ligament
balancing is more difficult, but is
usually possible. If, however, a
loose tibial component sinks down
on one side and remains there for
some time, intense ligament scar
ring may result. Removal of the
component slightly loosens the liga
ments on the loose side and, in
spite of the most extensive release
possible of the sleeve on the tight
side, correction occasionally cannot
be achieved — hence, the use of a
Guepar II prosthesis in this situa
tion in eight cases.
• Recurvatum instability. Sig
nificant recurvatum deformity in
the arthritic knee can usually be
handled by inserting a semi-con
strained knee so tightly that the
patient ends up with a 10° fixed
flexion deformity. However, when
neurologic problems exist as they
may after poliomyelitis because the
patient has stretched out the cap
sule and ligaments, the same thing
will likely happen if a semi-constrained knee prosthesis is used.
Indeed, in these rare instances when
this type of surgery is necessary,
the knee is painful, not from arthri
tis but from a global instability due

to stretching of all the ligaments.
This is only likely to occur if there
are no functioning muscles below
the hip, so the knee must be capa
ble of a little hyperextension. It is
also more likely to occur if the hip
or ankle have been fused.
Although a range of stem sizes
would be of value, technical prob
lems in this series were surprisingly
few. The biggest problem was cor
recting previous rotatory deformity.
If the knee had been replaced and
the leg left in external rotation with
a dislocated patella, it was difficult
to correct even when the proximal
tibia was skeletonized. A frighten
ing amount of force sometimes had
to be used to connect the two
components, often coupled with a
wide lateral release. It is for this
reason that two patellas remained in
a significantly Baja position. After a
medial parapatellar approach and a
lateral release, a tibial tubercle
transfer was not attempted for fear
of totally devascularizing the patel
la.19
Considering the complexity of
the cases, the results achieved were
reasonably acceptable. It should be
emphasized, however, that the indi
cations for hinged total knee re
placement are few. The recent intro
duction of variable stem length im
plants virtually negates one of the
main indications used in this series
(i.e., bone loss). Furthermore, it is
becoming apparent that a posterior
stabilized knee gives adequate an
teroposterior stability when the pa
tella and cruciate ligaments have
been removed. Whether there is any
real load difference between a true
hinge such as the Guepar II and a
rotating platform hinge and a nonlinked hinge18 remains to be deter
mined.
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Concurrent Poland’s Syndrome and
Gynecomastia: a Case Report
James Mahoney, MD, FRCSC, FACS; Brian Hynes, BSc, MD
Gynecomastia (enlargement of the male breast) is a common occurrence during
puberty and usually resolves. Poland’s syndrome or hypoplasia of the chest wall is a
rare congenital anomaly associated with hypoplasia of the ipsilateral extremity.
Simultaneous presentation of gynecomastia and Poland’s syndrome in a 26-year-old
man increased the extent of asymmetry and the perception of each deformity.
Surgical reduction of the enlarged breast greatly reduced the asymmetry, giving a
satisfactory result.
La gynecomastie (le developpement de la poitrine chez l’homme) est frequemment
observee a la puberte et se corrige habituellement d’elle-meme. Le syndrome de
Poland, ou hypoplasie de la paroi thoracique, est une anomalie congenitale rare qui
est associee a une hypoplasie des membres ipsilateraux. Le developpement, chez un
homme de 26 ans, d’une gynecomastie et d’un syndrome de Poland exagera
l’etendue de l’asymetrie et la perception de chacune des difformites. Une reduction
chirurgicale de la poitrine reduisit l’asymetrie, laissant un resultat satisfaisant.

oland’s syndrome (hypoplasia
of the chest wall and ipsilateral
extremity) and gynecomastia (en
largement of the male breast) repre
sent two distinct chest-wall deformi
ties. We describe the simultaneous
appearance of Poland’s syndrome
and gynecomastia on opposite sides
of the chest wall in a 26-year-old
man. The conditions produced pro
found asymmetry, offering an un
usual challenge. Treatment of the
gynecomastia greatly reduced the
asymmetry and gave a satisfactory
result in this patient.

P

Case Report
A healthy 26-year-old man pre
sented with persistent unilateral
right gynecomastia, which had been
present for approximately 11 years.
His main concern was the obvious
asymmetry due to the enlarged

right breast which was accentuated
by contralateral chest-wall hypopla
sia.
His medical history revealed that
he was born at term after an un
complicated pregnancy. At the age
of 2 years he was seen by the family
doctor because of an absent left
nipple. Examination had revealed a
very small nipple on the left com
pared with the right. The left pectoralis muscle was deficient, caus
ing a sunken appearance to the left
side of the chest.
During puberty, unilateral clinical
right gynecomastia presented.
Other male secondary sexual cha
racteristics developed normally.
Our examination revealed obvi
ous chest-wall asymmetry. An en
larged right breast, which was non
tender, ptotic and of moderate size
with a firm consistency, was present
(Fig. 1). There was a large areola
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and nipple. The left anterior chest
wall had a hollow, sunken appear
ance. The sternal head of the pectoralis major and the left anterior
axillary fold were absent. The sub
cutaneous tissue appeared deficient.
The clavicular portion of the pectoralis major muscle was intact. A
2-mm hypoplastic left nipple with
out an areola was visible. Otherwise
the hands and arms on both sides
were similar. Laboratory tests in
cluding measurement of adrenocor
ticotropic hormone, folliclestimulating hormone, thyroidstimulating hormone, prolactin, tes
tosterone, cortisol and estradiol lev
els as well as a chest x-ray film were
all within normal limits.
Treatment was directed toward
the enlarged right breast. The uni
lateral right gynecomastia was re
sected through an inferior periareolar incision. Fibroadipose tissue,
weighing 180 g and measuring 11
X 8 X 3 cm, was excised. Care was
taken to maintain the nipple projec
tion. His postoperative course was
uncomplicated. Examination 3
months postoperatively revealed im
proved symmetry between the two
sides (Fig. 2). The patient was very
pleased with the result and did not
request any further surgery.

Discussion
Our case represents an unusual
clinical situation in which two dif
ferent types of chest-wall abnormal
ity presented simultaneously, em
phasizing the abnormalities of each
deformity. The left hypoplastic nip
ple and pectoralis muscle, repre
senting an incomplete expression of
Poland’s anomaly, accentuated the
contralateral enlarged right breast,

POLAND’S SYNDROME AND GYNECOMASTIA

the patient’s main complaint.
Hypoplasia of the chest wall sec
ondary to Poland’s syndrome can
result in serious chest-wall deformi
ty. It was first described in 1841 by
Alfred Poland1 and involves a spec
trum of congenital anomalies, all of
which may or may not be present.
The classic features of the anomaly
are unilateral absence of the sterno
costal head of the pectoralis major
muscle, a hypoplastic hand and ipsilateral syndactyly, but considerable
variation has been reported,2-4 in
cluding hypoplasia or absence of
the breast, hypoplasia of the chest
subcutaneous tissue, ipsilateral brachysyndactyly, costocartilage and
vertebral defects, winged scapulas,
posterior shoulder girdle anomalies,
renal anomalies and even herniation
of the lung. For the patient, the
emotional stigma is often great,
especially in women. Poland’s
anomaly is thought to occur ap
proximately once in 25 000 births.2
The right side is affected more
frequently than the left. Although
most reports of the Poland anomaly
and its variants have been sporadic,
there is a handful of familial cases
suggesting autosomal dominant in
heritance.5 Minor manifestations of
the syndrome will easily be over
looked without careful examination
of the relatives. Various hypotheses
have been put forth regarding the
pathogenesis of the syndrome, in
cluding an intrauterine vascular in
sult causing hypoxia, arising from

arterial spasm or poor collateral
circulation.6-8 The developmental
insult is thought to occur between
6 and 8 weeks’ gestation, the peri
od during which upper extremity,
hand and pectoral development
takes place. Anomalies associated
with other organ systems have also
been reported. Treatment of the
chest deformity depends on the ex
tent of the anomaly and may re
quire the use of split rib or bone
grafts if there is a significant defect.
Breast reconstruction is commonly
requested. Soft-tissue augmentation
of the chest wall with the latissimus
dorsi island myocutaneous flap
combined with a prosthesis can pro
vide a very satisfactory result.910
Reduction or augmentation of the
opposite breast can also improve
breast symmetry.
Gynecomastia or excessive devel
opment of the male mammary gland
is the most common breast disorder
of males. An early historical de
scription was provided by Herodo
tus, who noted it amongst the Scy
thians. Paulus of Aegina (635 to
690 AD), the last of the great
physicians of Byzantium, clearly
recommended a surgical approach
to this disorder when the “deformi
ty had the reproach of effemina
cy”.11 Although the size of the
breast will vary, clinical diagnosis
requires that a 2-cm diameter of
subareolar mammary tissue be pres
ent.
Histologically, early gyneco-

FIG. 1. Right gynecomastia and con
tralateral Poland’s syndrome in
26-year-old man.

FIG. 2. Postoperative appearance fol
lowing surgical removal of breast tis
sue.

mastia is characterized by ductules
embedded in loose connective tis
sue. Later, ductular structures be
come less conspicuous in a dense
hyaline stroma.12 Gynecomastia can
be either physiologic, as in the
majority of cases, or pathological,
resulting from one of three basic
mechanisms: deficiency of testoster
one production or reduced respon
siveness to its action, increase in
estrogen production, and secondary
to the effects of drugs.13 As a
clinical entity, gynecomastia is seen
frequently.14 It is especially com
mon among males at puberty and
usually regresses spontaneously.
Gynecomastia persisting into man
hood is rare and is related to persis
tent breast or fatty tissue, or both.
Our patient gave a history of true
gynecomastia with enlargement of
the breast at puberty.
In the majority of instances the
cause of gynecomastia is unknown,
but it is thought to be a physiologic
response to the ratio of circulating
estrogens and androgens.14 Gyneco
mastia again increases in frequency
in later life as the amount of circu
lating androgen decreases. Male
breast enlargement associated with
mainly adipose tissue is seen at this
time and is not related to any
endocrine abnormality. Often a
cause cannot be identified. History
and physical examination should
include the drug history and exami
nation of the testes. Laboratory
investigations of liver function and
endocrine status (serum androstenedione or 24-hour urinary
17-ketosteroids, plasma estradiol,
luteinizing hormone and testoster
one) should be performed when the
drug history is negative, the breast
is tender (indicating rapid growth)
or palpable breast tissue is greater
than 4 cm in diameter, or when
based on the clinical findings.13
In Poland’s anomaly, develop
mental arrest of ectodermal and
mesodermal elements results in the
CJS, VOL. S3. NO. 1. FEBRUARY 1990
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absence of pectoralis muscle, sub
cutaneous tissue and breast tissue.
End-organ response secondary to
hormone-tissue receptor interac
tion is not possible. This patient’s
disposition to gynecomastia was
manifested on the right side where
the ectodermal-mesodermal deriva
tives were intact. We hypothesize
that the left side could not mount a
similar end-organ response second
ary to a developmental lack of re
ceptor-sensitive tissues and subse
quently less tissue was present on
that side and the asymmetry was
accentuated.
The object of surgical treatment
of gynecomastia, once an underly
ing cause has been ruled out, is to
restore the normal male contour of
the chest with minimal scarring.15
Different operations have been rec
ommended, depending on the size
of the affected breasts. A classifica
tion of the deformity, based on the
size of the breast and the recom
mended operation is available.16 Re
moval of the tissue, usually
through an inferior periareolar inci
sion, preserving adequate tissue be
neath the nipple to prevent retrac
tion, has been the usual approach.
In larger men who have redundant
skin, excision of the skin is neces
sary.12 Recently, suction lipolysis
has been used as an adjunct to
excision in some patients and can
effectively treat the problem alone
in patients with mildly to moderate
ly enlarged breasts, especially when
the deformity consists mainly of
adipose tissue.17 From the experi
ence of the senior author, complica
tions appear to be fewer with this
technique.
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Femorodistal Bypass Using the
Chemically Processed Human Umbilical
Vein Graft: 9-Year Experience
Michel Batt, MD;* Georges Avril, MD;*t Jean-Marie Gagliardi, MD; Randy Guzman, MD;t
Robert Guidoin, PhD;t Norbert Boas, MD;* Bruno Daune, MD;* Reda Hassen-Khodja, MD;*
Pierre Le Bas, MD;*
To evaluate patency, limb salvage rates and complications associated with the use of
human umbilical vein as an arterial substitute, the authors carried out a
retrospective review of 52 femorodistal bypasses performed over 9 years using
human umbilical vein. Indications for operation included acute ischemia, rest pain
and nonhealing ulceration or gangrene. There were 28 early occlusions, which
resulted in a 1-month primary patency rate of 46% and a secondary patency rate of
52%. The primary and secondary patency rates at 1 year were 18% and 19%
respectively. The mean limb salvage rate at 1 month was 57% and at 1 year 34%.
Three aneurysms occurred (two anastomotic, one graft). Factors found to have a
significant effect on patency rates were indication for operation and state of distal
runoff. Infection occurred in 6% of grafts and led to amputation in every case. These
disappointing results have caused the authors to discontinue use of human umbilical
vein as an arterial substitute.

Cette etude retrospective concerne 52 pontages femoro-jambiers realises a 1’aide de
la veine ombilicale humaine sur une periode de 9 ans. Les indications operatoires
ont ete une ischemie aigue, l’existence de douleurs de decubitus et l’existence
d’ulcerations ou de gangrene. Vingt-huit occlusions precoces sont survenues
donnant une permabilite primaire a 1 mois de 46% et une permabilite secondaire de
52%. Les taux de permabilite primaire et secondaire a 1 an etaient respectivement de
18% et 19%. Le taux de sauvetage de membre etait de 57% a 1 mois et de 34% a 1 an.
Trois anevrysmes ont ete constates (deux anastomotiques, un prothetique). Les
facteurs ayant une incidence sur le taux de permabilite ont ete l’indication
operatoire et le lit d’aval. L’infection est survenue dans 6% des greffes et toutes ont
conduit a une amputation. Ces resultats decevants ont conduit les auteurs a
suspendre l’utilisation de la veine ombilicale comme substitut arteriel pour les
revascularisations de jambe.
From the Department o f Surgery, H opital Annexe-Republique, Centre Hospitalier Universitaire
de Nice, France
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he concept of a readily avail
able graft of biologic origin and
the outstanding early patency rates
reported by several authors popu
larized the use of glutaraldehydetreated human umbilical vein (HUV)
as an arterial substitute. 1-3
Over the last decade, we have
routinely used this graft if the au
tologous saphenous vein was ab
sent or unsuitable for lower-limb
revascularization.
Bypass grafting to the tibial or
peroneal level has also gained ac
ceptance in limb salvage operations,
and many of the grafts used for
revascularization at these sites have
been HUV.4 The inferior patency
rates with bypasses to these levels
compared with more proximal levels
and the continuing controversy of
the ultimate fate of HUV grafts,
particularly with respect to aneu
rysm formation, have prompted us
to examine our own experience
with HUV grafts in femorodistal
bypasses.5'6
Our objectives were to evaluate
the patency rate, the limb salvage
rate and the complications associat
ed with the use of HUV for femoro
distal bypass grafting over a 9-year
period.

T

Patients and Methods
During the 9 years from January
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1978 to April 1987, 551 femoropopliteal or femorodistal bypass grafts
were inserted by surgeons in the
Vascular Surgery Department of
the Hopital Annexe Republique in
Nice, France. Of these, 279 were
femorodistal bypass grafts; autolo
gous saphenous vein was used in
227 and the HUV graft in 52 cases
in which the saphenous vein was
absent (17) or unsuitable (35).
These 52 femorodistal HUV grafts
and the accompanying data regard
ing patients, operations and follow
up formed the basis of this study.
Patients

There were 48 patients (28 men,
20 women). The average age was
74 years (range from 43 to 94
years). Most (44) underwent unilat
eral bypass; 2 patients had two
successive bypasses on the same
limb and 2 others required bilateral
bypass.
Associated diseases and risk fac
tors are shown in Table I. Twentytwo patients had previously under
gone vascular procedures (Table II).
The indications for operation
were acute reversible ischemia
(acute ischemia grade II7) in 21
cases; rest pain (chronic ischemia
grade II7) in 5 cases and nonhealing
ulceration or gangrene (chronic
ischemia grade III7) in 26 cases. All
patients underwent angiography
preoperatively so that we could de
termine the rate of runoff and select
the distal site of anastomosis. If the
angiogram was unsatisfactory, an
other angiogram was obtained in
the operating room immediately be
fore revascularization; the site was
selected by examining late films of
contrast injected either into the
common or deep femoral arteries or
films of contrast injected directly
into the distal popliteal artery. Run
off was considered acceptable if at
least one tibial or peroneal artery
was patent and there was a demon
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strable pedal arch (not necessarily
in continuity). Runoff was termed
poor when one of the tibial or
peroneal arteries was not patent or
when the pedal arch was not dem
onstrated.
The Operation

All operations were performed by
the same surgical team using the
same technique. The HUV graft was
prepared according to manufactur
er’s instructions.1'6 The distal anas
tomosis was performed first. In six
cases, a short segment of autoge
nous vein was interposed between
the graft and the distal anastomotic
site to facilitate the reconstruction.
The levels of proximal and distal
anastomoses are shown in Table III.
The grafts followed either a subcu
taneous (43 cases) or anatomic (9
cases) route. Clamps were never
applied to the graft and each anas
tomosis was performed using two
running monofilament propylene
sutures. The integrity of all distal
anastomoses was verified by angi
ography; any technical errors were
corrected immediately. Adjunctive
procedures are shown in Table IV.
Antibiotics were used prophylactically only in 21 patients who had
ulcers or gangrene. Postoperatively,
all patients were placed on antivita
Table 1. A s s o c ia te d D isease and R isk
F a c to rs

Disease

%

H eart d is e a s e
H y p e rte n s io n
D iabetes
C e re b ro v a s c u la r in s u ffic ie n c y
S m o k in g h is to ry

40
31
21
3
60

min K drugs unless these were
contraindicated.
Follow-up

Follow-up examinations were per
formed 1 and 3 months postopera
tively and every 6 months thereafter
during 9 years of follow-up. Graft
patency was confirmed by a palpa
ble graft pulse and by measurement
of distal pressures. Angiography
was performed if an abnormality
was detected.
Statistical Analysis

The actuarial method was used to
estimate graft patency and survival
rates. The confidence interval was
calculated using Student’s f-test.
Survival curves were compared
using the log rank test. Comparison
of results by period were made by
the x2 test.

Results
Patient Survival

The actuarial survival curve is
Table III. S ite o f P ro x im a l and D ista l
A n a s to m o s e s

No. of
cases

Site
P ro x im a l
C o m m o n fe m o ra l a rte ry
S u p e rfic ia l fe m o ra l a rte ry
D eep fe m o ra l a rte ry
P ro x im a l re v a s c u la riz a tio n
E x te rn a l ilia c a rte ry
D is ta l
P o s te rio r tib ia l a rte ry
A n te rio r tib ia l a rte ry
P eron e a l a rte ry

25
13
1
11
2
9
29
14

Table II. P re v io u s V a s c u la r P ro ce d u re s
Procedure
F e m o ro p o p lite a l b y p a s s
F e m o ro d is ta l b y p a s s
A o rto ilia c re v a s c u la riz a tio n
A x illo fe m o ra l b y p a s s
P ro fu n d o p la s ty
L u m b a r s y m p a th e c to m y

No. of
cases
12
10
7
5
6
24

Table IV. A d ju n c tiv e P ro ce d u re s to
F e m o ro tib ia l R e c o n s tru c tio n

Procedure
P ro x im a l re v a s c u la riz a tio n
P ro fu n d o p la s ty
T h ro m b e c to m y o f leg a rte rie s
L u m b a r s y m p a th e c to m y
S e q u e n tia l b y p a s s e s

No.
1
8
2
3
2
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shown in Fig. 1. Three patients died
within 30 days of operation — one
of a cerebrovascular accident, one
of pelvic ischemia and one because
of deterioration in general condi
tion. During the follow-up period,

Fig. 1. Actuarial survival curve.

17 patients died. Survival at 3 years
was 59%.
Graft Patency

Primary patency is shown in Fig.

2. There were 28 occlusions within
30 days of operation, giving a pri
mary patency rate of 46%. Restora
tion of patency by thrombectomy
was possible in 3 of the 28 cases,
giving a secondary patency rate of
52% at 1 month. These differences
are not statistically significant.
Of the 27 grafts that remained
patent for more than 1 month, 15
became occluded, but thrombecto
my was successful in two of six
cases. Primary and secondary pat
ency rates at 12 months were 18%
and 19% respectively. At 1 month,
the 27 limbs with poor runoff preoperatively had a significantly (p <
0.01) higher rate of graft occlusion
(21 of 27) than the 25 limbs with
acceptable runoff (7 of 25). This
trend persisted after 1 month, with
higher rates of occlusion in limbs
with poor runoff (6 of 6 versus 8 of
18 respectively), but the numbers
were too small to be statistically
significant.
Operations for acute ischemia
were also associated with a higher
rate of occlusion (16 of 21) than
those performed for chronic isch
emia (12 of 31).
Limb Salvage

Fig. 2. Actuarial curve of primary patency.

Fig. 3. Actuarial curve of limb salvage.

The 25 grafts that became oc
cluded within 30 days of operation
and remained occluded despite
thrombectomy led to 22 above-knee
amputations. The limb salvage rate
at 1 month was 57% (Fig. 3). At 1
year, 15 of the 27 grafts that
remained patent at 1 month had
become occluded and led to 10
above-knee amputations. Unsuc
cessful thrombectomy in this group
(four out of six cases) uniformly led
to above-knee amputation. This was
performed immediately upon graft
occlusion in five cases. In one case,
an above-knee amputation was per
formed after a new graft on another
leg artery had failed. Overall, limb
salvage at 1 year was 34%.
CJS, VOL. 33, NO. 1, FEBRUARY 1990
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Infection

Two cases of infection within the
first month led to above-knee ampu
tation and one of the amputations
was preceded by a failed extra-ana
tomic bypass. An infection at 3
months led to graft removal and
replacement which failed and subse
quently led to amputation.
Stability of HUV

One graft aneurysm occurred
during the second month after op
eration; at reoperation mural thin
ning was found. An HUV replace
ment graft subsequently occluded,
necessitating above-knee amputa
tion. Two cases of anastomotic an
eurysm at the femoral level ap
peared within an average of 30
months. One was a small aneurysm;
the other, larger aneurysm was re
sected without complication (Fig.
4).
One case of distal embolization
was suspected 1 week postoperatively, because a previously docu
mented peripheral pulse disap
peared despite a patent graft pulse.
Angiography revealed distal occlu
sion by an embolism which presum
ably had originated from the graft.
Thrombectomy failed and subse
quently amputation was necessary.
There was one case of mural

thrombosis of an HUV graft; the
graft was replaced with HUV (Fig.
5). The patient’s postoperative
course was uncomplicated. Another
graft failed 24 hours postoperatively when the proximal portion of the
graft rupured. At reoperation, the
wall had ruptured in an area of
mural thinning, but the Dacron
mesh was intact. The zone of rup
ture was resected and an interposi
tion polytetrafluoroethylene (PTFE)
graft implanted; unfortunately this
lasted only 6 months before occlud
ing.
Two cases of sterile serous effu
sion were documented. Despite re
currence after aspiration, they dis
appeared spontaneously over 6
months and both grafts remained
patent.

Discussion
There is general acceptance of
the rate of femorodistal bypass in
patients with rest pain, ulceration
or gangrene.8-10 The preferred graft
material, if available, is autogenous
saphenous vein, either reversed or
in situ.10 Five-year patency rates as
high as 70% and a limb salvage rate
of 65% can be achieved by experi
enced surgeons.4-10 Alternatives, if
the vein is not available or suitable,
are PTFE, composite grafts or, as

Fig. 4. Anastomotic aneurysm occurring in human umbilical
vein graft after 30 months’ implantation.
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in this series, HUV. Among the best
results using HUV for femorodistal
bypass grafts are those reported by
Dardik and colleagues1 who
achieved a 1-year patency rate of
62% and a 3-year rate of 58%.8
Cranley and Hafner3 reported 1- and
3-year patency rates of 55% and
38% respectively. At the other end
of the spectrum, more disappoint
ing results have been reported by
Harris and colleagues11 who had a
1-year patency of 34% and a 2-year
patency of 18%. The patency rate
reported in our series was 46% at 1
month and 18% at 1 year. Factors
found to be associated with de
creased patency were poor runoff
and operative indications (acute ver
sus chronic), similar to those of
other reports.8'12 Sites of distal
anastomosis, graft type and tobacco
use are also important determinants
of patency although we did not
investigate these factors in this
study.12 No effect of patency could
be demonstrated by comparing one
versus two operations; this finding
corresponded with that of Dalsing
and associates.9 A particular prob
lem in our study was the rate of
early occlusion (53%), which was
higher than that of most other
reports.2-3'5'1013-15 Potential causes
of this high rate were differences in
patient selection, distal runoff and a
discrepancy in the size of the graft

Fig. 5. Mural thrombus in graft after 3 months.
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versus the host artery, the presence
of free glutaraldehyde,15 irregulari
ties of the luminal surface of the
graft and persistence of air bubble
after rinsing.16 One report, which
examined virgin HUV grafts,
showed several structural defects,
including folds, which may predis
pose to thrombosis.17 We believe
that the high rate of early occlusion
in our study could be explained by a
relatively large number of patients
with far-advanced ischemia. In such
cases, a few authors have suggested
immediate amputation with no at
tempt at revascularization. Howev
er, our limb salvage rate of 34% at
1 year suggested that we should
pursue this treatment for ischemic
limbs.18 Nevertheless, the grafts
that suffered early occlusion did
have a higher rate of amputation
(22 of 25) than grafts that suffered
late occlusion (10 of 15).
Infection was documented in 6%
(3 of 52) of cases, which is consis
tent with the reported range (1% to
6%) for prosthetic grafts.19 All three
cases eventually led to amputation.
Kikta and associates19 reported an
amputation rate of 79% (in 32 pa
tients with limb infection) and noted
that for the four largest individual
series the amputation rates ranged
from 36% to 75%. The structural
defects already noted,17 such as ir
regularities and folds not only rep
resent potential areas for thrombo
sis formation but also privileged
sites for bacteremic colonization.
Pathological findings of bacteria in
vading the wall of some infected
grafts would lead us to encourage
complete excision of the graft in
cases of clinical infection.20
Finally, two cases of anastomotic
aneurysm and one case of prosthet
ic aneurysm were documented in
our series. In a series of 907 cases
reported by Dardik and associates,21
there was a 1.4% incidence of anas

tomotic aneurysm and 30% inci
dence of aneurysmal formation (af
ter 5 years), but operation was
required in only 6% of cases.

Conclusions
A 1-month primary patency of
only 46% and 1-year patency of
18% are disappointing results. This,
combined with the potential phe
nomenon of biodegradation, have
led us to discontinue the use of
HUV grafts as an arterial substitute
for lower-limb revascularization.
We thank Professor Claude Poulin and
Drs. Claude Suisse and Louis-Jean
Roussel for their assistance with the
statistical analysis, and Marielle Corriveau, Karen Horth and Richard Cou
ture for their technical assistance. Meet
ings of the French and Quebec groups
were supported, in part, by les
Echanges France-Quebec.
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L angioplastie au laser: une nouvelle
approche dans le traitement de l’occlusion
iliaque
J. Laliberte, MD;* Y-M. Dion, MD, MSc, FRCSC;* G. Dionne, MD, FRCPCt
L’angioplastie thermique au laser est une technique nouvelle. Le suivi le plus long
date de 3 ans. Elle est presentement de plus en plus employee en vue du traitement
de la maladie vasculaire atheromateuse au niveau du segment femoro-poplite. Les
auteurs decrivent un cas de recanalisation fructueuse d’une artere iliaque externe
gauche completement obstruee, grace a la technique d’angioplastie thermique au
laser. L’abord chirurgical de l’artere s’est effectuee par une incision femorale
gauche. La patiente a eu son conge de l’hopital au 4e jour postoperatoire alors
qu’elle ne presentait plus de claudication intermittente. Les indications actuelles de
cette procedure, ses avantages et ses complications potentielles sont discutes.

Laser thermal angioplasty is a new technique. The longest follow-up is 3 years. It is
used increasingly for the treatment of atheromatous disease of the femoropopliteal
segment. The authors describe a case of successful recanalization of a completely
occluded left external iliac artery using laser thermal angioplasty. The artery was
approached through a left femoral dissection. The patient was discharged from the
hospital on postoperative day 4 without claudication. The present indications and
potential benefits and complications of this procedure are discussed.

u cours des dernieres annees,
nous avons assiste au developpement de nouvelles methodes
moins invasives de traitement de la
maladie vasculaire atheromateuse.
La plus connue et la plus repandue
est l’angioplastie de dilatation. Plus
recemment, la technologie du laser
a ete appliquee aux maladies vasculaires comme adjuvant a la dilata
tion,1 pour la recanalisation des

A

vaisseaux obliteres.2 Deja, sans
toutefois en faire un usage courant,
certains groupes ont utilise avec
succes l’angioplastie au laser pour
les obstructions femoro-poplitees.1
Son utilisation pour les obstruc
tions iliaques est beaucoup moins
repandue.1 Nous presentons un cas
d’obliteration iliaque symptomatique ou Tangioplastie au laser fut
utilisee avec succes.

Du *Departement de chirurgie et du fDepartement de radiologie, Hopital St-Frangois d'Assise,
Universite Laval, Quebec, PQ
Accepte pour publication le 28 septembre 1988
Les demandes de tires a part doivent etre adressees au: Dr Y-M. Dion, Hopital St-Frangois
d ’Assise, 10 de 1’Espinay, Quebec, PQ C1E 3L5
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Presentation de cas
II s’agit d’une patiente de 45 ans,
obese, fumant un paquet par jour,
hypertendue et angineuse depuis 3
ans, qui consulte pour claudication
du membre inferieur gauche. Le
questionnaire revele que ses problemes ont commence il y a plus de
2 ans. En janvier 1988, elle notait
l’apparition soudaine d’une douleur
suivie de decoloration bleutee du 5e
orteil du pied gauche, le tout ayant
rentre dans l’ordre en moins de 2
semaines. De plus, elle se plaignait
d’une claudication a la marche
apres environ 100 pieds sur terrain
plat, avec douleur au niveau du
mollet gauche. Depuis avril 1988,
elle accuse une exacerbation de la
claudication qui survient apres envi
ron 50 pieds avec une douleur qui
progresse du mollet a la cuisse si
elle persiste a marcher. Par ailleurs,
elle ne presente aucune douleur de
repos.
A l’examen vasculaire des membres inferieurs, les pouls sont tres
bien per$us a tous les niveaux du
cote droit. Du cote gauche, il y a
absence de pouls femoral et de tous
les pouls distaux avec cependant
une tres bonne coloration du mem
bre distalement.
Investigation

L’evaluation a l’echo duplex cou-

L’ANGIOPLASTIE AU LASER

leur des membres inferieurs est normale du cote droit mais, du cote
gauche, il y a obstruction complete
de l’artere iliaque externe sur plus
de 10 cm avec un arbre arteriel
distal normal.
L’arteriographie demontre l’obstruction complete sur environ 10
cm de 1’iliaque externe gauche avec
un arbre arteriel normal des deux
membres inferieurs (Fig. 1).

FIG. 1. Arteriographie preoperatoire
demontrant l’obstruction complete de
l'artere iliaque externe gauche des son
origine. Vascularisation de l’artere
femorale commune gauche par les col
laterals venant de l’artere iliaque in
terne.

FIG. 2. Arteriographie peroperatoire
demontrant la complete recanalisation
de l’artere iliaque externe gauche.

Procedure
Sous anesthesie generate, la patiente ayant ete drapee comme pour
un pontage, les arteres femorale
commune, profonde et superficielle
gauches sont dissequees. Apres
heparinisation systemique (5000
unites intra-veineuses), les femorales superficielle et profonde sont
clampees. Par la suite, l’artere
femorale commune est ponctionee,
puis dilatee jusqu’a un calibre 8 de
French pour y faire penetrer 1’introducteur (Cordis Corp., Miami, Fla.)
par lequel un guide Bentson (Cook
035; Cook Co., Bloomington, Ind.)
est passe jusqu’au travers de [’obs
truction, sous controle fluoroscopique. Enfin, une sonde du laser
(Trimedyne 775-2.5; Trimedyne,
Santa Ana, Calif.) est introduite sur
le guide et l’obstruction recanalisee
sous controle fluoroscopique en
delivrant 13 W de faqon continue
au laser YAG.
Une fois l’artere recanalisee, un
catheter a ballonnet (10 cm - 7
mm) est introduit pour dilater le
segment nouvellement recanalise.
Suite a la dilatation, l’arteriographie
revele la complete recanalisation du
segment anterieurement obstrue
(Figs. 2 et 3). Puis, l’introducteur

est retire, l’artere femorale refermee
par un seul point de Prolene 4-0 et
la patiente heparinee de faqon sys
temique pour maintenir un temps
de cephaline activee de 2.5 fois la
normale durant 24 heures. Par la
suite, elle est mise a 1’Entrophen10, a la dose de 1 comprime par
jour.

Evolution postoperatoire
En postoperatoire immediat, le
pouls de l’artere pedieuse et celui de
l’artere tibiale posterieure gauche
sont bien per?us et la patiente est
gardee a l’unite des soins intensifs
pendant 24 heures, puis mobilisee
le lendemain de l’operation. Quarante-huit heures apres l’operation, la
patiente marche sans aucune claudi
cation. L’index cheville-bras du cote
gauche est de 0.83. L’echographie
duplex couleur ne demontre aucune
stenose residuelle au niveau de l’iliaque externe gauche et presente
des ondes velocimetriques triphasiques normales au niveau de la femo
rale commune gauche. La patiente
est done liberee le 4e jour posto
peratoire, completement asymptomatique.

Discussion

FIG. 3. Detail de l’arteriographie pe
roperatoire demontrant l’origine de
l’artere iliaque externe gauche nou
vellement recanalisee.

Classiquement, l’approche therapeutique d’une claudication handicapante secondaire a une occlusion
iliaque d’origine atheromateuse est
soit la thrombo-endarteriectomie,
soit le pontage aorto-bifemoral, aorto-femoral unilateral ou femorofemoral.
L’interet pour des methodes
moins invasives du traitement de la
claudication secondaire a la maladie
iliaque a vu nattre, a la fin des
annees 70, l’angioplastie percutanee
de dilatation par ballonnet qui,
maintenant, est tres largement utilisee avec de tres bons resultats.
CJS, VOL. 33. NO. 1, FEBRUARY 1990
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Le succes de la dilatation transluminale a sans doute contribute fortement au developpement d’autres
techniques non invasives, dont l’angioplastie au laser qui est applicable
a l’obstruction complete.
Actuellement, la technique la
plus repandue en clinique utilise la
fibre optique par laquelle l’energie
du rayon laser est convertie en
chaleur sur une pointe metallique.
C’est done par un processus thermique que les plaques d’atherome
sont vaporisees et liquefiees sous
Taction du laser, permettant ainsi la
recanalisation d’une obstruction
avec un risque minimal d’embolisation peripherique.3
L’utilisation de Tangioplastie au
laser comme adjuvant a la dilatation
dans le traitement des occlusions
arterielles femoro-poplitees a deja
ete rapportee comme efficace et
securitaire.1’24-6 Sanborn et collaborateurs1 rapportent un taux de suc
ces initial de 83% chez des patients
avec obstructions femoro-poplitees
et Cumberland et collaborateurs6
avec des malades ayant des obstruc
tions iliaques ou femoro-poplitees,
rapportent un taux de recanalisa
tion de 89%. Les indications actuelles de Tangioplastie au laser sont la
presence d’une stenose tres serree
(difficilement dilatable) ou d’une oc
clusion sur un segment relativement court. Les arteres fortement
calcifiees et les occlusions longues
(plus de 12 cm) sont plus difficile
ment repermeabilisables.2
Les complications potentielles de
Tangioplastie au laser sont la perfo
ration, la reocclusion, la formation
d’anevrisme et Tembolisation peri
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pherique. Comme nous Tavons
mentionne plus haut, la vaporisa
tion de la plaque d’atherome par le
laser reduit au minimum le risque
d’embolisation. La reocclusion et la
thrombose a court terme peuvent
etre prevenues par une anticoagula
tion systemique lors de Tintervention et durant les premieres 24
heures. Un traitement a long terme
aux anti-plaquettaires est par la
suite institue. Finalement, la perfo
ration qui, lors des premieres etu
des, etait frequente peut etre prevenue de deux manieres: en limitant
Tenergie delivree par le laser7 et en
irriguant de fa?on continuelle le
vaisseau lors de la procedure.8
Bien que plusieurs articles aient
ete publies concernant les oblitera
tions femoro-poplitees la litterature
est plus silencieuse quant a [’utilisa
tion du laser comme adjuvant a la
dilatation pour les obstructions ilia
ques. Le cas que nous avons
preserves demontre la possibility
d ’application de cette methode au
niveau iliaque, avec un tres bon
resultat a court terme. Les avantages de Tangioplastie au laser au
niveau iliaque sont evidents. En
effet, elle est moins morbide qu’un
pontage aorto-femoral ou ilio-femoral ou qu’une thrombo-endarterectomie iliaque, reduisant ainsi le
sejour hospitalier au minimum
(moins de 1 semaine). De plus, le
patient peut retourner a ses activites normales dans les jours qui
suivent Tintervention.
Comme toute nouvelle technique,
Tangioplastie au laser devra subir
Tepreuve du temps avant que Ton
puisse conclure definitivement sur

sa valeur a long terme. Quoiqu’il en
soit, elle ouvre une nouvelle avenue
therapeutique pour certains patients
souffrant d’occlusion atheromateuse arterielle, tant au niveau femoropoplite qu’iliaque.
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HISTORY OF SURGERY

T w o Heroes of the Class of Onety-Seven:
Part I
Peter B. Samuels, MD, MSc, FRCSC, FACS
Frederick Banting and Norman Bethune were linked in time, place of birth, as
classmates in medical college, veterans of World War I and heroes to different
worlds. Both were surgeons, sharing the decisiveness that is characteristic of the
profession. Both had their surgical ambitions frustrated. Banting, a failed
orthopedist, was sidetracked to research: Bethune, a successful surgeon inactivated
by tuberculosis, was directed by his interest in his disease to thoracic surgery and
subsequently to became an advocate of socialized medicine.

Frederick Banting et Norman Bethune partageaient plusieurs points communs: nes
au meme moment et dans la meme region, ils devinrent compagnons de classe a la
faculte de medecine, veterans de la premiere guerre mondiale et heros de deux
mondes differents. Les deux etaient chirurgiens, partageant l’esprit de decision qui
characterise la profession. Les deux virent leurs ambitions de chirurgiens deques.
Banting, un orthopediste rate, devia vers la recherche: Bethune un chirurgien qui
avait du succes mais qui avait ete arrete par la tuberculose, se dirigea, consequence
de son interet pour sa maladie, vers la chirurgie thoracique, et consequemment, il
devint plaidoyer de la medecine socialisee.

outhern Ontario is a land of
farms and orchards. The peo
ple, of English and Scottish origin,
are conservative, devout, hard
working and reserved. In 1890 and
1891, in two small towns 75 km
apart, a boy was born to each of
two families. These boys would
achieve world fame, their paths
would intersect as young men and
then they would separate, never to
meet again. The older would be
acclaimed at the start of his career
and the younger would die in a
foreign land to be enshrined there
and later in his own country. His
Ontario home would become a mon

S

ument, and a society would be
founded to perpetuate his ideals.
Both these men enrolled in the
faculty of medicine at the University
of Toronto. Their names were Fred
erick Banting and Norman Be
thune. Grouped alphabetically, they
knew each other but were never
close friends. Bethune was outgo
ing and colourful, while Banting
was studious, though not brilliant,
and exceptionally persevering.

For King and Country
In 1914, a wave of patriotism
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swept Canada as war was declared
against Germany. Nine days later
Bethune enlisted in the Canadian
Army Medical Corps. Banting, sub
ject to urgent pleas of the faculty
that doctors would be needed as
soon as possible, very reasonably
stayed at home. Bethune served in a
medical unit as a stretcher bearer.
He was wounded in the leg by
shrapnel and was returned to hospi
tal in England in April 1915. When
he was discharged from the army in
November 1915, he rejoined his
medical class. Sixty-six men of 72
in the class of 1917 went overseas
as medical officers after an early
graduation of the class in December
1916. Banting was among them.
While serving at a front-line dress
ing station, he was shot through
the left forearm. At the time he was
the only medical man left to attend
the wounded troops. He continued
to work until he collapsed 10 hours
later from shock and blood loss. He
was sent back to hospital in En
gland and was later awarded the
Military Cross. Invalided out, Ban
ting returned to Canada where he
began training at the Hospital for
Sick Children in Toronto as an
orthopedic surgeon.
Meanwhile, Bethune was not sent
overseas upon graduation because
of his previous service and wound.
But when a young girl pinned a
white feather, the traditional badge
of cowardice to his coat, he re
enlisted in the navy as a surgeon.
Discharged from the navy in 1919,
Bethune remained in England and
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started surgical training at the Hos
pital for Sick Children on Great
Ormond Street in London. In his
spare time he joined the social
scene. He loved women, and his
charm made him a great favourite
with them; he was adopted by a rich
English widow who indulged him in
everything. After he briefly joined
the Royal Air Force Medical Corps
he settled down to complete his
surgical training at the Edinburgh
Royal Infirmary. There, he fell in
love with Frances Penney, a beauti
ful Scots girl from a prominent
family. In 1923, he completed his
training in Edinburgh and obtained
his fellowship. He married Frances
and went on a prolonged honey
moon (all expenses paid by her) and
in 1924 returned almost penniless
with his bride to Canada.
Banting, upon completing his or
thopedic training and with money
borrowed from his father, a pros
perous farmer in Alliston, Ontario,
set up practice in London, Ontario
as an orthopedic surgeon. The prac
tice did not boom. An engagement
ring passed back and forth between
him and his fiancee. As his practice
bounded and his mood sank, the
ring stayed permanently on his
watch chain. He obtained a position
as assistant in physiology and anat
omy at the University of Western
Ontario which helped defray his
expenses and more importantly
gave him something to do. On Oct.
30, 1920 he was preparing a lecture
on the physiology of the pancreas
when he came across an article in
the current issue of Surgery, Gyne
cology & Obstetrics by Moses Bar
ron entitled “Pancreatic lithiasis
and its possible relation to diabe
tes” .1 Banting theorized that liga
tion of the pancreatic duct would
lead to necrosis of the acinar en
zyme-producing tissue of the pan
creas, while leaving the islands of
Langerhans undamaged, and that
an extract of this remaining tissue
70

CJS. VOL. 33, NO. I, FEBRUARY 1990

would contain the active antidiabet
ic component.
So strong was Banting’s belief
that he gave up his practice and
appointment and went back to the
University of Toronto where he
talked Professor McLeod, chairman
of the Department of Physiology,
into giving him some laboratory
space. He was assigned a senior
biochemistry student, Charles Best,
to help in the experimental work
(Fig. 1).
In the summer of 1921, Banting
and Best established that an extract
of the duct-ligated dog pancreas
would lower the blood sugar level
in a depancreatized dog. More so
phisticated help from Professor
McLeod and James Collip, a bio
chemist on sabbatical at the Univer
sity of Toronto, was not long in
coming.
In 1922, an extract of cow pan
creas was used successfully to treat
diabetes in patients at the Universi
ty of Toronto. Banting had to fight
tooth and nail to hold onto what he
knew was his discovery. He had,
after all, a good many old friends at
the university and they helped him
resist attempts to shunt him aside.
The Discovery o f Insulin a recent
work by Michael Bliss of the Uni
versity of Toronto,2 covers this peri
od in great detail and reads like a
thriller.
A farmer’s son, somewhat bucol
ic, unsophisticated, big, tough and
competitive, who had failed in the
practice of orthopedic surgery, had
made the outstanding medical dis
covery of the 20th century. To do
this, he had blasted through all
opposition, enlisted help wherever
he could find it and within 3 years
had brought his ideas from concep
tion to save the lives of diabetics. In
1923, he received the Nobel prize
for medicine.
Bethune’s reaction to his class
mate’s triumph is not known. He
had his own problems. Finding no

opportunity in Canada, he started
surgical practice in Detroit. He se
cured an appointment at the Harper
Hospital and at the Detroit College
of Medicine. Charismatic and su
premely self-confident, his practice
was soon established. He charged
wealthy patients what the traffic
would bear and treated the poor for
nothing. He lived well beyond his
means.
His wife hated Detroit; she had
no friends in the city and her hus
band was too busy with his practice
to offer her much companionship.
Her circumstances became intolera
ble and in 1925 she left Bethune
and returned to Scotland. Theirs
had seemed a fairy tale romance;
the handsome, dashing young sur
geon and the beautiful heiress, but
from the start there had been con
flict. He had used up her inheri
tance and continually dominated
her intellectually and emotionally.

Bethune and Koch’s Bacillus
Bethune continued to work at a

FIG. 1. Banting and Best, 1922. (Re
produced from F.G. Banting Papers by
permission of Thomas Fisher Rare
Book Library, University of Toronto.)
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furious pace and for the first time
he experienced fatigue. In his youth
he was an athlete and had worked
as a lumberjack, but now he could
barely drag himself out of bed. He
lost weight, a flush developed and,
finally, a hemoptysis. Tuberculosis
was diagnosed. Fortunately, with
foresight rare in him, he had
bought a disability policy. He sold
his practice and in 1926 entered the
Trudeau Sanatorium in Saranac,
New York, with bilateral apical tu
berculosis.
On the other hand, Banting was
on top of the world. He was Cana
da’s and the world’s hero. He was
not, however, seduced by universal
acclaim. He lived with his own
conscience and fierce self-assess
ment, and he was concerned as to
his future role. Although he had
snared the great research prize he
was not a trained scientist and
although insulin was saving lives,
he was not really a skilled clinician.
He had turned his rights to insulin
over to the University of Toronto
and it was produced under licence
from the university by Eli Lilly
Company and Connaught Laborato
ries in Toronto.
Canada did not neglect her favou
rite son. Banting was appointed
professor of medical research at
$10 000/yr in perpetuity. One mil
lion dollars was forthcoming from
the Rockefeller Foundation to con
struct the Banting Institute, which
would house laboratories of pathol
ogy, biochemistry and physiology,
with the upper floor set aside for
the Banting research facility. In
1924, he married Marion Roberts, a
physiotherapist, whom he had met
at the hospital. They went on a
honeymoon trip to Central America,
all expenses paid by the United
Fruit Company. It was a wonderful
trip for the young celebrity and his
bride. Banting, conscientious to a
fault, addressed medical meetings
and met with leading physicians in

every capital that they visited.
Excerpts from his wife’s diary
show a pleasant, rather superficial
girl, dazzled by the reflected glory
of her husband, which was in stark
contrast to his down-to-earth atti
tude. Banting continued to wear a
rather ill-fitting evening suit which
he had bought second hand in 1919
and which he never replaced. When
the honeymoon was over he re
turned to Canada and his laboratory
and settled down to a life in medical
research.
Bethune, feeling better at the
sanatorium, quickly became the life
of the party. He defied all rules and
regulations, especially bed rest and
smoking, in obvious denial of his
serious condition.
In 1927, his wife instituted pro
ceedings for divorce. He left the
sanatorium and tried desperately to
return to teaching and practice in
Detroit. But his disease progressed
and he was forced to return to the
sanatorium, accepting bed rest
without enthusiasm. He studied the
entire subject of tuberculosis in the
well-stocked library and soon decid
ed that pneumothorax was needed
in his case. Much against the advice
of the conservative staff he got a
medical resident to perform a pneu
mothorax on him. He was soon on
the mend. The 6 months’ bed rest
gave him time to meditate and
re-evaluate his life’s aims. He con
cluded that the sirens of fame and
fortune were delusory and that he
would go into chest surgery, a new
unexplored field which would give
him the opportunity to save the
lives of tubercular patients.
He managed to gain acceptance
for training under Dr. Edward Ar
chibald, one of the doyens of tho
racic surgery, at McGill University.
Before assuming that post, he took
preliminary training in bacteriology
and biochemistry at the Ray Brook
State Hospital for Tuberculosis in
New York state. In 1928, at the age

of 38 years, he began his training in
thoracic surgery.

Where to Go From the Top
Banting had reached his position
of eminence by battering down ob
stacles in his path. He would not be
intimidated; he would not let others
get credit for ideas and experiments
he knew to be his and his alone. He
was not embittered. On the con
trary, as an administrator he be
came the advocate of the people in
his laboratory. It was a hard and
fast rule that work must first be
presented by its originators. Con
scious of the value of training,
perhaps through his own lack of it,
he was constantly sending his re
searchers all over the world to
acquire additional experience. He
had a good nose for talent. When
he found promising individuals he
allowed them, as far as possible, to
follow their own leads. His unbiased
approach and his refreshing can
dour soon became known through
out Canada.
He was appointed to a number of
investigative commissions and soon
left for an extensive trip through
Canada’s Northwest Territories and
Arctic to survey the health prob
lems of the Inuit. Banting was
especially adapted to going into the
field. He loved the outdoors and
could hike 30 km through the bush
without fatigue. Fortunately, he
was able to combine these field trips
with landscape painting. Art had
become an important part of his life
and he had become friendly with
leading Canadian artists in Toronto,
frequently joining them on their
expeditions into the countryside.
On his trip to the Northwest
Territories he found that the Inuit
were being grossly exploited by the
managers of the Hudson’s Bay
Company. The resultant malnutri
tion and poor sanitation had led to
CJS, VOL. 33. NO. 1. FEBRUARY 1990
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a high rate of nutritional deficiency
and infectious diseases among the
native people. When Banting re
turned from his trip he was, as
usual, met by the press. He told
them of his findings, off the record
and in confidence; he had not yet
made an official report to the Minis
ter of the Interior. Banting’s fury
when he read the reports of his trip
in the headlines of the next edition
of Toronto’s newspaper was unre
strained. He told the editor in no
uncertain terms what he though of
him and his cohort. Banting sin
cerely felt that legal proceedings
would be initiated against him. He
immediately went to Ottawa and
explained what had happened to the
minister. He also met with the gov
ernor of the Hudson’s Bay Compa
ny who accepted his explanation
without comment. The threatened
ejyNosion never occurred, the affair
quietened down and the company
took heed of his findings. Some of
the injustices that he had reported
were eliminated.
If Banting had a problem, it was
meeting the world’s expectation
that he would surpass insulin with
a cure for cancer and a multitude of
other human ills. His laboratory did
investigate cancer, but a cure was
not forthcoming. At the behest of
the government he investigated sili
cosis in the Ontario mines. This was
excellent pioneering work and such
was Banting’s prestige that he was
able to get the support of the mine
owners for the needed health mea
sures.
A son was born to the Bantings
in 1929. Although Banting was
often away from home, his relations
with his boy were excellent. Howev
er, his marriage deteriorated, end
ing in a particularly bitter divorce
battle in 1932. The press accorded
the proceedings the interest excited
by his superstardom. This led to
strained relations between Banting
and the media thereafter.
72

Bethune and the Battle of
Montreal
Bethune, now healthy, energetic
and enthusiastic, immersed himself
in thoracic surgery. As usual, his
flamboyant style made him endur
ing enemies and friends. He was
soon surgically independent of Dr.
Edward Archibald. Personally, they
were the antithesis of each other.
Archibald was courtly, quiet spo
ken, cautious and slow. Bethune
was exuberant, impatient, impulsive
and quick. Bethune’s solid contri
butions in research anchored him
against a tide of resentment by
some of his colleagues. Enjoying a
moderate success, Bethune induced
Frances to return from Scotland
and they were remarried in 1929.
All the basic instruments of tho
racic surgery were either revised or
invented by Bethune. He also de
vised the simplest and most reliable
pneumothorax apparatus. An entire
page in the George Pilling instru
ment catalogue for 1932 is devoted
to Bethune’s instruments.
In Montreal, Bethune, for the
first time, became involved in the
life of a city. Like Banting, he got
to know the artists of the city. He
took up painting, showing a re
markable aptitude. He boasted that
he would have a painting accepted
for the Spring Exhibition at the
Montreal Museum of Art — it was.
The painting, entitled Night operat
ing room, shows tiered seats starkly
white and empty, contrasting with
the night sky seen opposite
through the panoramic windows.
The pool of light in the centre of
the painting bathes a huddled
group operating. This painting now
hangs in the medical library of the
Royal Victoria Hospital in Montreal.
Bethune continued to stir up any
milieu in which he settled. He
shocked hostesses; he advanced
views intolerable to both the social
and medical establishments. In
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some ways he anticipated the sexu
al mores of the 1960s and later.
The situation at the Royal Victoria
Hospital boiled over and, in 1932,
Bethune was dismissed. Luckily, he
secured a job as chief of thoracic
surgery at the Sacre-Coeur Hospi
tal, a large French-Canadian hospi
tal in Cartierville near Montreal,
where he was very much at home.
All physicians have had patients
who are so overwhelmed by poverty
and a hostile environment that any
treatment given is a stop-gap. Tu
berculosis was the disease with
which Bethune dealt most frequent
ly. No disease is as directly linked
to poverty, and no place in North
America in the 1930s had so many
tuberculous people as the Province
of Quebec. Surgery could limit the
tuberculous lesion in such patients,
but often the patient returned to an
environment in which the tubercu
lous disease soon revived.
Bethune became increasingly
aware of the economics of medical
care. He realized that many people
in Montreal could not afford private
medical care. He attacked the prob
lem with characteristic energy. He
spoke to the various business and
professional groups, pleading to ex
tend support to those discharged
from sanatoria, and he opened a
free clinic in one of the poorest
sections of the city. Bethune, the
supreme example of an individual
ist, did not countenance any joint
activity of the state and medicine.
His activity was not revolutionary
but an extension of his characteris
tic “noblesse oblige”.
In 1935, an international physio
logical congress was held in Mos
cow, of which Ivan Pavlov was the
president. Among the seven Canadi
an delegates were Norman Bethune,
who was very interested in survey
ing a system that he had publicly
condemned, and Sir Frederick Ban
ting, who was an invited guest and
whose true motive in visiting Russia
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was to investigate the research fa
cilities under socialism. Banting
stayed on after the conference to
survey all of Russia and its medi
cine (Fig. 2).
After he returned to Canada,
Banting gave a number of addresses
portraying the Russian medical and
research system in a very favoura
ble light. The Russians thought
that science was a good bet and
subsidized research heavily. With
this, Banting concurred; he was
foremost a Canadian patriot and he
saw the need for national utilization
of all available research facilities
and personnel. Appointed chairman
of the new Medical Research Com
mittee of the National Research
Council, Banting set to work to
increase research funds and to facil
itate exchange of information. He
was especially interested in prevent
ing the talent in small institutions
from draining into the research pool
at Toronto and McGill. In the fall of
1938, he set out to visit all the
research facilities in Canada from
Dalhousie University to the Univer
sity of British Columbia. He had a
fervent belief in the productive ca

pacity of research. Another motive
in his drive to organize research
was his growing conviction that
another war was inevitable. He was
convinced that the war in the air
would be the deciding factor in the
conflict to come and he set up the
cooperative study throughout the
medical schools of Canada on prob
lems germane to air warfare; pilot
fatigue, decompression sickness, ac
celeration and deceleration stresses
and adaptation to night vision.
Bethune returned from Russia a
changed man. He left Quebec with a
strong feeling that things were not
right, that society should not let
people sink without offering aid.
Everywhere, healthy men were job
less, hungry and homeless; the
sickly were helpless without any
recourse to medical aid.
Bethune tackled the problem
head-on. He would convince his
profession of the necessity of social
ized medicine. He advised the Mon
treal Med-Chi of his feelings. The
first time he spoke, he was the last
speaker in a group that had visited
Russia and he gave an allegorical
talk entitled, “Through the looking

FIG. 2. Pavlov and Banting, 1936. (Reproduced from F.G. Banting Papers by
permission of Thomas Fisher Rare Book Library, University of Toronto.)

glass”.3 The second speech he made
was an advocacy of socialized medi
cine in the province. These talks did
not go down well. He had managed
to alienate his colleagues at every
level — social, professional and
political.
He set up a society, the Montreal
Group for the Security of the Peo
ple’s Health, whose goal was to
plan a system of socialized medicine
for Canada. He went to Memphis,
Tennessee, ostensibly to lecture on
advances in anesthesia for thoracic
surgery to a very conservative
group, the Mid-South Medical As
sembly. Bethune appended, unan
nounced, his plan for state medi
cine. The newspapers picked up this
addition and the newspaper picture
(Fig. 3) of a radiant Bethune along
side the officers of the assembly,
their eyes averted from Bethune or
fixed in another area, their faces
frozen and noncommittal, is a
comic one. Bethune’s group sug
gested plans for both private and
public financing of medical care.
Variations of these plans have been
adopted, partially or completely, in
both Canada and the United States.

FIG. 3. Bethune with members of the
Mid-South Medical Assembly. (Repro
duced by permission from Stewart R:
The Mind o f Norman Bethune, Fitzhenry & Whiteside, Toronto, 1977.)
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This plan was separately submitted
to representatives of organized
medicine, politicians and the public.
Organized medicine condemned
him, politicians either ignored him
or were apathetic and the public did
not become involved at all.
Bethune gravitated towards the
Communists, a group whose com
mitment to action paralleled his
own desire to change a system that
he found wanting. He did not, how
ever, become a Communist al
though he began to study Marxism
seriously.

Bethune was a lonely man for he
had divorced Frances for the second
time in 1932. He set up an art
centre for children taught by local
artists at his expense. They en
hanced the lives of Montreal’s chil
dren dulled by the depression and
stimulated some of them to become
artists.
At this point in their lives, both
men had gone beyond their medical
calling and entered a political arena
— Banting, with prescience, orga
nizing research for a war he felt

would come soon and Bethune re
solving to cure a sick society.
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BOOK REVIEWS
continued from page 11

less exposure than before to disorders
of the spleen, but the need to be
informed on all aspects of splenic disor
ders is greater than ever among all
medical specialties.
This book is an ambitious attempt to
cover the anatomy, pathophysiology,
pathology, imaging and management of
splenic disorders. It comes in a hand
some hard-cover jacket, with glossy
pages and easily read type. The section
headings have been thoughtfully
planned. The text, tables and illustra
tions are well balanced, making it a
pleasure to read.
Any multiauthored book is suscepti
ble to inequalities in coverage and em
phasis on selected subjects. In this
book, many discussions are repeated in
different sections, a shortcoming that
could have been avoided by tighter
editorial control. For example, there is a
section devoted to splenic imaging, a
topic that is also covered in the section
entitled “Splenomegaly — a diagnostic
overview”.
There is a notable pediatric slant to
many of the sections, which reflects the
predominance of pediatricians among
the authors. A chapter on indications
for splenectomy in childhood is not
balanced by a chapter on splenectomy
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in adults. The table on indications for
splenectomy is based on the experience
in a children’s hospital.
The section on anatomy is well writ
ten. An indication of its thoroughness is
the description of Schweigger-Seidel
sheaths in the vessels emerging from
the marginal zone. This structure, al
though not as well developed in hu
mans as in other species, is not even
mentioned in most standard histology
textbooks. A few more line drawings or
photomicrographs instead of electron
micrographs would have been prefera
ble. A more detailed discussion of the
immunoarchitecture would also have
been helpful.
The chapter on hyposplenism may
prove to be the most sought after by
readers of this book, since it provides
an in-depth account of a topic that is
only briefly covered in most standard
textbooks. It also provides a lucid de
scription of the use of imaging and
laboratory techniques in evaluating hy
posplenism. The section on pathology is
succinct and well illustrated and should
be a good reference for general patholo
gists. Although the potential of flow
cytometry, immunohistochemistry and
DNA studies is alluded to in the final
paragraph, no instructive examples are

given. A section devoted to the surgical
problems of diseases of the spleen
would have made this book more ap
pealing to surgeons.
One would expect that a book such
as this would aim for an international
readership. Disorders of the spleen are
an important cause of morbidity in the
tropics, but the meagre attention given
to tropical diseases of the spleen is
disappointing. Only passing mention is
made of malaria and the tropical spleno
megaly syndrome, far more frequent
problems than the storage diseases
which are covered in great detail.
In spite of the minor deficiencies, I
found this book useful because it pro
vided a wide range of information about
an organ that has not received its fair
share of attention. I would recommend
this as a helpful reference book for
pathologists, hematologists, radiolo
gists and pediatricians.
B.J. Fernandes, MD, FRCPC, MRCPath,
FRCPA
Laboratory Hematology and
Anatomical Pathology,
Mount Sinai Hospital.
600 University Ave.,
Toronto, Ont.
M5G 1X5
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SESAP VI Critique
Item 206

Two of the anesthetic agents listed in this item have an undeserved bad reputation for producing cellular
derangements. Administration of halothane, particularly on multiple occasions, has been associated with some
incidence of jaundice and evidence of hepatocellular disease, and the term “halothane hepatitis” crept into the
literature. A large multicenter study did not show a significant difference between the incidence of jaundice
associated with halothane and jaundice associated with other anesthetic agents. The hepatocellular derangement
produced by halothane is due to an idiosyncratic reaction, and not to direct cellular damage. Enflurane produces
fluoride as a metabolite and thus causes renal toxicity. Although it has not been shown to produce direct hepatic
damage, it is no longer used. Ether and isoflurane have never been shown to produce direct cellular damage.

¥
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TABLE 2

continued from nae'e 20
Renal
Function

Creatinine
Clearance
mL/s
mL/min

Reconstitution Table for Standard Vials - I.M. Injection
Less Severe
Infections

Life-Threatening
Infections

Mild
Impairment

0.83-1.32

50-79

500 mg
q8h

750 mg to 1.5 g
q8h

Moderate to severe
impairment

0.08-0.82

5-49

250 or 500 mg
q12h

500 mg to 1.0 g
q12h

Hemodialysis
patients*

0-0.07

0-4

500 mg q48h or
250 mg q24h

500 mg to 1.0g
q48h or 500 mg
q24h

Vial
Size

Diluent to be
Added to Vial

Approximate
Available
Volume

Approximate
Average
Concentration

19
2g

3.0 mL
6.0 mL

3.7 mL
7.4 mL

270 mg/mL
270m g/m L

4
i

Shake well until dissolved.
For Intravenous Injection: Reconstitute only with Sterile W ater for Injection.

. .

Reconstitution Table for Standard Vials - I.V. Injection

‘ In patients undergoing hemodialysis no additional supplemental dosing is required.
DOSING, HOWEVER, SHOULD BE SCHEDULED SO THAT THE PATIENT RECEIVES THE
DOSE AT THE END OF THE DIALYSIS. When started 24 hours after administration of 1 g of
CefizoxTM, hemodialysis has been shown to reduce serum levels by 50%.

Vial
Size

Diluent to be
Added to Vial

Approximate
Available
Volume

Approximate
Average
Concentration

1g

When only the serum creatinine level is available, creatinine clearance may be calculated
from the following formulae (for patients 18 years and over only). The serum creatinine level
should represent renal function at the steady state.

2g

10 mL
20 mL

10.7 mL
21.4 mL

95 mg/mL
95 mg/mL

Shake well until dissolved.

A
V
i,
is

For Intravenous Infusion: Reconstitute as for intravenous injection. Further dilute the

Males:
Creatinine Clearance

reconstituted solution to 50 to 100 mL with one of the “ Solutions for Intravenous
Infusion” (see below).

Weight (kg) x (140 -age)

(mUmin)

72 x serum creatinine (mg/100 mL)

Creatinine Clearance

TABLE 4: Solutions for Intravenous Infusion

Weight (kg) x (140 - age)

(mL/s)

49 x serum creatinine ( //m ol/L)

Females: 0.85 of the above values
Infants and Children: The following dosage schedule is recommended:
TABLE 3
Age Group
Infants (6 mo-2 yrs.),
and
Children (2-12 yrs.)

Unit Dosage

Frequency and Route

50 mg/kg IV or IM

q6h orq8h, IV or IM

The pediatric dosage should not exceed the maximum adult dosage for serious infections.

Sodium Chloride Injection
5% or 10% Dextrose Injection
4
5% Dextrose and 0.9% , 0.45% or 0.2% Sodium Chloride Injection
Ringer’s Injection
Lactated Ringer’s Injection
r ' "C
10% Invert Sugar in Sterile Water for Injection
5% Sodium Bicarbonate in Sterile W ater for Injection
5% Dextrose in Lactated Ringer’s Injection ONLY when reconstituted with 4% Sodium^
Bicarbonate Injection.
STABILITY OF SOLUTIONS
Storage: All reconstituted solutions and those further diluted should be used within 2I
hours if stored at room temperature or within 48 hours if refrigerated. These storage Ii m it ^ j
are from the tim e of the initial reconstitution.
Incompatibility: CefizoxTM should not be added to blood products, protein hydrolysates]
or amino acids. CefizoxTM should not be mixed together with an aminoglycoside.
DOSAGE FORMS

ADMINISTRATION
Intramuscular: The reconstituted solution of CefizoxTM should be injected well within the
body of a relatively large muscle, such as the gluteus. When administering 2 g IM doses, the
dose should be divided equally and then injected into different large muscle masses.
intravenous: Injection (bolus): The reconstituted solution of CefizoxTM should be injected
slowly over 3 to 5 minutes, directly or through the tubing system by which the patient is
receiving another compatible intravenous solution. During administration of the solution
containing CefizoxTM, it is desirable to temporarily discontinue administration of the other
solution.
Intermittent or continuous infusion: The further diluted reconstituted solution of CefizoxTM
should be administered over a 20 to 30 minute period.
NOTE: CefizoxTM solutions should not be physically mixed with any other drug. There is a
known incompatibility with aminoglycoside antibiotics. Therefore, they should not be
physically mixed with CefizoxTM solutions nor administered at the same site.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFIZOXTM
Proper Name: Ceftizoxime Sodium
Chem ical Name: Sodium [6R-(6<*, 7 B (Z )]]-7 -[[(2 ,3 -d ih y d ro -2 -im in o -4 -th ia z o ly l)
(m e th o x y im in o )a c e ty l]a m in o ]-8 -o x o -5 -th ia -1 -azabilcyclo[4.2.0] o c t - 2 -e n e - 2 carboxylate
Structural Formula:

XT

^H
>—
A
H- I —

M olecular Formula: C i 3 H-|2 N 505 S 2 Na
M olecular W eight: 405.38

Availability: CefizoxTM js available as a sterile powder in Standard Vials of 1 gram o r l
2 grams, containing ceftizoxime as sodium salt.
Storage: CefizoxTM powder for injection should be stored at room temperature (15°-30°C).|

FOOTNOTES
1As indicated in the manufacturer's product monograph Cefizox. Smith Kline & French Canada Ltd . 1988
2As indicated in the manufacturer s product monograph cefoxitin, Merck Sharp & Dohme Canada, 1985
3Lou M.A. etal.: 14th International Congr. Chemother., Kyoto. Japan. June 1985, pp 2378-2379
4Neu H.C , Chin N X.: The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics. I
Chemioterapia 1985;4:271-277.
5Fu K P , Neu H.C.: Antibacterial activity of ceftizoxime. a B-lactamase-stable cephalosporin. Antimicrob Agents
Chemother. 1980;12:583-590.
6Thornsberry C.: Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotiefsagainst clinically important bacteria. Am J. Med. 1985:79 (Suppl 2A): 15-20.
7Drulak M W.. Chow A W. Comparitive in vitro activity of ceftizoxime cefoperazone and cefoxitin against anaerobe
bacteria. Antimicrob. Agents Chemother. 1981;20:683-685.
8Aldridge K.E. et al.: Comparision of the activities of penicillin G and new B-lactam antibiotics against clinical isolates of
Bacteroides species. Antimicrob. Agents Chemother 1984:26(3) 410-413.
*
9Adapted from Parker D.D.: Abstr. Annu. Meet. Am. Soc. Microbiol .Atlanta. GA, March 1987, Abstract no. A-107, p 18
10Kitzmann R. Cost analysis of the ecomomic effect of replacement of cefoxitin with ceftizoxime. Presented at the 45th
Annual Meeting, American Society of Hospital Pharmacists. San Francisco. California
11Guastell C. Cost savings realized from interchanging ceftizoxime for cefoxitin. Am J Hosp Pharm 1988
Nov;45:2376-2377.
4
12Wikler M.A. et al.: Efficacy of ceftizoxime administered twice daily for the treatment of serious infections in hospitalized
patients. Infect. Med 1986;(Suppl.):9-12.
13Data on file. Smith Kline & French Canada Ltd.
14Sanford J.P: Guide to Antimicrobial Therapy. West Bethesda, MD:Antimicrobial Therapy Inc.. 1988:50
15Richards DM. Heel RC. Ceftizoxime: A review of its antibacterial activity, pharmacokinetic properties and therapeutfc
use. Drugs 1985:29:281-329.
16DiPiro J. May JR. Use of cephalosporins with enhanced antianaerobic activity for treatment and prevention of
anaerobic and mixed infections. Clin Pharm 1988 Apr:7:285-302.
^
17BellomoS. Antimicrobial activity of cefizoxime sodium: Comparision with cefoxitin Hosp Formul 1988:23
(Suppl. D): 18-27.
^

Description: Ceftizoxim e Sodium is a white to pale yellow crystalline powder.
Composition: CefizoxTM vials contain ceftizoxim e sodium (expressed in terms of free
acid). The sodium content of each gram of CefizoxTM is approximately 60 mg (2.6 mEq
sodium ion).
Solutions of CefizoxTM range from colourless to pale yellow, depending upon the diluent
and volume used. The solution should be discarded if it becomes cloudy. The pH of
freshly reconstituted solutions usually ranges from 6.0 to 8.0.
A solution of 1 g CefizoxTM in 13 mL Sterile W ater for Injection is isotonic.
RECONSTITUTION
STANDARD VIALS (1 GRAM and 2 GRAMS)
For Intram uscular Injection: Reconstitute with Sterile W ater for Injection or Bacteriosta
tic W ater for Injection.

SMITH KLINE &FRENCH CANADA LTD. 1988
Mississauga, O ntario L5N 2V7
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Instructions to Authors
The Canadian Journal o f Surgery will consider manuscripts of original articles, clinical research, surgical
technique, clinical reviews, history of surgery, a limited number of case reports, editorials and letters.
Manuscripts, in English or French, should be submitted, in triplicate, to the Coeditors, Canadian Journal o f
Surgery, PO Box 8650, Ottawa, Ont. K1G 0G8.
A covering letter should state that the manuscript has not been published previously and is not under
consideration by any other journal. The authors must disclose any commercial interest they may have in the
subject of the study and the source of any financial or material support.

Manuscript Preparation
The style of the submission should be compatible with “Uniform requirements for manuscripts submitted to
biomedical journals” (Can Med Assoc J 1988; 138: 321-328, Br Med J 1988; 296: 401-405 and Ann Intern
Med 1988; 108: 258-265).
The authors’ names should appear on the title page and the back of each set of illustrations. All
acknowledgements should be placed on a separate unnumbered page after the list of references.
To facilitate editing and electronic scanning, all pages — title page, abstract, text, acknowledgements,
references, figures, legends and tables — must be double-spaced, in 10-pitch, letter-quality type, without right
justification or proportional spacing. Manuscripts should not be printed with the draft mode of a dot-matrix
printer.
For all manuscripts, authors should submit an original and two high-quality photocopies or additional
printouts of the text and tables, and three camera-ready copies of the figures.
In writing a case report it is not necessary to give a detailed patient history and results of physical
examination in the standard clinical format. Negative findings and normal results of laboratory tests need be
included only if they are essential for ruling out a possible diagnosis. It is enough to establish the reasons for the
diagnosis and the management. The clinical course should be described briefly and the significant observation or
event described in sufficient detail to establish its credibility. Reference to the literature should be confined to
supporting the principal point being made about the event or observation.
Abstracts are required for original, review and history articles and for case reports, but not for articles on
surgical technique and editorials. Abstracts should be brief, but detailed (from 60 to 150 words long).
References should be cited in numerical order of their appearance in the text. References cited in tables should
be numbered according to where the table is first cited in the text. The style for references should be that used
in this issue of the Journal.

Other Considerations
Colour figures can be reproduced only at the author’s expense. Authors should submit a positive transparency
and two colour prints of each figure.
When diskettes are sent in addition to the typed manuscript, specify the word processor and software
programs used. We edit manuscripts with an IBM-compatible word-processing system (WordPerfect 5.0 or 4.2)
and cannot edit from diskettes that are not IBM-compatible.
The process of initial consideration, peer review and editorial decision-making of the manuscript usually takes
about 8 weeks. The original copy of a rejected manuscript will be returned to the authors; all other copies will be
destroyed.
Accepted manuscripts will be edited not only to conform with CJS style and for correctness of grammar,
syntax and punctuation but also for clarity. The corresponding author will receive a copy of the edited
manuscript or a galley proof before publication and is responsible for obtaining coauthors’ approval of the
changes.
Authors will be expected to sign a document transferring copyright to CJS. All accepted manuscripts become
the permanent property of the CMA and may not be published elsewhere, in whole or in part, without written
permission of the publisher. Reprints will be available for purchase and may be distributed as the author
desires.*
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Directives aux auteurs
Le Journal canadien de chirurgie prendra en consideration les manuscrits d’articles originaux consacres a la
recherche clinique, a la technique chirurgicale ou a l’histoire de la chirurgie, des revues generates, un nombre
restreint d’observations cliniques, des editoriaux et des lettres. Les manuscrits, en franqais ou en anglais, doivent
etre adresses, en triple exemplaire, aux redacteurs scientifiques, Journal canadien de chirurgie. CP 8650,
Ottawa, Ont., K1G 0G8.
Dans la lettre d’accompagnement, l’auteur doit declarer que le manuscrit n’a pas ete publie auparavant et qu’il
n'a ete soumis a la consideration d’aucun autre journal. Les auteurs doivent devoiler tout interet commercial
qu’ils pourraient avoir en rapport avec le sujet de l’etude, ainsi que l’origine de tout appui materiel ou
commercial.

1

Organisation du manuscrit
Le style doit se conformer aux “Recommandations aux auteurs pour des manuscrits devant etre soumis a des
revues biomedicales” (Can Med Assoc J 1988; 138: 321-328, Br Med J 1988; 296: 401-405 et Ann Intern Med
1988; 108: 258-265).
Les noms des auteurs doivent apparaitre sur la page de titre, de meme qu’a l’endos de chaque jeu
d’illustrations. Les remerciements sont portes sur un feuillet separe, non pagine, a la suite de la bibliographie.
Pour faciliter la correction et la revision sur support electronique, toutes les pages (page de titre, resume,
texte, remerciements, bibliographie, figures, legendes et tableaux) doivent etre dactylographies en double
interligne, en caracteres de 10 points de qualite lettre, sans justification de la marge de droite ou espacement
proportionnel. Les manuscrits ne doivent pas etre imprimes en mode brouillon d'une imprimante a matrice.
Pour tout manuscrit, les auteurs doivent soumettre un original et deux photocopies de bonne qualite, ou deux
impressions su p p le m e n ta l du texte et des tableaux, et trois copies pretes a la reproduction photographique
des figures.
Pour les observations cliniques, il n’est pas necessaire de rapporter une anamnese detaillee avec les resultats
de l’examen physique courant. Les resultats negatifs ou normaux ne doivent etre mentionnes que s'ils sont
essentiels a l’exclusion d’un diagnostic possible. II suffit d’etablir les raisons qui ont contribue au diagnostic ou
au traitement. L’evolution clinique doit etre decrite succinctement et les observations ou evenements importants
doivent etre rapportes avec suffisamment de details pour en etablir la credibilite. La bibliographie doit se limiter
au soutien du point que Ton veut faire ressortir quant a l’evenement ou a l’observation.
Des resumes sont exiges pour les articles de revue, ceux sur l’histoire, ainsi que pour les observations
cliniques; ils ne sont pas requis pour les articles sur les techniques chirurgicales ou pour les editoriaux. Les
resumes doivent etre brefs mais, neanmoins, detailles (de 60 a 150 mots).
La bibliographie doit etre etablie numeriquement, selon l’ordre d’apparition dans le texte. Les references citees
dans les tableaux sont numerotees d’apres l’ordre de la premiere mention du tableau dans le texte. Le style
adopte pour la bibliographie est celui qui est utilise dans ce numero du Journal.

i

Autres considerations
Les figures en couleur sont a la charge de l’auteur. II lui faudra fournir une diapositive et deux cliches couleur
de chacune des figures.
Si le manuscrit est fourni sur disquette, en plus de la copie dactylographiee, veuillez preciser l’appareil de
traitement de texte et le logiciel utilises. Nous revisons les textes a l’aide d'un appareil a traitement de texte
compatible avec le systeme IBM (WordPerfect 5.0 ou 4.2) et nous ne pouvons corriger des disquettes qui ne sont
pas compatibles.
Le processus de prise en charge du manuscrit, la revue critique et la decision redactionelle prennent environ 8
semaines. L’original d’un manuscrit non retenu sera retourne aux auteurs; les copies seront detruites.
Les manuscrits retenus pour publication recevront les corrections necessaires pour les rendre conformes au
style du JCC, ainsi que pour la grammaire, la syntaxe et la ponctuation, de meme que toute correction
qu’exigerait la comprehension du texte. L’auteur designe recevra une copie de la version revisee ou une epreuve
d’imprimerie; il aura la responsabilite d’obtenir l’assentiment de ses co-auteurs pour les changements.
On s’attend a ce que les auteurs signent un document cedant leurs droits au JCC. Les manuscrits retenus
deviennent la propriete permanente de l’AMC et ne peuvent etre publies ailleurs, en tout ou en partie, sans
l’autorisation ecrite de l’editeur. Les tires a part sont disponibles sur commande et peuvent etre distribues selon
les desirs de l’auteur.B
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CLASSIFIED ADVERTISING

As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The deadline is 1
month before issue date. Regular classified rates (for each insertion): $50.00 for the first 40 words or less, additional words 650 each (additional
$20.00 for frame). Special Display under 100 words, 2>/4 in. X 2 in., $120.00. $15.00 charge (first insertion only) for CJS box numbers. Display
rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.

PLASTIC SURGEON: AB - The Department
of Surgery at the University of Alberta is
seeking a plastic surgeon who is willing to
commit a significant portion of time to the
medical and surgical care of patients in the
new Firefighter's Burn Treatment Unit in addi
tion to surgical practice. Clinical or basic
research experience is essential. Full universi
ty appointment at the assistant professor
level available for a suitable candidate. Appli
cation deadline: Apr. 30, 1990. Apply in
writing with accompanying curriculum vitae
to: Dr. G.L. Lobay, Room 240, 11044 - 82
Ave., Edmonton, AB T6G 0T2. The Univer
sity of Alberta is committed to the princi
ple of equity in employment but, in accor
dance with Canadian immigration require
ments, this advertisement is directed to
Canadian citizens and permanent resi
dents.
-S90-04

GENERAL SURGICAL ONCOLOGY FEL
LOWSHIP: ON - The Division of General
Surgery at the Toronto General Branch of the
Toronto Hospital is offering a 1 year clinical
fellowship available beginning July 1, 1990.
This fellowship provides excellent exposure
to complex general surgical oncological prob
lems including reoperative Gl cancer surgery,
endocrine malignancies, and head and neck
cancers. The fellow will also have the oppor
tunity to be involved in ongoing clinical trials
in adjuvant therapy of breast and colorectal
cancers and will be encouraged to initiate at
least one new prospective or retrospective
study with appropriate resources provided.
Block rotations of 6-8 weeks in the Depart
ments of Radiotherapy and Chemotherapy are
also an integral component of this program.
The fellow is also expected to take a minor
part in the training of residents in general
surgery. This fellowship is intended for indi
viduals who have completed a general sur

gery residency and are eligible for certifica
tion. Send enquiries and curriculum vitae to:
Dr. J. Ali, Director, Postgraduate Educa
tion, Department of Surgery, Banting Insti
tute, Room 311, 100 College St., Toronto,
O N M 5G 1L5.
-S 9 0-0 3

GENERAL SURGEON: BC - Cariboo Memo
rial Hospital invites applications for a general
surgeon to join a lucrative (fee-for-service)
private practice in the central interior of British
Columbia. The hospital has a catchment of
40 000 and call will be shared with one other
general surgeon. This is an excellent opportu
nity for a specialist to develop skills, enjoy
great recreational facilities, and join a group of
family physicians and specialists in a harmoni
ous working relationship. Applicants are invit
ed to seek further information from: Dr. J.
Grace, Chief of Staff, tel: (604) 398-8211, or
to request a medical staff application form
from: Executive Director, Cariboo M em ori
al Hospital, 517 N. 6th Ave., Williams
Lake, BC V2G 2G8. Tel: (604) 3 9 2 -4 4 1 1 .
-S 9 0 -0 5

CLINICAL BURN FELLOWSHIP: ON - A
12-month clinical burn fellowship is available
at the Toronto Regional Adult Burn Centre, at
the Wellesley Hospital, beginning July 1,
1990. The unit is a very well-staffed, new,
ultra-modern, self-contained burn centre, with
110 adult patients per year. Position totally
funded. Clinical research available. Extensive
research funding in place. Please contact: Dr.
W alter Peters, Suite 224, Turner Wing,
Wellesley Hospital, 160 Wellesley St. E.,
Toronto, ON M 4Y 1J3. Tel: (416)
9 2 6 -7 7 9 0 .
-S 8 9 -3 7

GENERAL SURGEON: ON - Excellent op
portunity exists in Sarnia/Lambton County to
develop a lucrative private practice covering
the full scope of general surgery. The Sarnia
hospitals provide a total of over 350 active
care beds with above-average support ser
vices. An interest in trauma surgery would be
useful in connection with patients admitted to
the Sarnia General Hospital Level II Emergency
Trauma Program. The city of Sarnia and
county of Lambton catchment area has a total
population of 120 000. Superior recreation
facilities for persons who enjoy sailing and
other water sports, golf and curling, etc., are
available. For further information call or write
to: K.E. Dickie, MD, FRCSC, Chief of Sur
gery, Sarnia General Hospital, 2 2 0 N. M itton St., Sarnia, ON N7T 6H6. Tel: (519)
3 3 2 -0 2 1 0 (office), or P.N. Mehta, M D,
FRCSC, Chief of Surgery, St. Joseph's
Hospital, 2 9 0 N. Russell St., Sarnia, ON
N7T 6S3. Tel: (519) 3 3 6 -7 8 6 0 (office).
-S 8 9-3 6

TRANSPLANT FELLOWSHIP, UNIVERSI
TY HOSPITAL. LONDON: ON - University
Hospital, London, Ontario has three openings
for fellows in multi-organ transplantation,
starting July 1, 1990. Our 2-year fellowship
program includes experience in clinical and
experimental transplantation. We expect to
perform 40-50 heart, heart-lung and lung
transplants; 70 liver transplants; 80 kidney
transplants and 5 bowel transplants in 1990.
Candidates who have completed their training
in anesthesia, internal medicine, general sur
gery or pediatrics, and are eligible for educa
tional or general licensure in Ontario, will be
given priority. Submit resumes to: Dr. David
R. Grant, Director, Transplant Unit, PO
Box 5 3 3 9, University Hospital, London,
ON N6A 5A5.
-S 8 9-3 8

CLASSIFIED ADVERTISING

PROFESSOR AND CHAIR OF SURGERY

Unlike a tabloid or newspaper that is read today and discarded
tomorrow, an advertisement in the Classified Advertising section
of CJS is read today and reread tomorrow.

Memorial University of Newfoundland invites applications for the
position of Professor and Chair of Surgery. This is the senior
academic appointm ent in the discipline. The successful
applicant will also be Chair of the Department of Surgery in one
of the Faculty’s affiliated institutions.

CJS is the only Canadian publication exclusively for surgeons.
No other Canadian surgical publication reaches over 9000
subscribers every 2 months, giving wide coverage for your
advertising dollar.
Average issue readership of CJS (81 %) is among the highest of
any medical journal in Canada, and the latest readership
studies confirm the best and most cost efficient way to reach
Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU

-

c j s -1

Candidates should have certification from the Royal College of
Physicians and Surgeons of Canada and be eligible for licensure
as a specialist in Newfoundland.
Applications and enquiries are invited, in the first instance, from
Canadian citizens and permanent residents of Canada. They
should be directed, on or before Mar. 1, 1990, to:
Dr. M .I. Bowraer
Chair, Search Committee
Memorial University o f Newfoundland
The Health Sciences Centre
St. John’s, NF A1B 3V6
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ISCOTT&WHITE

TEXAS A&M UNIVERSITY
C ollege of M edicine
TEMPLE CAMPUS

Cardiovascular
Research Scientist

Department of Surgery
Cardiovascular research scientists are invited to apply for the
position of Director of laboratory-based Cardiovascular
Surgical Research in the Department of Surgery, Faculty of
Medicine at the University of Alberta. A stimulating
environment and outstanding facility is available for the right
individual, preferably with training in CVT Surgery and
Ph.D. or M.Sc., computer skills and a proven research
record. Minimum salary is $50,000.00 per annum and up
with excellent benefits; salary negotiable based on
qualifications and experience.
In accordance with Canadian immigration requirements, this
advertisement is directed to Canadian citizens and permanent
residents of Canada.
Applicants should send curriculum vitae and the names of
three referees by April 30, 1990 to:
Dennis L. Modry, M.D., FRCS(C)
Director, Division of Cardiovascular and Thoracic Surgery
2D1.02, WC Mackenzie Health Sciences Centre
Edmonton, Alberta, Canada T6G 2B7

The University o f Alberta is committed to the principle of
equity in employment.
—S90-02

The Department of Neurologic Surgery of the Scott
and White Institutions and Texas A&M University
College of Medicine is seeking applications for
senior staff physician faculty in the Sections of
Pain/Stereotaxic Surgery or Neurosurgical Oncology.
Residency or post residency experience and a
defined interest in cither subspecialty area together
with a broad capability and interest in general
neurosurgical disorders is desired. Basic and clinical
research opportunities are available commensurate
with previous experience. Medical student and
resident teaching/daily responsibilities are required.
The main campus is located in central Texas, north
of Austin in the approximate center of the Dallas/ Ft.
Worth, San Antonio, Houston triangle and benefits
from easy access to other surrounding universities
(Southwestern University, Georgetown; University of
Mary Ilardin-Baylor, Belton; Baylor University,
Waco.)
For further information, please send curriculum
vitae and references to:
M itc h e ll S m ig ic l, M .D .
C h a i r m a n , N e u r o lo g ic S u r g e r y
S c o tt a n d W h ite , T e x a s A&M U n iv e r s ity
C o lle g e o f M e d ic in e
2 4 0 1 S o u th 3 1 s t S tr e e t
T e m p le , TX 7 6 5 0 8
—S90-06

ADVERTISERS’ INDEX

ORDER FORM

BOX NO.: YES □ NO □

ADVERTISEMENT:

NO. OF INSERTIONS:

Davis & Geek
Maxon

Outside Back Cover

Dornier Medical Systems
Inside Back Cover

Ethicon Canada Inc.
Vicryl

Inside Front Cover

MD Management Limited
28

Roussel Canada Inc.
Claforan

31,32

Royal College of Physicians and
Surgeons of Canada, The
4
INVOICE:

Scientific American Medicine
7

Smith Kline & French Canada Ltd.
Cefizox

12, 20, 76

Tri Hawk International
Lyostypt
80

15, 16

CJS. VOL. 33. NO. 1. FEBRUARY 1990

ALL ADVERTISEMENTS FROM OUTSIDE CANADA MUST BE PREPAID.
ADDRESS ORDERS TO: Classified Advertising,
Canadian Journal of Surgery,
P O Box 8650, Ottawa, ON K1G 0G8

An advanced systematic interplay of four
exclusive Dornier features, now being tested,
is designed to give physicians the ability to
visually lock on to stones and keep

Dormers MPL9000
Multi-Purpose Lithotripter
Targeting System Could
Bring This Instrument More
In Focus W ith Lithotripsy
^
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process:

• Dual Ultra
sound Imaging—
designed to allow
visualization from a trans
ducer mounted on an
articulated arm and
another in line
with the shockwave path.
• Computerized Patient
Positioning—designed
to automatically bring
the stone into the correct shockwave focus.
Therapyhead Positioning—
designed to keep the stone isocentrically
centered while the operator rotates the
therapyhead to choose the optimum
shockwave path.

I HAN EVtK DthUnb *-Isocen!ric
D o rn ie r
Deutsche Aerospace

• Real-Time Monitoring—designed to allow
the operator to view the stone disintegration
process, as it happens.
It’s all part of the Dornier MPL 9000 multi
purpose lithotripter, now undergoing clinical
trials. The MPL 9000 was designed to deliver
pain-free treatment without sacrificing
disintegration performance. It incorporates
Dormer's proven spark-gap technologyunsurpassed with more successful clinical
results than all other methods combined.
An optional x-ray upgrade designed to
provide extended capabilities, is also
planned.
Dornier is committed to continually
evolving the field of lithotripsy, and to then
make those advancements available to all our
customers.
This keeps you and Dornier on the leading
edge, where Dornier started it all.
Dornier Medical Systems,
208 Evans Ave., Suite 111, Toronto,
Ontario Canada M8Z1J7.
416-259-3981.

Dornier Medical Systems.

The Standard. The Leader.
The Future.

A
polyglyconate monofilament absorbable suture

Easier
handling
first throw
to last

Maxon. A softer, more supple suture that offers strength,
superior handling characteristics and patient benefits.

DAVIS+GECK
MEDICAL DEVICE DIVISION
Cyanam id Canada Inc

A World Leader in Wound Management

